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1. General introduction 
 
1.1 Cardiovascular risk factors 
 
Cardiovascular disease (CVD) has been a major cause of death for decades now1, and it will 
probably be for years hereafter, although the number of cardiovascular deaths decreases2. In 
2005 17.5 million cardiovascular deaths were registered globally, which was 30% of all global 
deaths3 and in the Netherlands a comparable trend was observed in 20074. Atherosclerosis is the 
underlying disease which is a gradual process and that finally leads to cardiovascular events5. 
Many risk factors have been identified that promote atherosclerosis, including obesity, 
hypertension, lipid disorders, smoking and diabetes mellitus1, 6-15. What we do not know is why 
some persons develop early CVD and why others do not, despite the presence of risk factors. 
Many cardiovascular (CV) risk factors have been discovered a long time ago. Cardiovascular 
risk prediction is mainly based on the assessment of these individual CV risk factors. Often only 
the most conventional CV risk factors are determined and treated to reduce CV risk. However, 
still many CV deaths occur in patients who were not identified as high-risk patients. Moreover, 
despite blood pressure control, optimizing lipid levels and lifestyle advices, approximately 50% 
of the patients who died from cardiac arrest, were in the intermediate risk category of 
Framingham, as described by Taylor in 200216. Novel strategies are warranted to identify 
subjects at high-risk as early as possible17. Therefore, last few years research focused on new 
biomarkers of atherosclerosis, including markers of inflammation and oxidative stress. So far, 
none of the new biomarkers appeared to have additional prognostic power in CV risk prediction 
beyond the traditional risk scores18-20.  
One of the current concepts in atherosclerosis is that a specific cluster of risk factors 
increases cardiovascular (CV) risk. Many definitions of such clusters have been defined during 
the past decade, known as the Metabolic Syndrome (MetS) or Syndrome X21-25. Most of the 
definitions include abdominal obesity, atherogenic dyslipidemia, elevated blood pressure, and 
insulin resistance or glucose intolerance. In the United States, based on the definition of the 
National Cholesterol Education Program, the prevalence of the MetS among adults is about 34% 
among men, and 35% among women26. In European-origin populations, including the 
Netherlands, the prevalence of the MetS is estimated to be 20-25%27,28. The cluster of risk 
factors should damage the arterial walls more than the risk factors individually or the damage 
caused by other combinations of risk factors. In patient care, we are frequently unaware of the 
exposure time of the CV risk factors; when patients present themselves at the clinic because 
they experience a CV event, most of the damage has already been done. Therefore, 
atherosclerosis must be discovered as early as possible in primary prevention settings.  
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1.2 Atherosclerosis 
 
Atherosclerosis causes damage to the arterial wall. The arterial wall consists of several layers; 
the outer layer of the arterial wall is the adventitia, the media is the middle layer and the inner 
layer of the arterial wall is the intima. Figure 1 visualizes these different layers. As we grow 
older, the characteristics of the arterial wall change; elastic fibers decrease, collagen content 
increases, and the wall thickens29. The progression rate of these changes with age is not entirely 
known and differs among individuals. The hypothesis is that this heterogeneity may be due to 
differences in risk factor exposure29-33.  
 
 
 
 
 
 
 
Figure 1: The different layers of the arterial wall. 
 
 
  
Arterial wall 
Chapter 1 
16 
 
1.3 Non-invasive measurements of atherosclerosis 
 
A major problem in clinical medicine is that at every level of the traditional risk factor exposure, 
there is a large inter-individual variation in the amount of atherosclerosis and the development 
of CVD. This variation is probably due to genetic susceptibility, combinations and interactions 
between risk factors, including life style habits, duration of exposure to specific levels of the risk 
factors, and factors such as biological and laboratory variability. A current concept is that by 
measuring atherosclerosis directly in the arterial wall, the damage caused by known and 
unknown risk factors can be determined, which would allow us to better estimate CV risk at the 
level of the individual patient. This also provides the opportunity to measure atherosclerosis 
before developing symptoms of CVD, as changes in the arterial wall precede the clinical 
symptoms of CVD. Thus, subclinical disease measurements, representing the final result of risk 
exposure, may be useful for improving CVD risk prediction, therapeutic strategies and evaluation 
of risk factor modification, as recently described in a review34.  
 
Several invasive techniques to visualize the arterial system and the extent of atherosclerosis are 
available, such as angiography, which has been the ‘gold standard’ measurement for the 
presence of coronary atherosclerosis for years now. It does not need further explanation that 
invasive techniques are not suitable as a screening tool in the general population. More recently, 
less invasive techniques became available to visualize the arterial system, such as computed 
tomography (CT) and magnetic resonance imaging (MRI), although sometimes detergents are 
needed to optimize the pictures, which have to be injected. Moreover, these techniques expose 
patients to radiation, they are not widely available and very expensive at this time, and they 
cannot be applied to every patient.  
 
Because of the above described issues, many efforts have been made to develop relatively 
simple and cheap non-invasive measurements of atherosclerosis. A variety of these non-invasive 
techniques has been developed last few years, each measuring different aspects of the 
atherosclerotic process. These are inexpensive techniques that can easily be applied to nearly all 
patients. In this thesis, we explored the use of four non-invasive measurements of (subclinical) 
atherosclerosis (NIMA) as depicted in Figure 2 and described in the next section.  
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BAD 
PWV 
PWA parameters 
IMT 
Presence of plaque 
Plaque thickness 
FMD 
NMD 
ABI at rest 
ABI after exercise 
Non-Invasive Measurements of Atherosclerosis (NIMA): 
 
      1.Endothelial (dys) function               2. Arterial stiffness 
Parameters:     Parameters: 
Flow-mediated dilation (FMD)   Pulse wave velocity (PWV) 
Nitroglycerin-mediated dilation (NMD)  Pulse wave analysis (PWA): augmentation  
Brachial artery diameter (BAD)   index, central augmented, systolic, and  
      central diastolic pressure 
 
       3.Thickness of the arterial wall                 4.Peripheral flow 
 Parameters:     Parameters: 
Intima-media thickness (IMT)   Ankle-brachial index (ABI) at rest  
Presence of plaque    Ankle-brachial index after exercise 
Plaque thickness 
 
 
        
    
 
 
 
 
 
 
Figure 2: Cross-section of an artery with progressive atherosclerotic lesions including the different non-invasive 
measurements of atherosclerosis and the derived parameters used in this thesis. In the boxes at the bottom the 
change in the NIMA parameters with progression of atherosclerosis is depicted. 
 
 
1.3.1 Endothelial dysfunction 
 
Dysfunction of the endothelium, a monolayer of cells that cover the intima, is one of the first 
signs of (subclinical) atherosclerosis and is already present before structural changes appear35. 
Endothelial dysfunction can be measured non-invasively by flow-mediated dilation (FMD) with 
ultrasound at the brachial artery36, as depicted in Figure 3.   
First, the diameter of the brachial artery is measured three times at baseline. Then a cuff is 
placed around the forearm and occluded for 4 minutes, resulting in ischemia distal from the cuff. 
When the cuff is deflated after 4 minutes, blood flow increases to restore the circulation, 
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resulting in increased sheer stress on the endothelium. A healthy endothelium produces nitric 
oxide, which causes dilation of the artery to increase the blood flow to the peripheral circulation. 
 
 
 
Figure 3A: On the left, the method of FMD is visualized. On the right, the radio frequency signals obtained by the 
ultrasound transducer are depicted. The two peaks represent the arterial walls and the distance between these peaks 
represent the arterial diameter.  
 
 
                         
 
Figure 3B: The pre- and post-occlusion diameters are depicted as measured with analyzing software. The red dotted 
line represents the mean baseline diameter. At baseline, three subsequent measures of the diameter are performed 
and these are depicted as the dots on the left. After 4 minutes of occlusion, the cuff is deflated and the diameters are 
then measured every 10 seconds during 2 minutes; the first six measures are depicted as the dots on the right panel. 
First there is an increase in diameter after occlusion, and the diameter returns to baseline values in time. 
 
After deflation of the cuff, the brachial diameter is measured every 10 seconds for 2 minutes. 
The maximum post-occlusion diameter is used for the calculation of the FMD which is calculated 
as the post-occlusion diameter divided by the baseline diameter and is expressed as a 
percentage. The dilation caused by the increase in blood flow is dependent on the function of 
the endothelium and is called flow-mediated dilation. When the endothelial function is 
impaired, a lower FMD is measured.  
Beside endothelium-dependent vasodilation, the endothelial-independent vasodilation can be 
determined by administration of nitroglycerin. Nitroglycerin causes relaxation of the smooth 
muscle cells, which results in dilation of the arteries, and is independent of the function of the 
endothelium. First, the baseline diameter of the brachial artery is measured. After 
administration of nitroglycerin, the diameter is measured every 10 seconds for 4 minutes and 
the maximum diameter is used to calculate the nitroglycerin-mediated vasodilation (NMD); the 
maximum diameter after nitroglycerin is divided by the baseline diameter and expressed as a 
percentage. When the function of the smooth muscle cells is impaired, the NMD is decreased. 
Diameter 
Pre-occlusion diameter Post-occlusion diameter 
Diameter 
Radio frequency signal 
Time 
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The NMD is used to check whether the attenuation of FMD is caused by damage in the 
endothelium and not as a consequence of changes in the smooth muscle cells.  
We performed the FMD and NDM measurements according to the guidelines provided by the 
International Brachial Artery Reactivity Task Force37. FMD seems to be a promising technique for 
cardiovascular risk assessment in selected high-risk patient groups38-44, but until recently, 
prospective data of population-based cohorts were scarce and the reported results were not 
consistent45, 46. FMD was related to CV risk factors in some47,48, but not all studies in the general 
population45,49,50. The brachial artery diameter (BAD), the measure FMD is based on, also 
appeared to have predictive value in CV risk assessment in recent publications49, 51, 52.  
 
 
1.3.2 Arterial stiffness 
  
Due to ageing and due to the progression of atherosclerosis, the arterial wall changes, and 
besides dysfunction of the endothelium, these changes result in arterial stiffness53. Arterial 
stiffness can be measured non-invasively with pulse wave analysis (PWA) and pulse wave 
velocity (PWV) using tonometry. The heart ejects a bolus of blood into the arterial system with 
every heartbeat and this causes a blood pressure wave through the arteries. When the wave 
arrives at an artery, this causes expansion of the artery, as depicted in Figure 4. This 
phenomenon can be observed as the arterial pulse, normally palpated at the wrist or at the 
carotid artery in the neck. A tonometer is a device that registers the changes in diameter of 
arteries, as shown in figure 4. Figure 5 shows the technique of tonometry. By gently pressing the 
tonometer to the artery (A+B), the changes in diameter(C) of the artery can be measured. 
 
                                                 
 
                      
 
Figure 4A: Cross-sections of an artery. The red area represents the lumen, surrounded by the different arterial layers. 
Figure 4B: The heart ejects a bolus of blood into the arteries, which causes an increase in pressure. When the 
pressure/blood wave passes an artery, the artery dilates (A1) and when the wave has passed, the artery regains its 
original size (A2).  
Pressure/ 
Diameter 
Time 
A 
B 
1 
2 
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1.3.2.1 Pulse wave analysis 
 
PWA is commonly measured at the right radial artery (Figure 5A). By applying a validated 
transfer function54,55, many central pressure parameters can be derived from the registered 
radial wave form, such as augmentation index (AIx) and central blood pressure parameters such 
as central augmented pressure (CAP), central systolic pressure (CSP) or central diastolic pressure 
(CDP). Since AIx strongly depends on heart rate56, AIx corrected for a heart rate of 75 beats per 
minute is used. The pressure wave generated by contraction of the left ventricle travels along 
the arterial tree. The amplification of the pressure wave increases as it travels distally, resulting 
in a difference between brachial and central blood pressure of approximately 44% in healthy 
subjects with a mean age of 45 years57. The amplification of the pressure wave is known as the 
augmentation index (AIx) and is one of the calculated central pressure parameters. AIx reflects 
the overall interaction between the arterial tree and the left ventricle58. Men have lower AIx 
values than women59,60 and AIx plateaus at the age of 60 and therefore can only be considered 
as a measure of vascular age in younger individuals61-63. As atherosclerosis increases, 
augmentation index increases and the increased AIx has been associated with increased CV 
risk64. Other central parameters generated by the system are the central augmented pressure, 
central systolic pressure, and central diastolic pressure. The central pressure parameters are 
indirect measures of arterial stiffness, whereas pulse wave velocity is a direct non-invasive 
measure of arterial stiffness. 
 
 
 
  A    B    C  
Figure 5: Method of tonometry used to determine pulse wave analysis and velocity; the tonometer is gently pressed 
against the artery and registers the changes in diameter of the artery over time. On the right an example of an 
obtained waveform, this is composed of a forward wave in the systolic phase and a backward wave in the diastolic 
phase. 
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1.3.2.2 Pulse wave velocity 
 
PWV is a measure of the speed of the wave, which is propagated by contraction of the heart and 
travels along the arterial tree. To determine PWV, pulse waveforms are recorded at two sites 
sequentially (right carotid artery and left femoral artery), and wave transit-time can be 
calculated using the R-wave of a simultaneously recorded electrocardiography (ECG) as a 
reference frame, as depicted in Figure 6. Surface distance between the two recording sites can 
be measured parallel to the plane of the examination table. The distance between the carotid 
artery site and the supra sternal notch has to be subtracted from the distance between the 
supra sternal notch and the femoral artery site. PWV is calculated by dividing the traveled 
distance by the time. As the arteries become stiffer with age and with progression of 
atherosclerosis, PWV increases. We based our measurement protocol on the recommendations 
for user procedures provided by Van Bortel et al. in 200265. In 2006, PWV measured between the 
right carotid and the left femoral artery has been described as the gold standard measurement 
of arterial stiffness by a panel of experts53. PWV has shown to be an independent predictor of 
CVD in selected patient groups, especially hypertensive patients66,67 and in the general 
population67-74 and could provide additional information in clinical practice for CV risk 
stratification75. 
                 
                
Figure 6: The concept of measuring pulse wave velocity: A-left: Difference in time of departure (green line) from the 
heart and arrival (red line) of the wave at the measurement site. A-right: measurement of the distance the wave 
travelled between 1 and 2. B: The speed of the wave can be calculated: pulse wave velocity = distance/time in m/sec.  
The ECG as a timer
The distance from the measurement
site to the heart
1 
2 
time 
distance 
Heart beat 
Pressure wave 
A 
B 
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1.3.3 Thickness of the arterial wall 
 
As described before, the arterial wall consists of different layers. Using ultrasound, the arterial 
wall can be visualized and the thickness of the arterial wall can be measured, as depicted in 
Figure 7. Intima-media thickness (IMT) is an established measure of (subclinical) atherosclerosis 
and has shown to predict CVD, as well in patients as in asymptomatic individuals76-84.  IMT can be 
measured at different sites of the arterial tree. The most common place to measure IMT is the 
distal common carotid artery. In our studies, we measured IMT at the most distal centimeter of 
both common carotid arteries, before the bifurcation into the internal and external carotid 
arteries, as depicted in Figure 8.  We measured the thickness of both near walls and far walls at 
the angle that showed the optical thickest IMT. Furthermore, both carotid arteries (as well the 
common carotid, internal carotid, as the external carotid arteries) were scanned from most 
proximal to most distal to check for focal thickenings. Focal thickening of the arterial wall is 
called a plaque. The presence of a plaque in our studies was defined as a focal thickening of the 
arterial wall of at least 1.5 x the mean IMT, as defined by the Mannheim Intima-media thickness 
consensus85.  
     
           4 3 2              1                   2 3 4 
Figure 7: Ultrasound image of an artery with the different layers of the arterial wall on the left. On the right, the 
schematic view of the arterial walls is depicted. The red line represents the IMT. 
 
 
 
 
Figure 8: Measurement of the thickness of the arterial wall using ultrasound at the carotid artery. The most distal 10 
mm of the common carotid artery is measured. ECA = external carotid artery, ICA = internal carotid artery, Bul = 
bulbus and CCA = common carotid artery. The striped areas show plaques. 
1. Lumen 
2. Intima 
3. Media 
4. Adventitia 
4 3 2  
1 
2 3 4  
1 cm 
ECA 
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With ageing and progression of atherosclerosis the arterial wall thickens and this increase in IMT 
is associated with unfavorable levels of cardiovascular risk factors, atherosclerosis elsewhere in 
the arterial system, and with cardiovascular disease76-78,86-94. It is a well-established surrogate 
marker of CVD widely used in current research. In Figure 9 examples of IMT are depicted. The 
green lines follow the outer layer of the arterial wall and the red lines follow the inner layer. An 
example of a normal IMT is depicted in Figure 9A, Figure 9B shows an example of an increased 
IMT, and Figure 9C shows advanced atherosclerosis, including focal thickenings as depicted by 
the arrows.  
   
A        B             C   
Figure 9: Images of the carotid artery using ultrasound; A: normal intima-media complex; B: increased thickness; C: 
severe atherosclerosis with plaques. The outer layer of the wall is colored in green and the inner layer of the arterial 
wall is colored in red, the presence of plaque is indicated by the yellow arrows. 
 
 
1.3.4 Peripheral flow 
 
A measure of the blood flow through the peripheral circulation is the ankle-brachial index (ABI). 
To determine the ABI, blood pressures are measured using a hand-held Doppler device at both 
arms and both ankles. By dividing the lowest of the four ankle pressures by the highest of the 
two arm pressures, the ABI is calculated. The ABI can be measured at rest and after exercise 
(ABI-ex). The measurement sites for determining the ABI and an example of a hand-held Doppler 
device is depicted in Figure 10. When atherosclerosis is present, this can cause an obstruction in 
the peripheral arteries which results in a lower blood pressure at the ankle and thus a lower ABI. 
An ABI below 0.9 is considered abnormal. A low ABI is a marker of future CV events, as well in 
high-risk patients as in the general population43,95-102 and may improve the accuracy of CV risk 
prediction beyond traditional risk factor screening103,104. The ABI is the only NIMA used in the 
present thesis that is routinely applied in clinical practice.  
 
 
 
 
Figure 10: The principle of measuring the ankle-brachial 
index: arm and ankle pressures are measured using Doppler 
ultrasound and the blue cuffs; the ankle-brachial index (ABI) 
was calculated: ABI= ankle pressure/arm pressure.  
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2. Outline of the thesis 
 
Although it seems clear that some non-invasive measurements of atherosclerosis are predictive 
of incident cardiovascular disease, two important issues remain unclear. Firstly, how much 
additional information beyond that provided by traditional risk factors is gained by inclusion of 
NIMA in CV risk stratification?  Secondly, what is the comparative performance of the different 
imaging modalities in predicting cardiovascular events?  
Most of the previous studies only evaluated the predictive value of one NIMA. However, each 
NIMA reflects a different characteristic of the atherosclerotic process, involving functional 
and/or morphological changes in the arterial wall. Furthermore, the extent of atherosclerosis 
differs along the arterial tree. In different populations at risk of atherosclerosis, different 
characteristics of the atherosclerotic process may be present or accelerated. Therefore, 
simultaneous measurements of different NIMA could theoretically enhance the power to 
improve CV risk assessment. We designed a large prospective study to evaluate this. 
 
 
2.1 Design of the Non-Invasive Measurements of Atherosclerosis (NIMA) study  
 
The research described in this thesis is part of the large prospective Non-Invasive Measurements 
of Atherosclerosis (NIMA) study. The overall aim of the project is to determine the associations 
between 4 different NIMA and traditional and new CV risk factors. The predictive value of each 
technique and the derived parameters in CVD risk assessment will be determined in both a low 
and a high-risk population. In the low-risk population participants aged 50 to 70 years from a 
population-based cohort were included, who were recruited from the Nijmegen Biomedical 
Study (NBS). The high-risk population consists of families with Familial Combined Hyperlipidemia 
(FCH). Additional aims of the NIMA study are to evaluate the possible superiority of one 
technique above the other and the additive value of different combinations of NIMA. 
Furthermore, new biochemical and genetic risk factors will be delineated, allowing earlier and 
more effective preventive therapy. Finally, this research should provide guidelines for use of 
NIMA in an outpatient setting to facilitate early detection of increased CV risk and monitor 
lifestyle and pharmaceutical interventions. The design of the NIMA study is depicted in Figure 
11. 
 
When NIMA have predictive value in CV risk assessment, we hypothesized that NIMA should be 
associated with CV risk factors. Therefore, the main objective of the research described in this 
thesis was to determine whether NIMA were indeed associated with CV risk factors and 
prevalent CVD, both in a low-risk and in a high-risk population. The first part of this thesis 
describes the associations between NIMA and CV risk factors and prevalent CVD in the low-risk 
population (NBS) and the second part describes these associations in the high-risk population 
(FCH families). 
 
In clinical practice, reliable and reproducible tests should be available, preferably during the 
course of the whole day for practical reasons, so the first step in our project was to validate the 
new techniques in our Department of Vascular Diagnostics. Furthermore, a large number of 
subjects were to be measured, and to shorten the time frame in which this could be finished, in 
chapter 2 we study whether the outcomes of NIMA performed in the morning in fasting state 
differ from the outcomes of NIMA when performed in the afternoon after a standardized 
breakfast six hours prior to the measurements. All measurements during the morning visit are 
performed twice by two sonographers to determine both the intra-observer and the inter-
observer variability.  
 
 
  
  
  
General introduction & outline of the thesis 
 
25 
 
 
 
Figure 11: Design of the NIMA study including the time frame. NBS= Nijmegen Biomedical Study. FCH= Familial 
Combined Hyperlipidemia. 
 
 
 
PART I: Non-invasive measurements of atherosclerosis in relation to cardiovascular risk factors 
and prevalent CVD in a low-risk population: the Nijmegen Biomedical Study, a population-
based cohort. 
 
Part I of this thesis describes the associations of NIMA with CV risk factors and prevalent CVD in 
a low-risk population. Our low-risk population consists of 50 to 70 year-old participants of the 
Nijmegen Biomedical Study, which is a population-based survey. In chapter 3, we study the 
measurement of the earliest stages of atherosclerosis, flow-mediated dilation (FMD) as a 
measure of endothelial (dys) function. We determine the relation of FMD, the brachial artery 
diameter (BAD), and nitroglycerin-mediated dilation (NMD) with CV risk factors, prevalent CVD, 
and with IMT, as a surrogate marker of atherosclerosis. In chapter 4, the effect of clustering of 
specific CV risk factors on NIMA is investigated by comparing the impact of three different 
definitions of the Metabolic Syndrome and their individual traits on subclinical atherosclerosis, 
as determined by the 4 NIMA.  
 
Abdominal obesity is an important risk factor for atherosclerosis. Recently adiponectin has been 
identified as a new biochemical marker of abdominal obesity. Adiponectin has been proposed to 
be the missing link between obesity and cardiovascular risk and therefore, in chapter 5, we 
evaluate waist circumference, a simple measurement of abdominal obesity using a measuring 
tape, and adiponectin level to determine which of these markers of abdominal obesity shows 
the strongest association with subclinical atherosclerosis.  
Low-risk population 
NBS 
N=1517, aged 50-70 years 
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Dyslipidemia is another important risk factor for cardiovascular disease. Low-density lipoprotein-
cholesterol (LDL-c) is used as a therapeutic target in the treatment of patients with prevalent 
CVD and individuals at high CV risk worldwide. The last few years focus has shifted towards 
apolipoproteins as risk markers for CVD. In chapter 6, we compare apolipoprotein B, non-HDL-c 
and LDL-c in identifying individuals at increased CV risk. We compare the CV risk profiles and the 
extent of subclinical atherosclerosis of individuals with levels of apoB, non-HDL-c and LDL-c in 
the top quartiles to individuals with all three levels in the bottom quartiles. Recently, a 
diagnostic algorithm based on apolipoprotein B has been developed to distinguish different 
types of dyslipidemias and in chapter 7 we apply this algorithm to the NBS population. The 
cardiovascular risk profiles of the different dyslipidemias are presented, both by clinical and 
biochemical characteristics and by the extent of subclinical atherosclerosis, as measured with 
NIMA.  
 
 
PART II: Non-invasive measurements of atherosclerosis in relation to cardiovascular risk 
factors and prevalent CVD in a high-risk population: a cohort of FCH patients and their 
relatives. 
 
Part II describes the associations between NIMA and CV risk factors and prevalent CVD in the 
high-risk population. The high-risk population consists of families with Familial Combined 
Hyperlipidemia (FCH), both FCH patients and their unaffected relatives were included. Patients 
with FCH are characterized by hypercholesterolemia, hypertriglyceridemia and increased levels 
of apolipoprotein B. In addition, FCH is associated with obesity, hypertension, and insulin 
resistance. Patients with FCH have a 2 to 5 fold increased cardiovascular risk compared to 
normolipidemic individuals. In chapter 8, we investigate whether FCH is associated with early 
functional vascular wall changes, as represented by endothelial dysfunction and we determine 
the independent predictors of endothelial (dys) function.  
In chapter 9, we investigate whether FCH is associated with increased arterial wall stiffness, and 
whether measures of arterial wall stiffness in FCH family members can contribute to 
cardiovascular risk assessment.  
Finally, in chapter 10, we investigate which of the clinical and biochemical characteristics of FCH 
patients contribute most to their increased risk of cardiovascular disease, by determining the 
association of broad variety cardiovascular risk factors with IMT. 
 
In chapter 11, the general discussion, the non-invasive measurements of atherosclerosis are 
discussed. Our results are placed in the context of current evidence with regard to 
implementation of NIMA in clinical practice. The chapter finishes with future perspectives for 
cardiovascular research. Chapter 12 summarizes the results of the studies described in this 
thesis.  
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Abstract 
 
Background: Although it is often recommended to standardize the time day when performing 
non-invasive measurements of vascular function, the exact influence of  time of day on the 
outcome of IMT (intima-media thickness), PWV (pulse wave velocity), AIx ( augmentation-index), 
and FMD (flow mediated dilation) measurements has not been reported before.  
 
Methods: Nineteen healthy volunteers visited our department on two different occasions: the 
first visit was at 9:00 hours after an overnight fast, and the second visit was at 14:00 hours after 
a standardized breakfast. Non-invasive measurements of atherosclerosis were performed twice 
at 9:00 hours and once on the second visit at 14:00 hours.  
 
Results: Measurement of IMT, PWV, AIx, and FMD was reproducible according to the method of 
Bland and Altman. The absolute difference between repeated measurements at 9:00 hours 
showed no significant difference compared with the absolute difference between  9:00 hours 
and 14:00 hour for IMT (0.029 ± 0.014 compared with 0.021 ± 0.014 mm, p=0.27), PWV (0.63 ± 
0.50 compared with 0.75 ± 0.74 m/s, p=0.52), for AIx ( 4.0 ± 4.0 compared with 5.5 ± 5.2 %, 
p=0.35), and FMD ( 3.8 ± 3.7 compared with 4.2 ± 2.9 %, p=0.70.  
 
Conclusion: Our results show that, in healthy volunteers during daytime, IMT, PWV, AIx, and 
FMD outcomes are not confounded by variation in the exact time of the examination as long as 
other (exogenous) conditions including food intake, smoking and intake of alcohol are carefully 
controlled for.  
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Introduction 
 
Atherosclerosis is known to be a gradual process, which can be measured with a variety of non-
invasive techniques, each of which quantifies a different stage of the atherosclerotic process. 
Early functional changes can be quantified by FMD (flow-mediated dilation), AIx (augmentation 
index) and PWV (pulse wave velocity), whereas IMT (intima-media thickness) and ABI (ankle-
brachial blood pressure) measurements can be used to quantify later and more structural 
changes in the arterial wall. As NIMA (non-invasive measurements of atherosclerosis) become 
more and more important in clinical practice to evaluate the risk of coronary heart disease (CHD) 
and the effect of treatment, reliable and reproducible tests should be available, preferably 
during the course of the whole day for practical reasons. 
It is recommended by International Task forces1,2 to standardize patient-conditions when 
performing NIMA since there is abundant evidence that various exogenous variables, including 
smoking3,4, vitamin intake5,6, alcohol intake7,8, use of oral contraceptives9, and food intake10-12, 
affect the outcome of PWV, AIx, and FMD measurements. It is also often recommended to 
standardize the time of the NIMA-measurements. However, data concerning on the effect of 
time of day of the measurements on AIx, PWV, and IMT-outcomes are lacking. Only a few 
studies have addressed the effect of the time of measurement on FMD-outcomes, with opposing 
results13-15. In these studies the “overall-circadian variation” in FMD, due to both variation in 
point of time of the measurement, and to variation in exogenous influences like physical activity 
and food-intake were investigated. Hence, recommendations to standardize the time of 
measurements are thus confounded by postprandial haemodynamic changes, since food intake 
exerts a significant effect on cardiac output, heart rate16, and  blood pressure17
The aim of the present study was to quantify the effect of time of day on the outcome of four 
NIMA, including IMT, PWV, AIx, and FMD.  
, all determinants 
with an important influence on NIMA. 
 
 
Methods 
 
Subjects 
A total of 19 healthy volunteers, aged 25-63 yr, without history of cardiovascular diseases, 
hypertension or diabetes were studied. None of the participants used any medication or vitamin 
preparations except for one subject who used atorvastatin. The Medical Ethics Committee of the 
UMC Nijmegen approved the study protocol, and all participants provided written informed 
consent.  
 
Experimental protocol 
Subjects were invited to come to the vascular laboratory twice within 2 weeks. The first visit was 
at 9:00 hours after an overnight fast, the second visit at 14:00 hours after a standardized 
breakfast of 400 kcal (where 1 kcal=4.184 kJ) at 8:00 hours. On both occasions the subjects 
abstained from alcohol and caffeine-containing products for at least 24 hours, and did not 
smoke for at least 6 h before the measurements.  
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At the 9:00 hours visit, AIx, PWV, and IMT measurements were carried out twice by two 
sonographers each within 30 minutes in order to estimate reproducibility of these techniques. 
Therefore, in total, four measurements were performed for each patient. FMD was measured 
only once by one sonographer since reproducibility for this entity was already obtained in a 
previous study, including 15 healthy volunteers, aged 23-56 yr, with FMD  measured twice after 
overnight fast on two different morning occasions within 1 week. Single measurements of IMT, 
PWV, AIx, and FMD were repeated by one sonographer on the 14:00 hours visit in order to be 
able to quantify the effect of measurement time as a cause of variability in outcome.  
 
Laboratory measurements 
On both occasions peripheral blood was drawn. The plasma glucose was measured using the 
glucose oxidation method (Glucose Analyzer II, Beckman, Palo Alto, CA). Plasma triacylglycerol 
(triglyceride) concentrations were determined by a commercially available enzymatic reagent 
(Sera Pak, Miles, catalog No. 6639).  
 
FMD measurement 
Ultrasound images of the brachial artery were obtained using a 7.5 MHz linear-array transducer 
of an AU5 ultrasound system (Esaote Biomedica, Genova, Italy), connected to a computer with a 
data acquisition board. Dedicated software (Wall Track System 2.0; Pie Medical, Maastricht, the 
Netherlands) was used to measure and analyze the changes in vessel diameter. All 
measurements were performed by the same trained sonographer, and independently analyzed 
off-line by another investigator. 
FMD was assessed in the subject’s right arm in the supine position in a temperature controlled 
room (24°C) after a 10-minute equilibration period. For image optimization we used a stereo 
static arm with a holder for the probe and a gel pad to optimize focal depth and prevent 
compression of the artery. Measurement of FMD was by the method of Celermajer et al18
 
. 
Briefly, three baseline measurements of brachial artery diameter and flow velocity were 
performed, after which a pneumatic tourniquet (placed around the forearm distal to the 
segment of artery scanned) was inflated. After 4 minutes, the tourniquet was deflated and flow 
velocity was recorded instantly. Vessel diameter was recorded continuously in 4-s frames every 
15 s after deflation for at least 4 minutes to detect shear-stress-mediated changes in vessel 
diameter. FMD was calculated as the difference between the maximum post-occlusive diameter 
and the average baseline diameter, relative to the average baseline diameter, and expressed as 
a percentage. 
AIx and PWV measurement 
AIx was determined by recording the peripheral pulse wave on the radial artery by the 
SphygmoCor system (Atcor Medical, Sydney. Australia) using a high-fidelity micro manometer 
(SPC-301; Millar Instruments, TX, USA) after the subject had had a ten-minute supine rest. After 
20 sequential pulse waveforms had been recorded, an average peripheral waveform was 
generated, from which ejection duration was determined. Subsequently, the corresponding 
central waveform was derived by applying a validated integral transfer function on the average 
peripheral waveform, after which AIx could be calculated19-21. All waveforms were calibrated 
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using the brachial blood pressure, which was recorded in accordance with the international 
recommendations22 immediately before AIx measurement, using an oscillometric 
sphygmomanometer (Critikon model no.1846, Critikon inc., Tampa, USA). Since AIx is inversely 
correlated to the subject’s heart rate23
To determine PWV, pulse waveforms were recorded at two sites (right carotid artery and left 
femoral artery), and wave transit-time was calculated using the R-wave of a simultaneously 
recorded ECG as a reference frame. Then surface distance between the 2 recording sites was 
measured, in order to calculate PWV. To reduce the influence of body contours on the distance 
measure, the tape measure is held above the surface of the body, parallel to the plane of the 
examination table. All measurements of AIx and PWV met the criteria of optimal quality as 
defined by the fore mentioned manufacturer.  
, correction for this parameter has been carried out for 
each individual . 
 
IMT measurements 
Carotid IMT was determined using an AU5 Ultrasound machine (Esaote Biomedica, Genova, 
Italy) with a 7.5 MHz linear-array transducer. Longitudinal images of  the distal-most 10 mm of  
both the far wall and the near wall of both common carotid arteries were obtained in the 
optimal projection (anterolateral, lateral or posterolateral), as described before24. The same 
projection was used for the two 9:00 hours scans as well as the 14:00 hours scan. The actual 
measurement of the IMT was performed off-line by the sonographer at the time of the 
examination, using semi-automatic edge-detection software (M’AthStd version 2.0,Metris, 
Argenteuil, France) as described previously25
 
. All measurements were carried out in end-
diastole, using again the R-wave of a simultaneously recorded ECG as a reference frame.  From 
each frame the mean IMT was calculated over at least 7.5 mm of the above mentioned 10 mm 
segment (yielding a quality index of at least 75%). The outcome variable was defined as the 
mean IMT of the near and far wall of both common carotid arteries.  
Statistical Analysis: 
Values are given as means ± standard deviation (SD), unless otherwise stated. As the normal 
physiological range for AIx is from negative to positive values, the use of the coefficient of 
variance is inappropriate. Instead, all data were analysed using Bland-Altman plots, and 
reproducibility was expressed in terms of both absolute differences and mean difference ±  (SD)  
between paired measurements for all variables, as described by Bland and Altman26
The Shapiro-Wilk algorithm was used to determine whether each variable had a normal 
distribution. Paired (IMT, PWV, and AIx) and unpaired (FMD) two-tailed t-tests or Wilcoxon 
signed-rank tests were used to test for significant differences where appropriate. A p-value of 
less than 0.05 was considered as significant. Statistical analyses were performed using SPSS 
12.0.1 for windows (SPSS Inc., Chicago Illinois, USA) and Excel 2000 (Microsoft Corporation, 
Seattle, Washington, USA). 
.   
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Results   
 
Subject Characteristics 
 
The study population consisted of 5 male and 14 female subjects. Eleven female subjects were 
pre-menopausal, five of them using oral contraceptives. The mean age of the subjects was 39.3 
± 10.5 yr. They had a mean BMI (body mass-index) of 22.9 ± 2.4 kg/m2
 
 and a mean WHR (waist-
to-hip ratio) of 0.82 ± 0.07. There were three current smokers, and the mean alcohol intake was 
5.6 international units per week. No significant differences in the mean values of systolic and 
diastolic blood pressure, heart rate, ejection duration, triglyceride, and glucose levels were 
observed between 9:00 and 14:00 hours (Table 1). 
Table 1. Subject characteristics (n=19) 
 9.00 AM 2.00 PM Absolute difference p-value 
Systolic blood pressure (mmHg) 117.6 ± 12.4 119.2 ± 11.7 6.3 ± 6.7 NS 
Diastolic blood pressure (mmHg) 67.5 ± 9.5 66.4 ± 10.5 5.8 ± 4.9 NS 
Heart rate (bpm) 58 ± 8 57 ± 7 5 ± 3 NS 
Ejection duration (ms) 342  ± 18 346  ± 19 12 ± 10 NS 
Triglycerides (mmol/l)       0.81 ± 0.25 0.91 ± 0.34 0.27 ± 0.27 NS 
Fasting glucose (mmol/l) 4.31 ± 0.41 4.21 ± 0.38 0.49 ± 0.89 NS 
Data are presented as mean value ± SD.  9.00 AM is fasting, 2.00 PM is 6 hours after a standardized breakfast. 
 
Repeatability of NIMA 
 
There was no significant difference between the NIMA in the two recordings. The absolute 
difference, averaged for both investigators, for repeated measurements at 9:00 hours was 0.029 
± 0.014 mm for IMT, 4.0 ± 4.0 % for AIx, and 0.63 ± 0.50 m/s for PWV. For FMD the absolute 
difference between repeated measurements was 3.8 ± 3.7%.  Bland-Altman plots for the mean 
within-observer variability in measurements of both observers are shown in Figure 1, and do not 
show any trend for reproducibility to be dependent on the underlying mean value. The mean ± 
SEM difference between the first and the second recording on 9:00 hours was 0.003 ± 0.007 mm 
for IMT, 0.68 ± 0.86 % for AIx, 0.19 ± 0.12 m/s for PWV, and –1.05 ± 1.12 % for FMD. The SD of 
the mean-differences was 0.032 mm for IMT, 4.87% for AIx, 0.52 m/s for PWV, and 4.87% for 
FMD. Since (more than) 95% of all readings for IMT, AIx, PWV and FMD are within the error 
range defined by the coefficient of repeatability, we can conclude that the procedure is 
reproducible as defined by the British Standards Institution27
 
.  
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Figure 1. Bland-Altman plots showing the within-observer differences in measurements against 
the mean value 
 
Bland-Altman plots showing the within-observer differences in measurements against the mean value     
(          , mean;           1,96 SD). A; flow mediated dilation. B; augmentation index. C; pulse wave velocity. D; intima-
media thickness. 
 
Morning-afternoon effect on the outcome of NIMA 
 
The Bland-Altman plots for the variability in measurements between 9:00 and 14:00 hours are 
shown in Figure 2, and do not show any trend for variability to be dependent on the underlying 
mean value. The mean (± SEM) difference between 9:00 and 14:00 hours was 0.009 ± 0.005 mm 
for IMT, 0.95 ± 1.68 % for AIx, -0.37 ± 0.23 m/s for PWV, and –0.71 ± 1.18 % for FMD-
measurements. The SD of the differences between 9:00 and 14:00 hours was 0.023 mm for IMT, 
7.35% for AIx, 1.00 m/s for PWV and 5.15% for FMD. All observations for PWV, and FMD 
measurements and all but one observation (95 %) for AIx and IMT lay within the error range 
defined by repeatability coefficient.  
Although there appeared to be a tendency towards slightly lower FMD’s at 9:00 hours compared 
with 14:00 hours (4.47 ± 4.53% compared with 5.18 ± 3.55%), the absolute difference was not 
significant. The same holds for PWV-measurements (6.46 ± 1.08 compared with 6.83 ± 1.13 
m/s). On the contrary, there is a tendency towards slightly higher values at 9:00 hours compared 
with 14:00 hours for AIx measurements (9.8 ± 14.5 compared with 8.9 ± 13.4%), but here 
differences were also not significant. IMT was equal at the 9:00 hours and 14:00 hours 
recordings (0.63 ± 0.08 mm). 
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Repeated measurements at 9:00 hours compared with morning-afternoon differences. 
 
The absolute difference between repeated measurements at 9:00 hours showed no significant 
difference compared with the absolute difference between 9:00 and 14:00 hours for IMT (0.029 
± 0.014 compared with 0.021 ± 0.014 mm, p=0.27), PWV (0.63 ± 0.50 compared with 0.75 ± 0.74 
m/s, p=0.52), for AIx ( 4.0 ± 4.0 compared with 5.5 ± 5.2 %, p=0.35), and  FMD ( 3.8 ± 3.7 
compared with 4.2 ± 2.9 %, p=0.70). 
 
Figure 2. Bland-Altman plots showing the differences between measurements at 9.00 and 14.00 
hours against the mean value. 
 
Bland-Altman plots showing the within-observer differences in measurements against the mean value    
(          ,mean;             1,96 SD). A; flow mediated dilation. B; augmentation index. C; pulse wave velocity. D; intima-
media thickness 
 
 
Discussion 
 
The reproducibility of the IMT, PWV, AIx, and FMD measurements is comparable with studies 
reported previously28-31
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. However, the present study is complementary with these previous 
studies by showing that reproducibility remains high, even when measurements are carried out 
at different time points during the day, as long as all other patient conditions are carefully 
standardized. Furthermore, we have shown that the absolute differences between repeated 
measurements on 9:00 hours are equal to the absolute differences between the measurements 
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at 9:00 and 14:00 hours. Therefore, even if there is biological variability in IMT, PWV, AIx, and 
FMD due to variation in the time of day of the measurements, its effect is minor compared with 
measurement variability. This has important implications, since NIMA are accepted as reliable 
surrogate markers of the process of atherosclerosis and are frequently used in clinical trials to 
evaluate therapeutic interventions. 
Our present data show that it is not mandatory to standardize the time of NIMA. This appears to 
be in contradiction with the observation that a close interaction between the sympathetic nerve 
system and the endothelium exists32-34. Diurnal changes in sympathetic activity are generally 
held responsible for diurnal changes in NO (nitric oxide) availability and a morning surge in 
cardiovascular events. However, in our study we did not find sympathetic activity  (and resultant 
NO-availability) at 9:00 hours to be different from 14:00 hours; there were no differences in 
heart rate and other cardiovascular physiological parameters (systolic blood pressure/diastolic 
blood pressure, and ejection duration) between recordings at 9:00 and 14:00 hours, whereas 
Heijmering et al. showed that heart rate and (muscle) sympathetic nerve activation are closely 
related32. This could simply be explained by the fact that all recordings at 9:00 hours were 
performed a substantial period after the patient woke up. Therefore, by the time of 
measurement, the characteristic morning surge in cortisol and catecholamine blood-levels and 
the resultant concomitant change in related cardiovascular parameters (such as blood pressure, 
heart rate and total peripheral resistance) had already taken place35
 
. 
Prior studies have addressed the topic of circadian variation in FMD13-15. In contrast with the 
present study, they did find clues for the existence of a circadian rhythm. Some groups found 
significantly higher FMD in the afternoon compared with the morning13,14,  where others found 
the contrary15
Since different studies showed that FMD is remarkably affected shortly after food intake and 
that these changes last for 4-6 h
. The discrepancy with our present findings could be explained by the fact that the 
studies mentioned above investigated the composite effect on endothelial function of both 
endogenous factors (such as circadian autonomic nerve activity), and  certain exogenous factors 
(such as food intake, smoking and caffeine intake), whereas, in our present study, these 
conditions were carefully controlled for and, as a consequence, plasma glucose and 
triacylglycerol levels were equal at 9:00 and 14:00 hours.  
10,12
 
, we may conclude that exogenous conditions (like food 
intake) probably exert an influence on FMD measurements which is more extensive than the 
influence of variability in the exact time of the measurements. 
Variability in food-intake during the day is also a reason for the Task Force III on Clinical 
Applications of Arterial Stiffness advising measurements of arterial stiffness (like PWV and AIx) 
to always be performed on the same time of the day2. It is common knowledge that food intake 
decreases systemic vascular resistance, with an accompanied increase in heart rate and cardiac 
output and, particularly in elderly subjects, a decrease in blood pressure17. Since direct 
correlation exists between (diastolic) blood pressure and both AIx36 and PWV37 as well as an 
inverse correlation between heart rate and AIx38, we may assume that measurements of 
vascular stiffness are significantly affected in the postprandial-state. 
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Previous studies have shown significant differences in diameter and compliance of large arteries 
between night and daytime2,39
Finally, we could not demonstrate any variability in IMT during the daytime. However, it was not 
expected to find any differences between the measurements at 9:00 and 14:00 hours, since IMT 
is a marker of more structural changes in the atherosclerotic vessel wall and is supposed to be 
insensitive to short-term alternations of endogenous and/or exogenous variables like 
sympathetic output and food intake. 
, which were attributed primarily to circadian changes in 
autonomic nerve activity. Our present data suggest that, during daytime, the variability in 
sympathetic activity is too small to demonstrate the resultant variability in stiffness properties of 
large arteries as measured by PWV and AIx, when standardization for exogenous conditions has 
taken place.  
 
In conclusion, the results of this study have the practical implication that, when evaluating the 
risk of CHD or therapeutic interventions on endothelial function or vascular stiffness with NIMA, 
it does not appear to be mandatory to always perform measurements at exactly the same time 
of the day, as long as the other experimental conditions are carefully standardized. However, 
since both measurement times in the present study are during the daytime, (with blunted 
circadian variation in sympathetic activity and the resultant heart rate and blood pressure) the 
results cannot be extrapolated over the whole day. Furthermore, it must be noted that this 
study was performed in a group healthy volunteers, and that the results cannot be automatically 
extrapolated to patients suffering from cardiovascular diseases, especially not when they have a 
disturbed lipid metabolism and/or insulin resistance. Further research is required to study the 
influence of time variability on measurement outcomes in these groups of patients.  
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Abstract:  
 
Background: Previous reports showed inconsistent results about the potential role of flow-
mediated dilation (FMD) in cardiovascular (CV) risk prediction. Few data are available about the 
role of nitroglycerin-mediated dilation (NMD), but recently, brachial artery diameter (BAD) 
appeared to have predictive value in CV risk prediction.We determined the relation of FMD, 
BAD, and NMD  with known CV risk factors and intima-media thickness (IMT), a well-established 
surrogate marker of atherosclerosis, in a community-based population, the Nijmegen Biomedical 
Study (NBS).  
 
Materials & Methods: FMD, BAD, and NMD were measured in the brachial, and IMT in the 
common carotid artery ultrasononically in 337 participants, aged 50-70 years. Traditional clinical 
and biochemical parameters were determined. 
 
Results: Both FMD and NMD were not correlated with most CV risk factors or prevalent CVD. 
However, both IMT and BAD did show significant correlations with CV risk factors. In accordance, 
both IMT and BAD were significantly correlated with prevalent CVD (r=0.62 and r=-0.37, 
respectively). Furthermore, FMD was not correlated with IMT and did hardly (R2
 
=1.1%) improve 
the prediction of IMT by CV risk factors in regression analysis. However, both BAD and NMD did 
correlate with IMT (r= -0.29 and r=0.25, respectively).        
Conclusion: In our study, FMD and NMD were not related to known CV risk factors and prevalent 
CVD, and FMD was not correlated with IMT, a surrogate marker of atherosclerosis. Most 
intriguingly, BAD was significantly correlated with some CV risk factors, prevalent CVD and IMT. 
So, BAD is a potential valuable tool in CV risk prediction in middle-aged low-risk populations, 
whereas FMD is not. 
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Introduction 
 
Endothelial dysfunction is one of the first signs of (subclinical) atherosclerosis1. Endothelial 
dysfunction can be measured non-invasively by flow-mediated dilation (FMD) with ultrasound. It 
appeared to be a promising technique for cardiovascular risk assessment in selected high-risk 
patient groups2-7, but until recently, prospective data of population-based cohorts were still 
lacking. Recent prospective data of population-based cohorts have shown that FMD has 
prognostic value for cardiovascular disease (CVD), although the measurement adds very little to 
risk stratification based on the traditional risk factors8,9. However, most population-based 
studies excluded participants with prevalent CVD. Very recently, two studies reported the 
independent prognostic value of FMD, although these were selected healthy populations10,11
Recently, a few reports documented the correlation of brachial artery diameter (BAD) and CV 
risk factors and/or CV events in the general population. BAD is a simple and reproducible 
measurement and has been suggested a more promising tool in CV risk prediction than FMD
. 
Little is known about the correlation of nitroglycerin-mediated dilation (NMD) with CV risk 
factors, since this measurement is used as a control measurement of FMD and not considered as 
a non-invasive tool to estimate CV risk. 
9,12-
14.  IMT is widely used as a surrogate marker of subclinical atherosclerosis nowadays. Several 
studies reported about the predictive value of IMT in CV risk stratification15-18 and IMT has been 
depicted as a strong predictor of future vascular events19.  The correlation between FMD and 
IMT is less clear. Although some studies have shown an inverse relation between brachial artery 
FMD and carotid IMT20-23, others have not been able to reproduce these results in the general 
population24,25
 
.  In the present study, we investigated whether FMD, BAD, and NMD were 
associated with CV risk factors, prevalent CVD, and IMT, a surrogate marker of subclinical 
atherosclerosis, in a low-risk population.  
 
Materials and Methods 
 
Study population 
Our study was performed as part of the Nijmegen Biomedical Study (NBS). The NBS is a 
population-based survey, as described before26,27
 
. We invited 337 subsequent participants aged 
50 to 70 years to come to our institute to undergo the non-invasive measurements and to 
donate fasting venous blood samples. All lipid-lowering medication when used was discontinued 
for four weeks prior to the measurements. All participants filled out a questionnaire about their 
previous history of vascular diseases, use of medication, and smoking habits. CVD was defined as 
reported myocardial infarction, treated angina, transient ischaemic attack, cerebrovascular 
accident, peripheral arterial disease, coronary artery bypass, or angioplasty. The Medical Ethics 
Committee of the Radboud University Nijmegen Medical Centre approved the study protocol (in 
accordance with the Declaration of Helsinki) and all participants provided written informed 
consent. 
Clinical evaluation and biochemical analysis 
Systolic and diastolic blood pressure was measured using an oscillometric sphygmanometer 
(Criticon model no. 1846, Criticon Inc., Tampa, USA). Hypertension (HT) was defined when 
systolic blood pressure (SBP) level was ≥ 140 mmHg and/or diastolic blood pressure (DBP) was ≥ 
90 mmHg or previously determined and treated HT. Diabetes mellitus type 2 (DM 2) was defined 
as a glucose level of ≥ 7.0 mmol/l after an overnight fast or previously determined and treated 
DM 2. Waist circumference was measured at the level of the umbilicus, hip circumference was 
measured at the level of the trochanter major and waist-to-hip ratio (WHR) was calculated. 
Weight and height were measured and body mass index (BMI) was calculated as body-weight (in 
kilograms) divided by the square of height (in meters). Plasma total cholesterol (TC), HDL-
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cholesterol (HDL-c), triglycerides (TG), and glucose concentrations were determined using 
commercially available enzymatic reagents (AEROSET® System, Abbott, Chicago Illinois). LDL-
cholesterol (LDL-c) levels were calculated according to the Friedewald method28.  Total plasma 
apolipoprotein B (apoB) concentration was determined by immunonephelometry29
 
.  
Experimental protocol  
The measurements were performed after an overnight fast or in the afternoon six hours after a 
standardized breakfast. Participants were asked to abstain from caffeinated products for at least 
twelve hours and they were asked not to smoke for 12 hours before the visit. As published 
before there were no significant differences between the measurements performed in the 
morning and afternoon after the measurement conditions were standardized30. Experiments 
were performed in a temperature-controlled room (23-24°C) with the patients in supine 
position. The equipment used was a 7.5 MHz transducer of an AU5 ultrasound system (Esaote 
Biomedical, Genova, Italy), connected to a computer with a data acquisition board. All 
measurements were highly standardized and performed by well-trained and certified 
sonographers, as described before and as recommended by the International Brachial Artery 
Reactivity Task Force in 200231,32
The diameter of the brachial artery was measured at the ante cubital fossa in 
longitudinal plane. A cuff was placed at the forearm, 5-10 cm below the scan area. The 
transducer was placed in a stereo static arm to avoid movement of the transducer during the 
measurement. To prevent compression of the artery the transducer was placed in a water bath. 
First baseline diameter of the brachial artery was measured three times and the average of 
these three measurements was calculated. The cuff around the forearm was than inflated 50 
mmHg above the systolic blood pressure during four minutes. After four minutes the cuff was 
deflated and flow-velocity was measured to control the hyperaemic effect of the occlusion 15 
seconds after deflation of the cuff. Subsequently, the diameter was measured continuously 
every 15 seconds in four second frames until 4 minutes after deflation of the cuff. Flow-
mediated dilation was calculated as the difference between the maximum diameter post-
occlusion and the average baseline diameter, relative to the average baseline diameter and 
expressed as a percentage. In total, FMD could be calculated for 263 (78%) participants. The 
other 74 measurements were excluded from the analyses because of technical problems. We 
reported the reproducibility of FMD in our laboratory before; the  mean ± SEM  difference was -
1.05 ± 1.12%
. Dedicated software (Wall Track System 2.0; Pie Medical, 
Maastricht, The Netherlands and AIM-WTS software, University Hospital Groningen, The 
Netherlands) was used to record the brachial artery diameters.  
30
Thereafter, fifteen minutes were allowed for vessel recovery before the nitroglycerin-
mediated dilation (NMD) was measured as described before
. The mean absolute difference in baseline diameter was 0.22 ± 0.17 mm and the 
mean absolute difference in post-occlusion diameter was 0.19 ± 0.11 mm. 
32
Carotid IMT was determined using semi-automatic edge-detection software (M’AthSTD 
version 2.0, Metris, Argenteuil, France) as described before
.  Sublingual nitroglycerin spray 
(Nitrolingual® 400 ug per dose, G. Pohl-Boskamp Gmbh&Co. KG, Germany) was administered 
and the diameter was continuously recorded every 15 seconds after administering the spray for 
two to ten minutes. NMD was calculated as the difference between the maximum diameter 
after administration of the nitroglycerin and the average baseline diameter, relative to the 
average baseline diameter and expressed as a percentage. NMD could be calculated for 311 
(92.3 %) participants. 
33.  IMT was defined as the mean IMT 
of four measured segments of the distal common carotid artery: far wall left, near wall left, far 
wall right and near wall right. Reproducibility of our IMT-measurements was investigated and 
reported before30
 
.   
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Statistical analyses 
The relationship between the non-invasive measurements of atherosclerosis (IMT, FMD, BAD, 
and NMD) with prevalent CVD and risk factors for CVD were expressed as standardized 
regression coefficients using multivariate linear regression models with adjustment for age and 
gender.  Similar models were used to evaluate the relationship between FMD, BAD, NMD, and 
IMT. Finally,  we analysed the explained variance (R2) of different regression models, to evaluate 
how these non-invasive measurements of atherosclerosis were explained by different 
combinations of traditional CV risk factors (including with the Systematic COronary Risk 
Evaluation chart (SCORE)34
 
,  and prevalent CVD.  All analyses were performed using STATA 
9.2 (StataCorp LP, College Station, Texas, USA).   
 
RESULTS 
 
Subject characteristics 
The characteristics of the study population are shown in Table 1. Of the 337 participants, 57.6% 
were males. Men in our NBS population were older, smoked more, were more obese, had higher 
blood pressure levels, and a more atherogenic lipid and lipoprotein profile compared to women.  
Furthermore, men had more prevalent CVD and hypertension and used more frequently anti-
hypertensive and lipid-lowering medication.  
Thirty-three men suffered from prevalent CVD; defined as reported ischaemic myocardial 
infarction (N=14), treated angina (N=16), cerebrovascular accident (N=3), transient attack (N=1) 
and peripheral arterial disease (N=10). Fifteen women suffered from prevalent CVD; 10 were 
treated for angina, 3 suffered from myocardial infarction, 4 had a cerebrovascular accident, one 
had a transient ischaemic attack, and three women suffered from peripheral arterial disease.  
Forty-two men (21.6%) used anti-hypertensive medication, including diuretics (4.6%), beta 
blockers (18%), calcium channel blockers (6.7%), ace inhibitors (5.7%), angiotensin receptor 
blockers (2.1%), and nitroglycerin (1.5%). Thirty-four women (23.8%) used anti-hypertensive 
medication; 11.2% used diuretics, 14.7% used beta blockers, 2.8% calcium channel blockers, 
7.0% ace inhibitors, 2.8% angiotensin receptor blockers, and 2.1% used nitroglycerin. 
 
Non-invasive measurements of atherosclerosis 
The characteristics of FMD, BAD, NMD, and IMT are depicted in Table 2.  
The outcomes of these four non-invasive measurements differed between men and women. 
Compared to women, men had larger basal diameters of the brachial artery, thicker carotid IMT, 
and attenuated endothelial-dependent and endothelial-independent function as reflected by 
lower FMD and NMD, respectively.  
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Table 1: The clinical and biochemical characteristics of the participants of the NBS study. 
 Men N=194 Women N=143 
Age (y) 61.3 (56.7-66.2) 58.5 (53.7-64.3) 
Weight (kg) 82 (76-91) 68 (61-77) 
Body mass index (kg/m2 26.1 (24.4-28.7) ) 25.2 (22.8-28.3) 
Waist circumference (cm) 97 (91-105) 85 (79-94) 
Waist-to-hip ratio 0.94 (0.89-0.99) 0.84 (0.80-0.89) 
Systolic blood pressure (mmHg) 131 (123-142) 130 (116-145) 
Diastolic blood pressure (mmHg) 80 (73-86) 73 (64-80) 
Total cholesterol (mmol/l) 5.6 (4.9-6.2) 5.7 (5.2-6.4) 
Triglycerides (mmol/l) 1.30 (0.94-1.79) 1.03 (0.75-1.48) 
High-density lipoprotein-cholesterol (mmol/l) 1.30 (1.12-1.55) 1.65(1.39-1.96) 
Low-density lipoprotein-cholesterol (mmol/l) 3.60 (3.05-4.16) 3.59 (3.11-4.16) 
Fasting glucose (mmol/l) 5.2 (4.9-5.5) 5.1 (4.7-5.5) 
Apolipoprotein B (g/l) 0.97 (0.84-1.14) 0.97 (0.85-1.13) 
   
Smoking (past and current) 151 (77.8%) 102 (71.3%) 
Cardiovascular disease 33 (17.0%) 15 (10.5%) 
Hypertension 81 (41.8%) 51 (35.7%) 
Diabetes mellitus type 2 12 (6.2%) 10 (7.0%) 
Lipid-lowering therapy 30 (15.5%) 14 (9.8%) 
Anti-hypertensive therapy 42 (21.6%) 34 (23.8%) 
Continuous variables are presented as the median (inter quartile range (ICR)). Dichotomy variables are presented as N 
followed by percentage.  
 
 
Table 2: Descriptive statistics of the non-invasive measurements including brachial artery 
diameter, flow-mediated dilation, nitroglycerin-mediated dilation, en intima-media thickness in 
the NBS population 
 
 N Men  N=194 Women   N= 143 
BAD (mm) 311 5.50 (5.01-5.93) 4.51 (4.10-4.87) 
FMD (%) 263 1.01 (-0.20-1.98) 1.97 (0.84-3.24) 
NMD (%) 311 11.47 (7.24-14.62) 12.83 (9.64-18.01) 
IMT (mm)  337 0.84 (0.77-0.91) 0.79 (0.73-0.85) 
Values are presented as median (ICR). BAD: brachial artery diameter, FMD: flow-mediated dilation, NMD: 
nitroglycerin-mediated dilation, IMT: intima-media thickness. 
 
 
Univariate correlations of FMD, BAD, and NMD with CV risk factors, prevalent CVD, and IMT  
The univariate correlation coefficients of FMD, BAD, NMD, and IMT are shown in Table 3. All 
analyses were adjusted for age and gender.  FMD was not correlated to any of the clinical and 
biochemical CV risk factors or prevalent CVD. The only significant correlations were found with 
the use of lipid-lowering and anti-hypertensive medication. NMD only showed a significant but 
small correlation with SBP, weight, BMI, and waist; no correlation with prevalent CVD was found. 
In contrast, BAD did show a strong and significant correlation with both CV risk factors (including 
smoking, DBP, and weight) and prevalent CVD. As expected, nearly all CV risk factors and 
prevalent CVD correlated significantly with IMT.   
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There was no significant correlation between FMD and IMT (r= 0.04, p=0.625), whereas the 
correlation between BAD and IMT as well as NMD and IMT was significant (r= 0.25, and  
r=-0.29, respectively; p<0.001 for both correlations).  To verify these results we determined the 
correlations of the non-invasive measurements with the Systematic COronary Risk Evaluation 
chart (SCORE), the European (high-risk) chart for the prediction of CV risk. FMD (β=-0.03), NMD 
(β=0.02) and BAD (β=-0.08) were not significantly correlated with the SCORE, whereas IMT 
(β=0.20) did significantly correlate with the SCORE. The SCORE explained 3.3% and 11.9% of the 
variance in FMD and NMD, respectively. For BAD and IMT the SCORE explained 44.5%, and 
33.6%, respectively. 
 
 
Table 3:
 
  Age- and gender-adjusted correlation coefficients for IMT, FMD, BAD, and NMD with 
clinical and biochemical parameters  
       IMT          FMD       BAD NMD 
Total Cholesterol (mmol/l) 0·13* 0·10‡ −0·05‡ 0·10† 
Triglycerides (mmol/l) 
‡ 
0·17* 0·08‡ −0·07† 0·01† 
High-density lipoprotein-cholesterol (mmol/l) 
† 
−0·08 −0·01† −0·04† 0·08† 
Low-density lipoprotein-cholesterol (mmol/l) 
† 
0·13* 0·08‡ −0·02† 0·08† 
Fasting glucose (mmol/l) 
† 
0·10 0·00‡ 0·06† −0·05† 
Apolipoprotein B (g/l) 
† 
0·17* 0·11‡ −0·03† 0·03† 
Weight (kg) 
† 
0·15* 0·00‡ 0·20*† −0·12*§ 
Body mass index (kg/m
‡ 
2 0·15*) 0·02‡ 0·08† −0·13*† 
Waist circumference (cm) 
‡ 
0·15* 0·01‡ 0·09† −0·12*† 
Waist-to-hip ratio 
‡ 
0·13* −0·03‡ 0·00† −0·08† 
Systolic blood pressure (mmHg) 
† 
0·21* 0·03§ 0·08† −0·12*† 
Diastolic blood pressure (mmHg) 
‡ 
0·04 −0·03† 0·15*† −0·06‡ 
Smoking (past + current) 
† 
0·34* 0·03¶ −0·32*† 0·11¶ 
Cardiovascular disease 
‡ 
0·62* 0·25¶ −0·37*§ 0·10¶ 
Hypertension 
‡ 
0·30* 0·06 ¶ 0·13 −0·10‡ 
Diabetes mellitus type 2 
‡ 
0·41 −0·23¶ −0·20§ −0·16§ 
Lipid-lowering therapy 
‡ 
0·66* 0·39*¶ −0·18¶ −0·04‡ 
Anti-hypertensive therapy 
† 
0·13 0·29*‡ −0·18§ 0·17‡ 
Abbreviations as in Table 2. *denotes 
‡ 
P < 0·05. 
†β < 0·10;  ‡β 0·10–0·20;  §β 0·20–0·30;  ¶
 
β > 0·30 
  
Multivariate regression analysis of FMD, BAD, NMD, and IMT 
We examined how the variance in the non-invasive measurements of atherosclerosis was 
explained by combinations of different CV risk factors and prevalent CVD (Table 4).  Age and 
gender explained a large proportion of IMT and BAD, whereas for NMD the explained variance 
was much smaller and for FMD nearly absent. Biochemical parameters and blood pressure 
parameters explained most of the variance in IMT and FMD, whereas clinical parameters 
explained most of the variance in BAD and NMD. Prevalent CVD only explained a substantial part 
of IMT and BAD and not of FMD and NMD. These results confirm that IMT and BAD are more 
closely related to CV risk factors and prevalent CVD than FMD and NMD. Finally, we performed 
Chapter 3 
 
54 
 
multivariate regression analysis of IMT with adding successively FMD, BAD, and NMD to the 
model with clinical and biochemical characteristics. FMD increased the explained variance of 
IMT with 1.1%, BAD did not increase the percentage and NMD increased the percentage 
explained variance of IMT with only 0.3%.  The overall explained variance of IMT by clinical and 
biochemical characteristics was 43.3 %. 
 
Table 4:  Prediction (R2
 
) of non-invasive measurements by different CV risk factor combinations 
and prevalent cardiovascular disease 
IMT FMD BAD NMD 
 1. Cardiovascular disease 5·3* 0·8 † 1·9* 0·1 
  2. Smoking (past and current) 2·2* 0·0 2·0* 0·2 
  3. BMI, weight, hip, waist, waist-to-hip ratio, height 3·4 1·7 † 7·4* 2·2 † 
  4. Lipid-lowering therapy, TC, TG, HDL-c, LDL-c, apoB 6·7* 5·9*† 1·6 † 2·0 
  5. Hypertension, anti-hypertensive therapy, SBP, DBP 5·9* 2·1 † 2·9 2·3 † 
  6. Diabetes mellitus type 2, fasting glucose 1·5 0·5 1·0 0·3 
  7. Age and gender 29·1* 3·3*† 43·5*† 11·3*† 
  8. Total (all CV risk factors and age and gender) 
† 
43·3* 14·2*† 52·9*† 18·5*† 
Model 1–6: age- and gender-adjusted values of IMT, FMD, BAD, and NMD. BMI= body mass index, 
TC=total cholesterol, TG=triglycerides, HDL-c=high-density lipoprotein-cholesterol,   LDL-c=low-density 
lipoprotein cholesterol, apoB=apolipoprotein B, SBP= systolic blood pressure, DBP=diastolic blood 
pressure, CV=cardiovascular. * denotes 
† 
P < 0.05.  † R2
 
 > 2·5%. 
 
Discussion 
 
Correlation between FMD and CV risk factors 
The main finding of our study is the lack of correlation between FMD and CV risk factors.  The 
lack of this correlation in our study is intriguing and may reflect the complexity of endothelial 
(dys) function, which is the result of the interplay of a wide range of systemic factors, not only 
those acting for years or decades, but also direct influences. Three population-based studies 
reported the association of FMD with CV risk factors35-37. In contrast with these studies (and in 
accordance with our data) Jensen-Urstad & Johansson found no correlations between any of the 
conventional CV risk factors in a population of 55 years of age12. In accordance with literature, 
we argue that this might be due to the high prevalence of risk factors in older populations, 
resulting inevitably in endothelial dysfunction. So, endothelial dysfunction is a measure of early 
atherosclerosis and will not differ in older populations where multiple risk factors are present. 
However, in a population of young adults, Leeson et al. also demonstrated no correlation of FMD 
and NMD with CV risk factors38.  Yan et al. recently showed a weak relationship between FMD 
and blood pressure (n=1600). However, there was no correlation with age, other risk factors or 
Framingham Risk Score24
 
.  In our multivariate regression analysis, the combination of lipid 
parameters and the use of lipid-lowering medication contributed most to FMD, explaining 5.9% 
of the variance in FMD. Our results in combination with several reports in literature, question 
whether FMD is a sensitive marker of vascular health in older populations.  
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Correlation between FMD and prevalent CVD and IMT 
Another important outcome of the present study is the lack of correlation between brachial 
artery FMD and prevalent CVD or carotid IMT in middle-aged men and women from the general 
population. As the number of subjects with prevalent CVD is relatively small, we used IMT as a 
surrogate marker of atherosclerosis. Our finding could have several explanations. The FMD 
measurement is a technically challenging one, as well as for the technician as for the patient. As 
a result, FMD has a relatively large variability.  Woodman et al. in 2001 reported intra-observer 
coefficients of variation of 1.8 to 23.0 %, but when expressed as a percentage, coefficients of 
variation increased to 28-33%39. In 1995 Sorensen et al. calculated that a mean improvement of 
FMD over 2% is necessary to detect a treatment benefit and that for any individual a difference 
of 4-8% is necessary to account for natural variability40.  Therefore, we did a power analysis. We 
calculated for a power of 80% and alpha-error of 5% that 14.336 measurements of FMD are 
needed to detect a difference of 0.5% in CVD (http://statpages.org/postpowr.html). The number 
of participants in a low-risk population needed to prove whether FMD is or is not a valuable tool 
in risk stratification is therefore very high.  Another explanation could be that carotid IMT and 
brachial artery FMD measure different stages of the atherosclerotic process. Endothelial 
dysfunction is a measure of early atherosclerosis and will therefore be present in older 
population where multiple risk factors are present for many years12. Furthermore, we support 
the opinion of Yan and colleagues that there might have been an under-reporting of negative 
studies24. In 1999 Hasimoto et al. described a negative correlation between FMD and IMT in 
men, but the number of subjects was small21. However, Yan et al. found no significant 
association of FMD with either CV risk factors or carotid IMT in a study of 1578 middle-aged 
male fire fighters24. Recently, Yeboah et al. also reported that IMT and FMD were not related in 
population-based older adults25
 
.  Our study supports these results, and most importantly 
extends these results, as we also included women and men with and without prevalent CVD.  
Correlation between NMD and CV risk factors, prevalent CVD, and IMT 
NMD showed only few and small correlations with CV risk factors and was not related to 
prevalent CVD. However, NMD was inversely associated with IMT, suggesting a link between 
subclinical atherosclerosis and impaired smooth muscle relaxation in the brachial artery. The 
pathophysiological basis underlying the association between atherosclerosis and impaired NMD 
is not clear. NMD is an endothelium-independent response that depends upon the intactness of 
arterial smooth muscle cells and their reactivity to NO, released from the intracellular 
conversion of nitroglycerin. NMD is generally used as a control measurement of FMD and not as 
a measure of subclinical atherosclerosis. 
 
Correlation between BAD and CV risk factors, prevalent CVD, and IMT 
Intriguingly, we show a strong correlation of BAD with several CV risk factors and prevalent CVD. 
Fifty percent of the variation in BAD could be explained by age, gender, prevalent CVD, and CV 
risk factors. Furthermore, we demonstrate an association between BAD and subclinical 
atherosclerosis as measured by IMT, indicating that arterial remodelling in atherosclerosis may 
be a systemic process. Whether brachial dilation represents structural change in vessel wall 
components or an effect of CV risk factors on vascular tone is not clear. Our study suggests that 
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BAD, a simple and reproducible measurement, might be a valuable measurement in CV risk 
prediction.  
There are a few limitations of our study. In the calculation of the FMD we did not correct for 
stimulus as recently suggested14,41-43
 
. The presence of CVD was determined by questionnaire. We 
do not yet have prospective follow-up data, so we cannot investigate the prognostic value of the 
non-invasive measurements for CVD prediction. The strength of the present study is that we 
included middle-aged asymptomatic and symptomatic participants drawn directly from the 
community, which is the population of interest for the purpose of primary prevention and risk 
identification, stratification, and reduction.  
In conclusion:  In our middle-aged population-based cohort, FMD and NMD were not related to 
CV risk factors and prevalent CVD and FMD was not related to IMT, a surrogate marker of 
atherosclerosis. We show that BAD was significantly correlated with some CV risk factors, 
prevalent CVD and IMT. So, BAD could be a potential valuable tool in CV risk prediction in 
middle-aged low-risk populations, whereas FMD is not. Our results underscore the need for well-
designed large prospective studies aimed at evaluating the additive value of FMD, BAD, and 
NMD in predicting CV events, especially in younger populations. 
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Abstract 
 
Context & objective: The metabolic syndrome (MetS) indicates an increased cardiovascular (CV) 
risk. The objective of the present study was to determine the impact of the MetS and its 
individual traits on subclinical atherosclerosis, as measured with six non-invasive parameters of 
atherosclerosis (NIMA) in a 50-70-year-old Dutch population-based cohort. Furthermore, we 
determined the impact of three different definitions of the MetS. 
 
Design: We performed NIMA in 1517 participants of the Nijmegen Biomedical Study. The MetS 
was defined by definitions of the National Cholesterol Education Program (NCEP), International 
Diabetes Federation (IDF), and the World Health Organization (WHO). 
 
Results: Participants with the MetS (NCEP) were characterized by increased subclinical 
atherosclerosis compared to participants without any trait of the MetS, as reflected by lower 
ankle-brachial index at rest((%change [95%CI]) M:-5.2% [-9;-1] ,F:-3.1% [-6;-1]) and after exercise 
(M:-7.7% [-17;+2], F:-6.6% [-11;-2]), higher augmentation index (M:+4.8% [+3;+7] , F:+1.9% 
[+4;+18]), increased pulse wave velocity (M:+22.8% [+15;+32], F:+20.5% [+14;+28]), increased 
intima-media thickness (M:+9.3% [+5;+13], F:+6.9% [+3;+11]), and thicker plaques (M:+17.6%    
[-2;+41], F:+26.6% [+5;+53]). Most intriguingly, the number of traits was strongly associated with 
the severity of subclinical atherosclerosis as all NIMA gradually deteriorated with increasing 
number of traits present; NIMA were already deteriorated when one or two traits were present 
and further deteriorated when 4 or 5 traits of the MetS were present. Similar results were found 
when IDF and WHO definitions of the MetS were used.  
 
Conclusions: For cardiovascular risk prediction it is more important to take into account the 
presence of each individual trait and the number of traits of the MetS than to diagnose the 
presence of the MetS.  
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Introduction 
 
The metabolic syndrome (MetS) is a clustering of cardiovascular risk factors in one person. 
Different definitions have been developed by a number of organizations, including the National 
Cholesterol Education Program, Adult Treatment Panel III (NCEP)1, the World Health 
Organization (WHO)2, and the International Diabetes Federation (IDF)3. Most of them include 
abdominal obesity, atherogenic dyslipidemia, elevated blood pressure, and insulin resistance or 
glucose intolerance. Subjects with the metabolic syndrome are at increased risk of 
cardiovascular disease (CVD). In the United States, based on the NCEP definition, the prevalence 
of the MetS is about 34% among men, and 35% among women4. In European-origin populations 
the prevalence of the MetS is estimated to be 20-25%5. Using the NCEP definition of the MetS, a 
quarter of the Dutch population under the age of 60 is at increased risk for CVD6. 
Before clinical manifestations of CVD appear, subclinical atherosclerosis is already present and 
several non-invasive measurements of subclinical atherosclerosis have been developed. When 
subclinical atherosclerosis is detected at an early stage, patients can be treated and clinical 
events of CVD, such as myocardial infarction and stroke, can be prevented. Intima-media 
thickness (IMT) is a well established surrogate marker of subclinical atherosclerosis and the 
ankle-brachial index (ABI) is an indirect measure of (subclinical) atherosclerosis in the peripheral 
circulation. Pulse wave velocity (PWV) and augmentation index (AIx) reflect arterial stiffness, 
which is related to CVD and is also proposed to be a measure of subclinical atherosclerosis.  
The association between subclinical atherosclerosis and the MetS has been studied in relatively 
small, selected patient groups, using only one or two different non-invasive measurements of 
subclinical atherosclerosis7-10. Several studies reported on the associations of PWV and/or IMT 
with the MetS in the general population11-16. Only one study described the association of AIx17 
and two studies reported on the association of ABI with the MetS in the general population1819.  
Few reports documented the effect of an increasing number of traits of the MetS on subclinical 
atherosclerosis as measured with PWV and/or IMT  in selected patient groups7,9,20 and in healthy 
populations21-25. No study has described the impact of the number of components of the MetS 
on AIx and ABI after exercise.  
The objective of the present study was to determine the impact of the MetS and its individual 
traits on subclinical atherosclerosis, as measured with six different parameters of four non-
invasive measurements of atherosclerosis in a 50-70-year-old Dutch population-based cohort. 
Furthermore, we determined the impact of three different definitions of the MetS on subclinical 
atherosclerosis.  
 
 
 
Methods 
 
Study population 
In total 1517 participants from the Nijmegen Biomedical Study were included. The Nijmegen 
Biomedical Study is a population-based survey as described before26.  We invited participants 
aged 50 to 70 years to come to the hospital and performed PWV, AIx, IMT, plaque thickness, and 
ABI at rest and after exercise measurements and collected fasting venous blood samples. All 
participants filled out a questionnaire about their previous history of vascular disease, 
medication use, smoking, and exercise habits. CVD was defined as a reported myocardial 
infarction, transient ischaemic attack, stroke, peripheral arterial disease, coronary artery bypass 
or angioplasty, or treated angina. The Medical Ethics Committee of the Radboud University 
Nijmegen Medical Centre approved the study protocol (which is in accordance with the 
Declaration of Helsinki) and all participants provided written informed consent. 
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Clinical evaluation and biochemical analysis 
Systolic and diastolic blood pressure was measured using an oscillometric sphygmanometer 
(Criticon model no. 1846, Criticon Inc., Tampa, USA). Hypertension (HT) was defined when 
systolic blood pressure (SBP) was ≥ 140 mmHg and/or diastolic blood pressure (DBP) was ≥ 90 
mmHg or previously diagnosed and treated HT. Waist circumference was measured at the level 
of the umbilicus, hip circumference was measured at the level of the trochanter major and 
waist-to-hip ratio (WHR) was calculated. Weight and height were measured and body mass 
index (BMI) was calculated as body weight (in kilograms) divided by the square of height (in 
meters). Venous blood was drawn and plasma total cholesterol, high-density lipoprotein 
cholesterol (HDL-c), serum triglycerides (TG) and glucose concentrations were determined using 
commercially available enzymatic reagents (AEROSET® System, Abbott, Chicago Illinois). 
Diabetes mellitus type 2 (DM 2) was defined when glucose level was ≥ 7.0 mmol/l after an 
overnight fast or previously diagnosed and treated DM 2. Low-density lipoprotein cholesterol 
levels were calculated according to the Friedewald method27. Total plasma apolipoprotein B 
concentration was determined by immunonephelometry28. All lipid-lowering medication when 
used was discontinued for four weeks prior to the measurements.  
 
Definitions of the MetS 
The NCEP Adult Treatment Panel III guidelines define the MetS as the presence of at least three 
of the following five criteria: fasting glucose ( ≥ 5.6 mmol/l  [100 mg/dl]); abdominal obesity 
characterized by increased waist circumference (M:>102 cm; F:>88 cm); increased TG level (≥ 1.7 
mmol/l [150 mg/dl]); low HDL-c level (M: <1.04 mmol/l; F: <1.29 mmol/l [M: < 40 mg/dl; F: 
<50mg/dl]); or HT (≥ 130/85 mmHg)1. 
The definition of the WHO was recently modified for epidemiological studies and we used this 
modified WHO definition of the MetS involving evidence of impaired glucose regulation (fasting 
glucose ≥ 6.1 mmol/ l [110 mg/dl]) or hyperinsulinemia (based on fasting insulin levels in the 
upper quartile of the non-diabetic population, i.e. > 14 IU/l) together with at least two of the 
following components: central obesity characterized by WHR (>0.90) or BMI (>30 kg/m²); 
dyslipidemia characterized by elevated TG  ( ≥ 1.7 mmol/l [150 mg/dl]) and/or low HDL-c (< 0.9 
mmol/l [35 mg/dl]); or HT (≥ 140/90 mmHg)29. 
According to the IDF, the MetS is present when the waist circumference is increased (M: ≥94 cm; 
F: ≥80 cm) and at least two of the following fac tors are present: TG  ≥1.7 mmol/l  or specific 
treatment of this lipid abnormality; low HDL-c (M<1.03 mmol/l; F< 1.29 mmol/l) or specific 
treatment; SBP >130mmHg or DBP >85 mmHg or treatment of previously diagnosed HT; 
increased fasting plasma glucose (>5.6 mmol/l) or previously diagnosed DM3. 
 
Experimental protocol  
All non-invasive measurements of (subclinical) atherosclerosis (NIMA) measurements were 
performed after an overnight fast or in the afternoon six hours after a standardized breakfast. 
Participants were asked to abstain from caffeinated products and not to smoke for at least 
twelve hours before the visit. As published before there were no significant differences between 
measurements performed in the morning and afternoon after the measurement conditions had 
been standardized30. All measurements were taken with participants in supine position after at 
least 10 min rest in a temperature-controlled room (23-24° C)31 and performed by well-trained 
and certified sonographers according to highly standardized protocols.  
 
Pulse wave velocity and augmentation index  
Peripheral arterial pressure waveforms were recorded by applanation tonometry at the radial 
artery and AIx was calculated, using the commercially available SphygmoCor system version 7.1 
(Atcor Medical, Sydney, Australia) as described before32. As AIx is influenced by heart rate33, an 
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index normalized for heart rate of 75 beats per minute was used. To determine PWV, pulse 
waveforms were recorded at two sites sequentially (right carotid artery and left femoral artery), 
and wave transit-time was calculated using the R-wave of  a simultaneously recorded ECG as a 
reference frame as described before32. All measurements had to meet the criteria of optimal 
quality as defined by the manufacturer. According to these standards, AIx was acquired in 1369 
subjects (90.7%) and PWV in 1479 subjects (97.9%). The reproducibility of the AIx and PWV 
technique was good, as has been reported in a previous study30. The absolute difference for 
repeated measurements was 4.0 ± 4.0 % for AIx and 0.63 ± 0.50 m/s for PWV. The mean ± SEM 
difference between the two measurements was 0.68 ± 0.86% for AIx and 0.19 ± 0.12 m/s for 
PWV. 
 
Intima-media thickness and plaque thickness 
Carotid IMT was determined using an AU5 Ultrasound machine (Esaote Biomedica, Genova, 
Italy) with a 7.5 MHz linear-array transducer as described before34. Actual measurement of the 
IMT was performed off-line by the sonographer at the time of the examination, using semi-
automatic edge-detection software (M’AthStd version 2.0, Metris, Argenteuil, France). 
Reproducibility of our IMT measurements as investigated by the method of Bland and Altman 
has been reported before30.  The mean ± SEM difference was 0.003 ± 0.007 mm. The primary 
outcome variable was defined as the mean IMT of four measured segments of the common 
carotid artery: far wall left, near wall left, far wall right and near wall right. The mean far wall 
IMT was acquired in 1494 subjects (98.9%), and mean near wall IMT in 1478 subjects (97.9%). 
Secondary outcome variable was the thickness of plaques in the common carotid artery, internal 
carotid artery or carotid bulb (defined as thickening of the wall of at least 1.5 x the mean IMT).  
 
Ankle-brachial index at rest and after exercise 
Appropriately sized cuffs were placed around both arms above the elbow and around both legs 
just above the ankle. Resting blood pressures were measured at the left and right brachial 
artery, the left and right posterior tibial and dorsalis pedis arteries using an 8 MHz hand-held 
Doppler probe (IMEXDOPCT+™, Biomedic, Almere, The Netherlands). The highest of the two arm 
pressures was used to calculate ABI at rest for the posterior tibial and dorsalis pedis arteries. The 
lowest of the four ABIs was used in the analysis. In addition, participants were asked to perform 
a treadmill test for four minutes at a speed of 2 m/h and at an elevation of 10%. Immediately 
after the exercise test blood pressures were recorded at the arm with the highest pressure in 
rest and at both ankles and ABI after exercise (ABI-ex) was calculated for both legs. The lowest 
ABI-ex was used in the analysis. In total 1471 measurements of ABI at rest (97.4%) and 1435 
measurements of ABI-ex (95.0%) were suitable for analysis. 
 
Statistical analyses 
The clinical and biochemical characteristics are presented as means followed by the standard 
deviation (SD) for continuous variables and as N followed by the percentage for dichotomy 
variables. In Tables 2, 3 and 4 the geometric means of the non-invasive measurements with 95% 
confidence intervals (CI) are presented. To express the impact of the different definitions of the 
MetS, its individual traits, and the number of traits, the percentage difference followed by 95%CI 
is presented compared to the reference group. The reference group is composed of participants 
without any trait of the three definitions of the MetS present. Age adjusted values of the NIMA 
were used and all analysis were split according to gender. All analyses were performed using 
STATA 10.0  (StataCorp LP, Texas USA).  
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Results 
 
Subject characteristics 
 
In total 1517 participants were included in the study. Eleven participants were excluded from 
the analysis; 5 participants did not discontinue their lipid-lowering medication, 3 participants 
smoked within 6 hours prior to the measurements and 3 participants had had breakfast within 6 
hours prior to the measurements. Of the remaining 1506 participants included in the analyses, 
49.3% was male.  
Based on the definition of the NCEP, the prevalence of the MetS for men and women was 29.6% 
and 27.0%, respectively. Based on the definition of the IDF the prevalence of the MetS was 
37.6% and 29.9% and based on the definition of the WHO 9.9% and 5.0%, for men and women, 
respectively. The clinical and biochemical characteristics of the study population are shown in 
Table 1. Men in our study population were slightly older, had a larger waist contour, higher 
blood pressures, and had a more atherogenic lipoprotein profile as reflected by higher TG levels 
and lower HDL-c levels than women. They also suffered more from hypertension and 
cardiovascular diseases and had more pack years of smoking than women. 
 
 
Table 1: The clinical and biochemical characteristics of the participants of the Nijmegen 
Biomedical Study. 
 
 
Men Women 
 
(N=742) (N=768) 
Age (y) 61.8 (6.0) 60.6 (5.8) 
Pack years of smoking (y) 18.8 (18.9) 15.7 (15.7) 
Total cholesterol (mmol/l) 5.70 (1.0) 6.06 (1.0) 
Triglycerides (mmol/l) 1.56 (0.94) 1.34 (0.67) 
High density lipoprotein cholesterol (mmol/l) 1.28 (0.46) 1.55 (0.38) 
Low density lipoprotein cholesterol (mmol/l) 3.77 (0.90) 3.94 (0.94) 
Fasting glucose (mmol/l) 5.4 (1.1) 5.1 (0.8) 
Apolipoprotein B (g/l) 1.02 (0.23) 1.02 (0.24) 
Body mass index (kg/m2) 26.9 (3.5) 26.5 (4.5) 
Waist (cm) 99.6 (10.6) 89.4 (11.7) 
Waist-to-hip ratio 0.90 (0.1) 0.85 (0.1) 
Systolic blood pressure  (mmHg) 130.7 (14.5) 127.2 (15.9) 
Diastolic blood pressure (mmHg) 81.0 (9.4) 75.2 (10.7) 
Heart rate  in beats per minute 63.6 (10.4) 66.2 (10.1) 
   Lipid-lowering therapy 139 (18.7%) 87 (11.3%) 
Anti-hypertensive therapy 197 (26.5%) 203 (26.4%) 
Cardiovascular disease 118 (15.9%) 61 (7.9%) 
Hypertension  314 (42.3%) 263 (34.2%) 
Diabetes Mellitus type 2 57 (7.7%) 45 (5.9%) 
Continuous variables are presented as the mean followed by SD. Dichotomy variables are presented as N followed by 
percentage. 
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Impact of the MetS, its individual traits, and the number of traits on NIMA 
 
The impact of the MetS (according to the NCEP definition) and its individual traits on the 
outcomes of the NIMA is presented in Table 2 as percentage change compared to the reference 
group, composed of participants without any trait of the three definitions of the MetS present.  
Both men and women with the MetS (men: N=219; women: N=205) were characterized by a 
lower ABI at rest and after exercise, stiffer arteries as reflected by higher PWV and AIx values, 
increased IMT, and thicker plaques compared to the reference group. Furthermore, we present 
in Table 2 that the outcomes of all NIMA were similarly affected in both sexes, independent 
which of the traits of the MetS were present. Only AIx was less affected by the traits in women 
than in men. When diagnosing participants with the MetS according to the definitions of the IDF 
and WHO, similar results were found (tables S1 and S2 in the supplementary information).  
 
The impact of the number of traits of the MetS (NCEP) on the outcomes of NIMA is presented in 
Table 3.  The percentage change in outcomes of NIMA compared to the reference group is 
presented followed by the 95%CI. We show that in both men and women, all NIMA gradually 
deteriorated with increasing number of traits of the MetS. Increased subclinical atherosclerosis, 
as reflected by the deterioration of NIMA, was obvious when three components were present, 
necessary for the diagnosis MetS. We show that a further increase of the number of traits of the 
MetS (4 or 5) is associated with further deterioration of NIMA.  Furthermore, we also show that 
subjects with only one or two traits present already showed an increased presence of subclinical 
atherosclerosis as reflected by deteriorated NIMA. Similar results were found when patients 
were diagnosed with the MetS according to the definitions of the IDF and WHO (tables S3 and S4 
in the supplementary information). In addition, we determined the impact of the individual traits 
and the number of traits after adjustment for other major CV risk factors, including pack years of 
smoking and low-density lipoprotein-cholesterol (LDL-c), respectively. After adjustment for these 
important CV risk factors, comparable results were found (data not shown). 
 
Comparison of the impact of the different definitions of the MetS on NIMA 
 
In Table 4 the relative impact of the three different definitions of the MetS on the outcomes of 
NIMA compared to the reference group is depicted. In both men and women, all three 
definitions of the MetS showed comparable deterioration of NIMA. After adjustment for pack 
years of smoking and LDL-c, respectively, comparable results were found (data not shown). 
 
 
 
 
Ta
bl
e 
2:
 T
he
 im
pa
ct
 o
f t
he
 M
et
S 
(N
CE
P-
de
fin
iti
on
) a
nd
 it
s 
in
di
vi
du
al
 tr
ai
ts
 o
n 
th
e 
ou
tc
om
es
 o
f t
he
 n
on
-in
va
si
ve
 m
ea
su
re
m
en
ts
 o
f a
th
er
os
cl
er
os
is
 
 
 
Pe
rc
en
ta
ge
 c
ha
ng
e 
 
 
 
 
Re
fe
re
nc
e 
M
et
S 
M
et
S 
gl
uc
os
e 
M
et
S 
w
ai
st
 
M
et
S 
TG
 
M
et
S 
H
D
L-
c 
M
et
S 
H
T 
M
en
 (N
=7
41
) 
gr
ou
p 
N
CE
P 
≥ 
5.
6 
m
m
ol
/L
 
≥ 
10
2 
cm
 
≥ 
1.
7 
m
m
ol
/L
 
< 
1.
04
 m
m
ol
/L
 
≥1
30
/8
5 
m
m
H
g 
N
 
57
 
21
9 
17
1 
28
3 
23
7 
17
0 
48
7 
A
nk
le
-b
ra
ch
ia
l i
nd
ex
 a
t r
es
t 
1.
14
 
-5
.2
 
-4
.0
 
-2
.6
 
-5
.2
 
-5
.1
 
-3
.7
 
 
(1
.1
1 
; 1
.1
8)
 
(-
9 
; -
1)
 
(-
8 
; 0
) 
(-
6 
; +
1)
 
(-
9 
; -
1)
 
(-
9 
; -
1)
 
(-
8 
; 0
) 
A
nk
le
-b
ra
ch
ia
l i
nd
ex
 a
ft
er
 e
xe
rc
is
e 
1.
09
 
-7
.7
 
-4
.1
 
-2
.0
 
-7
.9
 
-8
.7
 
-3
.1
 
 
(1
.0
1 
; 1
.1
8)
 
(-
17
 ; 
+2
) 
(-
13
 ; 
+5
) 
(-
9 
; +
6)
 
(-
16
 ; 
+1
) 
(-
18
 ; 
+1
) 
(-
11
 ; 
+6
) 
Pu
ls
e 
w
av
e 
ve
lo
ci
ty
 (m
/s
) 
8.
5 
+2
2.
8 
+2
4.
9 
+1
8.
5 
+1
8.
5 
+1
5.
9 
+2
0.
1 
 
(8
.0
 ; 
8.
9)
 
(+
15
 ; 
+3
2)
 
(+
16
 ; 
+3
4)
 
(+
11
 ; 
+2
6)
 
(+
11
 ; 
+2
6)
 
(+
9 
; +
24
) 
(+
13
 ; 
+2
8)
 
A
ug
m
en
ta
tio
n 
in
de
x 
 
1.
18
 
+4
.8
 
+5
.0
 
+3
.4
 
+4
.5
 
+3
.1
 
+4
.5
 
 
(1
.1
6 
; 1
.2
0)
 
(+
3 
; +
7)
 
(+
3 
; +
7)
 
(+
1 
; +
5)
 
(+
3 
; +
6)
 
(+
1 
; +
5)
 
(+
3 
; +
6)
 
In
tim
a-
m
ed
ia
 th
ic
kn
es
s 
(m
m
) 
0.
80
 
+9
.3
  
+7
.5
 
+7
.8
 
+8
.2
 
+9
.6
 
+6
.4
 
 
(0
.7
8 
; 0
.8
3)
 
(+
5 
; +
13
) 
(+
3 
; +
12
) 
(+
4 
; +
12
) 
(+
5 
; +
12
) 
(+
5 
; +
14
) 
(+
3 
; +
10
) 
Pl
aq
ue
 th
ic
kn
es
s 
(m
m
) 
2.
08
 
+1
7.
6 
+2
2.
7 
+1
7.
3 
+1
6.
0 
+2
1.
8 
+1
9.
8 
 
(1
.7
1 
; 2
.5
4)
 
(-
2 
; +
41
) 
(+
3 
; +
46
) 
(-
1 
; +
39
) 
(-
4 
; +
40
) 
(0
 ; 
+4
8)
 
(+
1 
; +
42
) 
 
 
 
 
 
 
 
 
 
 
Pe
rc
en
ta
ge
 c
ha
ng
e 
 
 
 
 
   
 R
ef
er
en
ce
  
M
et
S 
M
et
S 
gl
uc
os
e 
M
et
S 
w
ai
st
 
M
et
S 
TG
 
M
et
S 
H
D
L-
c 
M
et
S 
H
T 
W
om
en
 (N
=7
65
) 
gr
ou
p 
N
CE
P 
≥ 
5.
6 
m
m
ol
/L
 
≥ 
88
 c
m
 
≥ 
1.
7 
m
m
ol
/L
 
< 
1.
29
 m
m
ol
/L
 
≥1
30
/8
5 
m
m
H
g 
N
 
74
 
20
5 
11
9 
40
4 
18
1 
20
4 
41
0 
A
nk
le
-b
ra
ch
ia
l i
nd
ex
 a
t r
es
t 
1.
12
  
-3
.1
  
-3
.5
 
-2
.8
 
-3
.0
 
-2
.4
 
-3
.2
 
 
(1
.1
1 
; 1
.1
4)
 
(-
6 
; -
1)
 
(-
6 
; -
1)
 
(-
5 
; -
1)
 
(-
5 
; -
1)
 
(-
5 
; 0
) 
(-
5 
; -
1)
 
A
nk
le
-b
ra
ch
ia
l i
nd
ex
 a
ft
er
 e
xe
rc
is
e 
1.
13
  
-6
.6
 
-5
.7
 
-4
.0
 
-7
.4
 
-5
.5
 
-3
.8
 
 
(1
.1
1 
; 1
.1
5)
 
(-
11
 ; 
-2
)  
(-
10
 ; 
-1
) 
(-
8 
; 0
) 
(-
12
 ; 
-3
) 
(-
9 
; -
2)
 
(-
8 
; 0
) 
Pu
ls
e 
w
av
e 
ve
lo
ci
ty
 (m
/s
) 
8.
1 
+2
0.
5 
+2
4.
6 
+1
1.
9 
+1
6.
8 
+1
3.
3 
+1
8.
0 
 
(7
.8
 ; 
8.
5)
 
(+
14
 ; 
+2
8)
 
(+
17
 ; 
+3
2)
 
(+
6 
; +
18
) 
(+
10
 ; 
+2
4)
 
(+
7 
; +
20
) 
(+
12
 ; 
+2
5)
 
A
ug
m
en
ta
tio
n 
in
de
x 
 
1.
29
  
+1
.9
  
+1
.8
 
+1
.0
 
+1
.9
 
+1
.0
 
+2
.4
 
 
(1
.2
7 
; 1
.3
1)
 
(0
 ; 
+3
) 
(0
 ; 
+4
) 
(-
1 
; +
2)
 
(0
 ; 
+3
) 
(-
1 
; +
3)
 
(+
1 
; +
4)
 
In
tim
a-
m
ed
ia
 th
ic
kn
es
s 
(m
m
) 
0.
76
  
+6
.9
 
+5
.9
 
+5
.1
 
+6
.5
 
+5
.3
 
+4
.8
 
 
(0
.7
5 
; 0
.7
8)
 
(+
3 
; +
11
) 
(+
2 
; +
10
) 
(+
2 
; +
8)
 
(+
3 
; +
10
) 
(+
2 
; +
9)
 
(+
2 
; +
8)
 
Pl
aq
ue
 th
ic
kn
es
s 
(m
m
) 
1.
83
  
+2
6.
6 
 
+3
3.
6 
+2
0.
5 
+2
6.
0 
+1
7.
1 
+2
4.
2 
 
(1
.4
6 
; 2
.2
9)
 
(+
5 
; +
53
) 
(+
10
 ; 
+6
2)
 
(0
 ; 
+4
5)
 
(+
4 
; +
53
) 
(-
5 
; +
44
) 
(+
3 
; +
49
) 
V
al
ue
s 
of
 t
he
 N
IM
A
 a
re
 p
re
se
nt
ed
 a
s 
ge
om
et
ri
c 
m
ea
ns
 a
nd
 9
5%
 C
I a
nd
 a
s 
pe
rc
en
ta
ge
 d
iff
er
en
ce
 c
om
pa
re
d 
to
 t
he
 r
ef
er
en
ce
 g
ro
up
 f
ol
lo
w
ed
 b
y 
95
%
 C
I. 
Th
e 
N
CE
P 
de
fin
it
io
n 
of
 t
he
 M
et
S 
w
as
 
us
ed
. P
ar
ti
ci
pa
nt
s 
w
it
ho
ut
 a
ny
 t
ra
it
s 
of
 t
he
 M
et
S 
ac
co
rd
in
g 
to
 a
ll 
th
re
e 
de
fin
it
io
ns
 p
re
se
nt
 w
er
e 
us
ed
 a
s 
th
e 
re
fe
re
nc
e 
gr
ou
p.
 A
ge
 a
dj
us
te
d 
va
lu
es
 o
f N
IM
A
 w
er
e 
us
ed
. 
 
Ta
bl
e 
3:
 T
he
 im
pa
ct
 o
f t
he
 M
et
S 
an
d 
th
e 
nu
m
be
r 
of
 t
ra
it
s 
(N
CE
P-
cr
ite
ri
a)
 o
n 
th
e 
ou
tc
om
es
 o
f t
he
 n
on
-in
va
si
ve
 m
ea
su
re
m
en
ts
 o
f a
th
er
os
cl
er
os
is
 
Va
lu
es
 o
f 
th
e 
N
IM
A
 a
re
 p
re
se
nt
ed
 a
s 
ge
om
et
ri
c 
m
ea
ns
 a
nd
 9
5%
 C
I a
nd
 a
s 
pe
rc
en
ta
ge
 d
iff
er
en
ce
 c
om
pa
re
d 
to
 t
he
 r
ef
er
en
ce
 g
ro
up
 f
ol
lo
w
ed
 b
y 
95
%
 C
I. 
Th
e 
N
CE
P 
de
fin
iti
on
 o
f 
th
e 
M
et
S 
w
as
 
us
ed
. P
ar
ti
ci
pa
nt
s 
w
it
ho
ut
 a
ny
 t
ra
it
s 
of
 t
he
 M
et
S 
ac
co
rd
in
g 
to
 a
ll 
th
re
e 
de
fin
it
io
ns
 p
re
se
nt
 w
er
e 
us
ed
 a
s 
th
e 
re
fe
re
nc
e 
gr
ou
p.
  A
ge
 a
dj
us
te
d 
va
lu
es
 o
f N
IM
A
 w
er
e 
us
ed
. 
 
 
 
Pe
rc
en
ta
ge
 c
ha
ng
e 
N
um
be
r 
of
 tr
ai
ts
 o
f t
he
 M
et
S 
 
M
en
 (N
=7
41
) 
Re
fe
re
nc
e 
gr
ou
p 
M
et
S 
N
CE
P 
1 
2 
3 
4 
5 
N
 
57
 
21
9 
19
5 
19
3 
13
8 
56
 
25
 
A
nk
le
-b
ra
ch
ia
l i
nd
ex
 a
t r
es
t 
1.
14
 
-5
.2
 
-1
.9
 
-2
.4
 
-4
.8
 
-4
.8
 
-9
.6
 
 
(1
.1
1 
; 1
.1
8)
 
(-
9 
; -
1)
 
(-
6 
; +
2)
  
(-
6 
; +
2)
  
(-
9 
; -
1)
 
(-
9 
; 0
) 
(-
15
 ; 
-4
) 
A
nk
le
-b
ra
ch
ia
l i
nd
ex
 a
ft
er
 e
xe
rc
is
e 
1.
09
 
-7
.7
 
+1
.2
 
0.
0 
-5
.2
 
-8
.3
 
-2
4.
5 
 
(1
.0
1 
; 1
.1
8)
 
(-
17
 ; 
+2
) 
(-
7 
; +
10
) 
(-
8 
; +
9)
  
(-
13
 ; 
+3
)  
(-
17
 ; 
+2
) 
(-
34
 ; 
-1
3)
 
Pu
ls
e 
w
av
e 
ve
lo
ci
ty
 (m
/s
) 
8.
5 
+2
2.
8 
+1
3.
7 
+1
5.
1 
+2
0.
7 
+2
6.
4 
+3
0.
9 
 
(8
.0
 ; 
8.
9)
 
(+
15
 ; 
+3
2)
 
(+
7 
; +
21
) 
(+
8 
; +
23
) 
(+
13
 ; 
+2
9)
 
(+
17
 ; 
+3
7)
 
(+
18
 ; 
+4
6)
 
A
ug
m
en
ta
tio
n 
in
de
x 
 
1.
18
 
+4
.8
 
+3
.0
 
+4
.0
 
+4
.4
 
+4
.5
 
+4
.3
 
 
(1
.1
6 
; 1
.2
0)
 
(+
3 
; +
7)
 
(+
1 
; +
5)
 
(+
2 
; +
6)
 
(+
2 
; +
6)
 
(+
2 
; +
7)
 
(+
1 
; +
8)
 
In
tim
a-
m
ed
ia
 th
ic
kn
es
s 
(m
m
) 
0.
80
 
+9
.3
  
+4
.2
 
+5
.8
 
+8
.5
 
+1
0.
8 
+1
2.
3 
 
(0
.7
8 
; 0
.8
3)
 
(+
5 
; +
13
) 
(+
1 
; +
8)
 
(+
2 
; +
10
) 
(+
4 
; +
13
) 
(+
6 
; +
16
) 
(+
6 
; +
19
) 
Pl
aq
ue
 th
ic
kn
es
s 
(m
m
) 
2.
08
 
+1
7.
6 
+2
0.
0 
+2
0.
4 
+1
3.
6 
+2
0.
7 
+2
9.
1 
 
(1
.7
1 
; 2
.5
4)
 
(-
2 
; +
41
) 
(0
 ; 
+4
4)
 
(+
1 
; +
44
) 
(-
5 
; +
36
) 
(-
1 
; +
48
) 
(+
3 
; +
62
) 
 
 
 
 
 
 
 
 
 
 
Pe
rc
en
ta
ge
 c
ha
ng
e 
N
um
be
r 
of
 tr
ai
ts
 o
f t
he
 M
et
S 
 
W
om
en
 (N
=7
65
) 
Re
fe
re
nc
e 
gr
ou
p 
M
et
S 
N
CE
P 
1 
2 
3 
4 
5 
N
 
74
 
20
5 
23
5 
16
7 
10
8 
74
 
23
 
A
nk
le
-b
ra
ch
ia
l i
nd
ex
 a
t r
es
t 
1.
12
  
-3
.1
  
-1
.6
 
-3
.2
 
-2
.8
 
-4
.0
 
-4
.2
 
 
(1
.1
1 
; 1
.1
4)
 
(-
6 
; -
1)
 
(-
4 
; +
1)
 
(-
5 
; -
1)
 
(-
5 
; 0
) 
(-
6;
 -1
) 
(-
8 
; -
1)
 
A
nk
le
-b
ra
ch
ia
l i
nd
ex
 a
ft
er
 e
xe
rc
is
e 
1.
13
  
-6
.6
 
-2
.0
 
-3
.2
 
-4
.8
 
-6
.7
 
-7
.2
 
 
(1
.1
1 
; 1
.1
5)
 
(-
11
 ; 
-2
)  
(-
6 
; +
2)
 
(-
7 
; +
1)
 
(-
9 
; 0
) 
(-
11
 ; 
-2
) 
(-
14
 ; 
0)
 
Pu
ls
e 
w
av
e 
ve
lo
ci
ty
 (m
/s
) 
8.
1 
+2
0.
5 
+6
.6
 
+1
2.
3 
+1
7.
9 
+2
3.
4 
+2
4.
0 
 
(7
.8
 ; 
8.
5)
 
(+
14
 ; 
+2
8)
 
(+
1 
; +
12
) 
(+
6 
; +
19
) 
(+
11
 ; 
+2
5)
 
(+
16
 ; 
+3
2)
 
(+
13
 ; 
+3
6)
 
A
ug
m
en
ta
tio
n 
in
de
x 
 
1.
29
  
+1
.9
  
+0
.9
 
+1
.2
 
+1
.6
 
+1
.7
 
+3
.8
 
 
(1
.2
7 
; 1
.3
1)
 
(0
 ; 
+3
) 
(-
1 
; +
2)
 
(0
 ; 
+3
) 
(0
 ; 
+3
) 
(0
 ; 
+4
) 
(+
1 
; +
7)
 
In
tim
a-
m
ed
ia
 th
ic
kn
es
s 
(m
m
) 
0.
76
  
+6
.9
 
+2
.2
 
+3
.7
 
+5
.9
 
+6
.4
 
+1
0.
1 
 
(0
.7
5 
; 0
.7
8)
 
(+
3 
; +
11
) 
(-
1 
; +
5)
 
(+
1 
; +
7)
 
(+
3 
; +
9)
 
(+
3 
; +
10
) 
(+
5 
; +
16
) 
Pl
aq
ue
 th
ic
kn
es
s 
(m
m
) 
1.
83
  
+2
6.
6 
 
+1
3.
0 
+1
3.
9 
+2
6.
5 
+2
4.
8 
+4
1.
0 
 
(1
.4
6 
; 2
.2
9)
 
(+
5 
; +
53
) 
(-
7 
; +
37
) 
(-
6 
; +
38
) 
(+
3 
; +
55
) 
(0
 ; 
+5
5)
 
(+
8 
; +
84
) 
Chapter 4 
 
68  
 
Table 4: Impact of the three different definitions of the MetS on the outcomes of the non-
invasive measurements of atherosclerosis 
  
Percentage change 
 
Men (N=741) 
Reference 
group MetS NCEP MetS IDF MetS WHO 
N 57 219 278 74 
Ankle-brachial index at rest 1.14 -5.2 -4.4 -6.7 
 
(1.11 ; 1.18) (-9 ; -1) (-8 ; -1) (-12 ; -1) 
Ankle-brachial index after exercise 1.09 -7.7 -4.4 -11.2 
 
(1.01 ; 1.18) (-17 ; +2) (-12 ; +4) (-22 ; +1) 
Pulse wave velocity (m/s) 8.5 +22.8 +20.6 +38.1 
 
(8.0 ; 8.9) (+15 ; +32) (+13 ; +29) (+27 ; +51) 
Augmentation index  1.18 +4.8 +4.3 +5.3 
 
(1.16 ; 1.20) (+3 ; +7) (+2 ; +6) (+3 ; +8) 
Intima-media thickness (mm) 0.80 +9.3  +8.7  +9.3  
 
(0.78 ; 0.83) (+5 ; +13) (+5 ; +13) (+5 ; +14) 
Plaque thickness (mm) 2.08 +17.6 +16.3 +23.3 
 
(1.71 ; 2.54) (-2 ; +41) (-1 ; +37) (+2 ; +49) 
  
Percentage change 
 
Women (N=765) 
Reference 
group MetS NCEP MetS IDF MetS WHO 
N 74 205 227 37 
Ankle-brachial index at rest 1.12  -3.1  -2.8 -4.4  
 
(1.11 ; 1.14) (-6 ; -1) (-5 ; 0) (-7 ; -1) 
Ankle-brachial index after exercise 1.13  -6.6 -6.0 -8.2 
 
(1.11 ; 1.15) (-11 ; -2)  (-10 ; -2)  (-13 ; -3)  
Pulse wave velocity (m/s) 8.1 +20.5 +19.1 +35.7 
 
(7.8 ; 8.5) (+14 ; +28) (+13 ; +26) (+25 ; +47) 
Augmentation index  1.29  +1.9  +1.6  +1.2  
 
(1.27 ; 1.31) (0 ; +3) (0 ; +3) (-1 ; +4) 
Intima-media thickness (mm) 0.76  +6.9 +6.5 +6.3 
 
(0.75 ; 0.78) (+3 ; +11) (+3 ; +10) (+3 ; +10) 
Plaque thickness (mm) 1.83  +26.6  +25.4  +46.5  
 
(1.46 ; 2.29) (+5 ; +53) (+4 ; +51) (+14 ; +89) 
Values of the NIMA are presented as geometric means and 95% CI and as percentage difference compared to the 
reference group followed by 95% CI. Participants without any traits of the MetS according to all three definitions 
present were used as the reference group. Age adjusted values of NIMA were used. 
 
 
 
Discussion        
 
The main outcomes of the present study are that both men and women with the MetS, 
regardless which definition was used, were characterized by increased subclinical 
atherosclerosis, as reflected by less favourable outcomes of all six non-invasive parameters of 
(subclinical) atherosclerosis. 
Most intriguingly, we show that the severity of subclinical atherosclerosis as measured by NIMA 
was related to the number of traits of the MetS present. Therefore, it seems more important to 
identify the individual traits and the number of traits of the MetS than to diagnose the MetS. 
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Impact of the diagnosis of the MetS on NIMA 
 
Both men and women with the MetS, regardless which definition was used, were characterized 
by increased arterial stiffness as reflected by increased PWV and AIx, increased IMT and thicker 
plaques, and lower ABI at rest and after exercise. This is the largest population-based study so 
far that measured six different parameters of subclinical atherosclerosis in relation to the MetS.   
 
The association between the diagnosis MetS and arterial stiffness has been studied before. The 
MetS was associated with PWV in a relatively small healthy subsample of the Finnish population, 
independent of other risk factors16. Maple-Brown et al. also reported this independent 
association of arterial stiffness as measured with PWV and AIx in a small sample of  Indigenous 
Australians15,17. Although different methods have been used for measuring PWV, the same 
results were found. Besides the study of Maple-Brown et al., other studies reported on the 
association between the MetS and AIx only in selected patient groups. In untreated hypertensive 
patients, the AIx was not influenced by the presence of the MetS20. In a population of 
normotensive subjects at risk for diabetes mellitus, AIx was not affected by increasing number of 
components of the MetS7 and in a cohort of treated hypertensive patients, AIx was also not 
modified by the presence of the MetS35. In our population-based study we show that the 
diagnosis MetS is associated with 20% increase in PWV, independent which definition of the 
MetS was used. The impact of the MetS on AIx is smaller than the impact on PWV, and was 
larger in men than in women. The augmentation index in women is already higher than in men, 
which might be an explanation for the smaller impact of the MetS in women. In addition, we 
show that the increase in arterial stiffness was not dependent on which of the different traits of 
the MetS was present. 
 
Several studies reported the association of IMT with the diagnosis MetS in larger population-
based studies. In a French population-based sample, the MetS predicted the number of plaques 
and IMT after adjustment for traditional risk factors11. The Atherosclerosis Risk In Communities 
study also reported the independent association of the MetS with IMT13.  Empana et al. reported 
that non-institutionalized elderly with the MetS had an altered structure of the carotid arteries 
compared to those without the MetS21.  A Japanese group even reported that the MetS had 
additive predictive impact on carotid atherosclerosis, although the MetS had no superiority to 
the Framingham Risk Score36. 
Few data are available on the association between the diagnosis MetS and the ABI at rest and 
after exercise. In the Dutch Second Manifestations of ARTerial disease study (N=502) the MetS 
was associated with advanced vascular damage, as measured with ABI at rest, but they only 
included patients with manifest vascular disease so it is unclear whether these result are the 
same in the general population18. 
 
In our study, all six non-invasive parameters of atherosclerosis were significantly associated with 
the MetS, independent of which definition was used. All three definitions of the MetS showed 
comparable relative impact on NIMA and adjustment for other major CV risk factors, including 
pack years of smoking and LDL-c, did not alter these results. These results indicate an increased 
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risk for CVD in participants diagnosed with the MetS. Our data supports previously published 
data and is complementary to these reports. In most studies only one or two NIMA were 
measured. The non-invasive measurements seem to reflect the damage of all risk factors 
together really well, but of course prospective data are needed to determine the predictive 
value of the NIMA in terms of cardiovascular risk.  
 
Some studies reported on differences in the effect of the diagnosis MetS on subclinical 
atherosclerosis between men and women. Two studies described the differences in effect of the 
MetS between the sexes in IMT and one described these differences in arterial stiffness in a 
population of treated hypertensive patients12,37,38. Very recently, Sipalä et al. showed that the 
MetS was independently of its traits associated with IMT in women but not in men, whereas the 
MetS was an independent determinant of IMT in both sexes in a population-based study of 
similar sample size and almost the same age-range (46-76 years) as our study39. In our study 
both men and women with the MetS had similarly increased PWV and IMT than men and 
women without any component of the MetS present, independent of which definition was used. 
Only the impact of the MetS and its traits on AIx was larger in men than in women. 
 
Impact of the number of traits of the MetS on the outcomes of NIMA  
 
Most intriguingly, the number of traits is strongly associated with the severity of subclinical 
atherosclerosis as all NIMA gradually deteriorated with increasing number of traits present. 
Deterioration of NIMA was already present with one or two traits present and further 
deteriorated when 4 or 5 components of the MetS were present. The impact of the individual 
traits on the outcomes of NIMA was comparable. So identifying the different components of the 
MetS seems more important than dichotomizing subjects with or without the MetS. In selected 
patient groups, the worsened outcomes of PWV, IMT, and ABI at rest with increasing number of 
components was shown before7,18,20,40. Also in healthy populations the increase of especially 
PWV has been studied before and some also studied IMT21-23,25. Almost all studies reported the 
increase in PWV and/or IMT by the number of components of zero, one, two and three or more 
components, but not of all five components of the MetS. Empana et al. added a group of four or 
more components in their analysis and a Dutch group showed, in patients with clinical manifest 
vascular disease, a gradual increase of the vascular damage, as measured with IMT and ABI at 
rest, with increasing number of components from zero to five18,21. 
In our study, the worsening of the outcomes in NIMA also proceeded after the presence of more 
than three components of the MetS. Our results show that even the presence of one or two 
components of the MetS already results in deterioration of NIMA. We believe that this is 
important information: a patient already has increased subclinical atherosclerosis when only one 
or two components of the MetS are present; so without fulfilling the diagnosis of the MetS, the 
patient is at increased risk of cardiovascular disease.  
 
In conclusion: We show that, regardless which definition was used, both men and women with 
the MetS were characterized by increased subclinical atherosclerosis, as measured with six 
different parameters of 4 non-invasive measurements, compared to participants without any 
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component of the three definitions of the MetS present. They had a lower ankle-brachial index 
at rest and after exercise, higher pulse wave velocity and augmentation index, thicker intima-
media thickness, and thicker plaques. Most intriguingly, the number of traits was strongly 
associated with the severity of subclinical atherosclerosis as all NIMA gradually deteriorated with 
increasing number of traits present; deterioration of NIMA was already present when one or two 
traits were present and further deteriorated when 4 or 5 traits of the MetS were present. 
Therefore, we conclude that, for cardiovascular risk prediction, it is more important to take into 
account the presence of each individual trait and the number of traits of the MetS than to 
diagnose the presence of the MetS. 
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Abstract  
 
Objective: Waist circumference is a clinical marker of obesity and an established risk factor for 
cardiovascular disease. Adiponectin, an adipocyte-derived hormone and new biomarker of 
obesity, was recently proposed as the missing link between obesity and increased cardiovascular 
(CV) risk. We evaluated waist and adiponectin in a middle-aged population-based cohort to 
compare the impact of both obesity-markers on subclinical atherosclerosis, in relation to other 
CV risk factors. 
 
Design, setting & subjects: Seven parameters of 4 non-invasive measurements of 
atherosclerosis (NIMA), as surrogate markers of (subclinical) atherosclerosis, were determined in 
1517 participants of the Nijmegen Biomedical Study, aged 50-70 years, who were drawn from 
the Dutch community.  
 
Results: Both men and women with a high waist (M>104cm; F>95cm) showed increased pulse 
wave velocity (PWV) (M:+9.4%; F:+8.3%) and thicker intima-media thickness (IMT) (M:+7.3%; 
F:+4.3%) and women also showed increased plaque thickness (+16.6%). After adjustment for 
other CV risk factors both men and women showed increased IMT (M:+4.8%; F:+2.8%) and men 
also showed increased PWV (+9.6%). Both men and women with a low adiponectin level (M<2.2 
mg/L; F< 3.5 mg/L) showed a decreased ankle-brachial index after exercise (M:-9.5%; F:-3.9%) 
and increased IMT (M:+3.7%; F:+3.6%) and women also showed increased PWV (+6.8%), but 
after adjustment for other CV risk factors low adiponectin level was no longer associated with 
deteriorated outcomes of NIMA. 
 
Conclusions: Waist circumference showed independent associations with non-invasive 
measurements of subclinical atherosclerosis, whereas the association of adiponectin level with 
subclinical atherosclerosis was not independent of other CV risk factors. Prospective studies are 
needed to elucidate if the atherogenic effect of a low adiponectin level is mediated by other CV 
risk factors and not by a low adiponectin level intrinsically.  
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Introduction 
 
Cardiovascular disease (CVD) is a major cause of death worldwide. Many risk factors have been 
identified which promote the atherosclerotic process, finally resulting in cardiovascular events. 
An important risk factor for atherosclerosis is obesity, especially abdominal obesity has been 
linked to an increased risk for CVD1, 2. Several different clinical measures of obesity are available, 
including body mass index (BMI), waist-to-hip ratio (WHR) and waist circumference (WC). WC is 
used in most definitions of the Metabolic Syndrome3, 4 and can easily be measured in clinical 
practice with a measuring tape. Recently adiponectin has been identified as a new biochemical 
marker of abdominal obesity.  Adiponectin is produced by fat cells and inversely related to 
abdominal fat accumulation. Low adiponectin levels have been associated with an increased risk 
for CVD5, 6, although other studies showed conflicting results7, 8. Adiponectin has been proposed 
to be the missing link between obesity and cardiovascular (CV) risk and could be an interesting 
tool in the assessment of CV risk prediction9
Before clinical events become manifest, subclinical atherosclerosis is already present. Several 
non-invasive measurements for the early detection of (subclinical) atherosclerosis have been 
developed in the past decades. Non-invasive measurements of atherosclerosis (NIMA) can 
identify patients at high risk for CVD
. 
10, so that preventive measures can be taken to delay the 
atherosclerotic process and to prevent CV events. Obesity, as measured with BMI, WHR, and 
WC, has been shown to be an independent predictor of subclinical atherosclerosis, although 
most studies were of small sample sizes and included only one or two NIMA11-13. Some studies 
have described the association of adiponectin with intima-media thickness (IMT)14, 15 or pulse 
wave velocity (PWV)16
Our objective was to evaluate waist circumference and adiponectin level in a relatively large 
middle-aged population-based cohort and to determine which of these markers of obesity 
showed the largest impact on subclinical atherosclerosis, in relation to other CV risk factors.  
 in the general population, but most studies were performed in selected, 
high-risk or healthy populations mostly of small sample sizes.  
 
 
Materials and methods 
 
Experimental protocol 
We included 1517 participants from the Nijmegen Biomedical Study (NBS) which is a population-
based survey as described before17. In total 2807 participants aged 50 to 70 years received an 
invitation including a questionnaire to participate in the present study. We received 2114 
completed questionnaires (response rate 75%) and 1517 of them finally participated in the 
current study (71.8% of the participants who returned the questionnaire and 54% of the eligible 
subjects). Clinical and biochemical characteristics were determined as described previously17. 
Plasma concentration of adiponectin was determined using enzyme-linked immunosorbent 
assays (Elisa development System, Duoset®, R&D Systems, Minneapolis, USA). All lipid-lowering 
medication, when used, was discontinued for four weeks prior to the measurements. All NIMA 
measurements were performed after an overnight fast or in the afternoon six hours after a 
standardized breakfast under highly standardized conditions. The methods of the non-invasive 
measurements were described in detail recently17
In short, peripheral arterial pressure waveforms were recorded by applanation tonometry at the 
radial artery and augmentation index (AIx) was calculated, using the commercially available 
SphygmoCor system version 7.1 (Atcor Medical, Sydney, Australia). Subsequently the waveforms 
of the right carotid and left femoral arteries were recorded, the travelled distance was 
measured, and PWV was calculated. AIx was acquired in 1369 subjects (90.9%) and PWV in 1479 
subjects (98.2%). 
 and can be found in the supplemental 
material. 
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Carotid IMT was determined using an AU5 Ultrasound machine (Esaote Biomedica, Genova, 
Italy) with a 7.5 MHz linear-array transducer. The mean IMT was calculated from the mean of all 
four measured segments of the distal common carotid artery: far wall left, near wall left, far wall 
right and near wall right. The mean far wall IMT was acquired in 1494 subjects (99.2%), and 
mean near wall IMT in 1478 subjects (98.1%). Subsequently the presence of plaque and plaque 
thickness in the common carotid, internal carotid, or external carotid artery or at the carotid 
bulbus were measured. The presence of plaque was defined as focal thickening of the wall of at 
least 1.5 x the mean IMT, according to the Mannheim intima-media thickness consensus18
Blood pressures at both arms and ankles were measured and the ankle-brachial index was 
calculated at rest (ABI at rest) and after exercise (ABI-ex). In total 1502 measurements of ABI at 
rest (99.7%) and 1469 measurements of ABI-ex (97.5%) were suitable for analysis. The Medical 
Ethics Committee of the Radboud University Nijmegen Medical Centre approved the study 
protocol (which is in accordance with the Declaration of Helsinki) and all participants provided 
written informed consent. 
. 
 
Statistical analyses 
Because of the well known differences in adiponectin levels and in WC between men and 
women19, 20
 
, all analyses were split according to gender. The clinical and biochemical 
characteristics as well as the crude outcomes of the NIMA for all quartiles of WC and 
adiponectin level were determined by linear regression analysis for continuous variables (by the 
STATA command regress) and with logistic regression analysis for dichotomous variables (by the 
STATA command logistic) (only top and bottom quartiles are presented to save space). Test for 
trend analysis was performed among all four quartiles. To be able to compare the relative 
impact of WC versus adiponectin level between all 7 NIMA parameters, the difference between 
the top and bottom quartiles is expressed as the percentage change (with 95%CI). The lowest 
quartile of WC and the highest quartile of adiponectin were used as the reference categories. 
Relative risk regression (log linear model) was used to determine the relative change in the 
presence of plaque.  To evaluate possible interaction we calculated the percentage change for 
combinations of WC and adiponectin. STATA 10.0 (StataCorp LP, Texas USA) was used to 
perform the analysis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 
Results 
 
Eleven participants were excluded from the analysis; 5 participants did not discontinue their 
lipid-lowering medication, 3 participants smoked and 3 participants had breakfast within 6 hours 
prior to the measurements. Of the remaining 1506 participants included in the analyses, 49.2% 
was male. The clinical and biochemical characteristics of the study population stratified by 
gender are provided in the supplemental material in Table I.  
 
Clinical and biochemical parameters by highest and lowest quartiles of WC and adiponectin level 
The clinical and biochemical characteristics are depicted in Table 1a and 1b by highest and 
lowest quartiles of WC and adiponectin level, stratified by gender, including p for trend among 
all four quartiles. In Table 1a we show that both men and women had a less favorable CV profile 
with increasing levels of waist; age and blood pressure increased and the prevalence of 
hypertension and in men the prevalence of CVD increased. Furthermore, participants were more 
obese and insulin resistant and they showed a more atherogenic lipid profile with increasing 
waist circumference. In Table 1b we show that with decreasing levels of adiponectin, both men 
and women had a more atherogenic lipid profile, an increased prevalence of CVD and they were 
more obese and insulin resistant. However, women were younger with decreasing levels of 
adiponectin and showed an increased prevalence of hypertension. 
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Outcomes of the non-invasive measurements of atherosclerosis  
 
In Table 2a and Table 2b the crude outcomes of NIMA are depicted by highest and lowest 
quartiles of WC and adiponectin level, stratified by gender, including p for trend among all four 
quartiles. As shown in Table 2a, with increasing waist, men showed a decrease in ABI after 
exercise and an increase in PWV, AIx and IMT, whereas women showed an increase in PWV, IMT, 
presence of plaque, and plaque thickness. In contrast, in Table 2b it is shown that with 
decreasing levels of adiponectin, both men and women only showed a decrease in ABI after 
exercise.  
 
Table 2a: Outcomes of NIMA by lowest and highest quartiles of waist circumference, stratified 
by gender. 
 
Men (N=742) 
 
Women (N=764) 
 
Waist circumference (cm) <93  >104  
 
< 81  > 95  
 
 
N=177 N=201 
p for 
trend 
N=176 N=200 
p for 
trend 
Ankle-brachial index at rest 1.12 (0.16) 1.10 (0.14) 0.404 1.10 (0.11) 1.08 (0.12) 0.039 
Ankle-brachial index after exercise 1.09 (0.21) 1.05 (0.23) 0.047 1.12 (0.14) 1.09 (0.15) 0.071 
Pulse wave velocity (m/s) 9.6 (4.5) 10.8 (3.1) 0.000 9.1 (2.2) 10.3 (2.8) 0.000 
Augmentation index  1.21 (0.09) 1.23 (0.09) 0.010 1.30 (0.08) 1.31 (0.07) 0.163 
Intima-media thickness (mm) 0.83 (0.11) 0.91 (0.16) 0.000 0.79 (0.11) 0.85 (0.12) 0.000 
Presence of plaque 72 (40.7%) 94 (46.8%) 0.154 47 (26.7%) 70 (34.8%) 0.016 
Plaque thickness (mm) 2.54 (1.22) 2.60 (1.00) 0.931 2.16 (0.77) 2.62 (0.88) 0.002 
Values of the non-invasive measurements are presented as means (SD) and the presence of plaque is presented as 
number followed by the percentage. P for trend among all four quartiles is presented. 
 
Table 2b: Outcomes of NIMA by highest and lowest quartiles of adiponectin level, stratified by 
gender. 
 Men (N=742)  Women (N=764)  
Adiponectin level (mg/l) >3.7  < 2.2 
 
> 6.3  < 3.5 
 
 
N=191 N=179 
p for 
trend 
N=194 N=181 
p for 
trend 
Ankle-brachial index at rest 1.12 (0.15) 1.10 (0.13) 0.602 1.09 (0.11) 1.09 (0.09) 0.964 
Ankle-brachial index after exercise 1.11 (0.21) 1.06 (0.24) 0.025 1.11 (0.13) 1.09 (0.16) 0.004 
Pulse wave velocity (m/s) 10.3 (3.0) 10.0 (2.5) 0.288 9.7 (2.2) 10.0 (2.7) 0.322 
Augmentation index  1.21 (0.09) 1.22 (0.08) 0.559 1.31 (0.07) 1.30 (0.07) 0.303 
Intima-media thickness (mm) 0.85 (0.12) 0.88 (0.18) 0.064 0.81 (0.09) 0.82 (0.12) 0.092 
Presence of plaque 80 (42.1%) 81 (45.3%) 0.569 60 (30.9%) 58 (32.0%) 0.762 
Plaque thickness (mm) 2.85 (1.14) 2.60 (1.09) 0.988 2.27 (0.77) 2.46 (0.87) 0.056 
Values of the non-invasive measurements are presented as means (SD) and the presence of plaque is presented as 
number followed by the percentage. P for trend among all four quartiles is presented. 
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Table 3a: Non-invasive measurement of atherosclerosis by lowest and highest quartiles of waist 
circumference. 
  
percentage change 
 MEN reference group model 1 model 2 model 3 
waist circumference (cm) < 93 > 104  > 104  > 104  
 
N=177 N=201 N=201 N=201 
Ankle-brachial index at rest 1.11 -1.3% -1.0% +0.8% 
 
(1.09 ; 1.14) (-4 ; +1) (-4 ; +2) (-2 ; +4) 
Ankle-brachial index after exercise 1.06 -1.4% +0.4% +6.5% 
 
(1.01 ; 1.11) (-9 ; +6) (-7 ; +9) (-2 ; +16) 
Pulse wave velocity (m/s) 9.3 +9.4% +10.7% +9.6% 
 
(9.0 ; 9.7) (+5 ; +14) (+6 ; +16) (+5 ; +15) 
Augmentation index  1.2 +1.2% +1.2% +0.5% 
 
(1.19 ; 1.22) (0 ; +3) (0 ; +3) (-1 ; +2) 
Intima-media thickness (mm) 0.82 +7.3% +6.8% +4.8% 
 
(0.81 ; 0.84) (+5; +10) (+4 ; +10) (+2 ; +8) 
Presence of plaque 72 (40.7%) +3.3% +1.8% -9.4% 
  
(-17 ; +29) (-17 ; +32) (-29 ; +15) 
Plaque thickness (mm) 2.33 +5.5% +5.5% +3.7% 
  (2.13 ; 2.55) (-5 ; +17) (-5 ; +17) (-7 ; +16) 
  
percentage change 
 WOMEN  reference group model 1 model 2 model 3 
waist circumference (cm) < 81 > 95  > 95  > 95 
 
N=176 N= 200 N= 200 N= 200 
Ankle-brachial index at rest 1.1 -1.2% -0.9% -0.3% 
 
(1.09 ; 1.11) (-3 ; +1) (-3 ; +1) (-2 ; +2) 
Ankle-brachial index after exercise 1.1 -1.6% -0.7% +0.3% 
 
(1.07 ; 1.14) (-5 ; +2) (-4 ; +3) (-4 ; +4) 
Pulse wave velocity (m/s) 8.8 +8.3% +7.4% +3.7% 
 
(8.5 ; 9.1) (+4 ; +13) (+3 ; +12) (-1 ; +8) 
Augmentation index  1.29 +0.6% +0.6% +0.6% 
 
(1.28 ; 1.31) (-1 ; +2) (-1 ; +2) (-1 ; +2) 
Intima-media thickness (mm) 0.79 +4.3% +4.1% +2.8% 
 
(0.77 ; 0.80) (+2 ; +7) (+2 ; +7) (+0.3 ; +5) 
Presence of plaque 47 (26.7%) +9.3% +7.5% +1.7% 
  
(-19 ; +47) (-21 ; +46) (-27 ; +41) 
Plaque thickness (mm) 2.03 +16.6% +13.8% +10.1% 
  (1.83 ; 2.25) (+3 ; +32) (+1 ; +29) (-4 ; +26) 
Values of the non-invasive measurements are presented as geometric means followed by 95% CI. Participants with a 
waist circumference in the bottom quartile are used as the reference group. The percentage change compared to the 
reference group is presented for the participants with a waist circumference in the top quartile. The impact of the 
presence of plaque is presented as relative risk ratio. Model 1 adjusted for age. Model 2 adjusted for age and 
adiponectin. Model 3 adjusted for age, adiponectin, high-density lipoprotein-cholesterol, apolipoprotein B, and fasting 
glucose level. 
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Table 3b: Non-invasive measurement of atherosclerosis by lowest and highest quartiles of 
adiponectin. 
  
percentage change 
 MEN reference group model 1 model 2 model 3 
Adiponectin level (mg/l) > 3.7 < 2.2 < 2.2 < 2.2 
 
N=190  N=179 N=179 N=179 
Ankle-brachial index at rest 1.12 -2.2% -2.2% -0.8% 
 
(1.10 ; 1.14) (-5 ; +1) (-5 ; +1) (-4 ; +2) 
Ankle-brachial index after exercise 1.08 -9.5% -9.9% -4.8% 
 
(1.03 ; 1.12) (-16 ; -2) (-17 ; -3) (-12 ; +3) 
Pulse wave velocity (m/s) 9.9 -0.6% -3.3% -3.5% 
 
(9.5 ; 10.3) (-5 ; +4) (-8 ; +1) (-8 ; +1) 
Augmentation index  1.21 +0.8% +0.6% +0.3% 
 
(1.20 ; 1.22) (-1 ; +2) (-1 ; +2) (-1 ; +2) 
Intima-media thickness (mm) 0.84 +3.7% +1.9% +0.5% 
 
(0.83 ; 0.86) (+1 ; +6) (-1 ; +5) (-2 ; +3) 
Presence of plaque 80 (42.1%) +10.6% +9.4% +5.6% 
  
(-11; +38) (-13 ; +38) (-17 ; +35) 
Plaque thickness (mm) 2.36 +3.8% +3.5% +3.6% 
  (2.16 ; 2.59) (-6 ; +15) (-7 ; +15) (-8 ; +16) 
  
percentage change 
 WOMEN reference group model 1 model 2 model 3 
Adiponectin level (mg/l) > 6.3  < 3.5  < 3.5 < 3.5  
 
N=194  N=181 N=181 N=181 
Ankle-brachial index at rest 1.1 -1.1% -0.6% -0.2% 
 
(1.08 ; 1.11) (-3 ; +1) (-2 ; +1) (-2 ; +2) 
Ankle-brachial index after exercise 1.11 -3.9% -3.6% -3.0% 
 
(1.08 ; 1.13) (-7 ; -1) (-7 ; 0) (-7 ; +1) 
Pulse wave velocity (m/s) 9.5 +6.8% +4.5% +2.2% 
 
(9.2 ; 9.8) (+2 ; +12) (0 ; +9) (-2 ; +7) 
Augmentation index  1.31 -0.1% -0.1% -0.1% 
 
(1.30 ; 1.32) (-1 ; +1) (-1 ; +1) (-1 ; +1) 
Intima-media thickness (mm) 0.8 +3.6% +2.4% +1.5% 
 
(0.79 ; 0.82) (+1 ; +6) (0 ; +5) (-1 ; +4) 
Presence of plaque 58 (32.0%) +22.6% +17.6% +11.5% 
  
(-8 ; +64) (-13 ; +59) (-20 ; +55) 
Plaque thickness (mm) 2.15 +10.7% +6.4% +3.5% 
  (1.98 ; 2.34) (-2 ; +24) (-6 ; +20) (-9 ; +18) 
Values of the non-invasive measurements are presented as geometric means followed by 95% CI. Participants with an 
adiponectin level in the top quartile are used as the reference group. The percentage change compared to the 
reference group is presented for the participants with an adiponectin level in the bottom quartile. The impact of the 
presence of plaque is presented as relative risk ratio. Model 1 adjusted for age. Model 2 adjusted for age and waist. 
Model 3 adjusted for age, waist, high-density lipoprotein-cholesterol, apolipoprotein B, and fasting glucose.  
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In Table 3a the percentage change in outcomes of NIMA after adjustment for age and other CV 
risk factors for high WC compared to the reference group are depicted, stratified by gender. In 
general, both men and women with a high waist showed deteriorated outcomes of age-adjusted 
NIMA compared to those with a low waist; both men and women with a high WC had an 
increased PWV and IMT and women also showed increased plaque thickness (model 1). 
Furthermore, a decreased ABI at rest and after exercise and more plaques were present, 
although these NIMA showed wide 95%CI. Adjustment for adiponectin level did not affect the 
results (model 2). After adjustment for other major CV risk factors, including high-density 
lipoprotein-cholesterol, apolipoprotein B, and fasting glucose level, in men the impact of high 
waist on PWV and IMT remained significant, although the impact on IMT decreased with 34%. In 
women, a high waist showed only significant impact on IMT after adjustment for other CV risk 
factors, the percentage change decreased with 35% (model 3). 
 
In Table 3b the percentage change in outcomes of NIMA are depicted when participants were 
stratified by quartiles of adiponectin level. In the age-adjusted model both men and women with 
a low adiponectin level showed a decreased ABI-ex and an increased IMT and women had an 
increased PWV compared to those with high adiponectin levels (model 1). After adjustment for 
WC, in men only the percentage change in ABI after exercise remained unchanged, whereas the 
impact on IMT decreased with almost 50% and was no longer significant. In women the 
percentage change in ABI after exercise, PWV, and IMT became borderline significant; the 
impact decreased with 8%, 34%, and 33% respectively (model 2). However, after adjustment for 
other major CV risk factors, the impact of low adiponectin level considerably declined and wider 
confidence intervals were observed and none of the NIMA showed significant deteriorated 
outcomes. Low adiponectin only showed impact on ABI after exercise, although the percentage 
change decreased with 50% in men and with 23% in women compared to the age-adjusted 
model (model 3). (P values are provided in the tables IIA and IIB in the supplemental material) 
 
 
Interaction between the effect of waist circumference and adiponectin level on NIMA  
In Table 4 the interaction between the effect of adiponectin level and WC is shown. Column A 
depicts the change in NIMA outcomes in participants with a high adiponectin level and a low WC 
compared to the reference group (low adiponectin and low WC). Neither in men nor in women 
the outcomes of NIMA differed between the groups having divergent adiponectin but similar 
low WC, suggesting a low impact of adiponectin level in participants with a low WC.  
In contrast, male participants with a high adiponectin and a high waist (column B) showed an 
increase in PWV, IMT, and the presence of plaque, whereas in women no differences in the 
outcomes of NIMA were observed compared to the reference group. Column C depicts the 
impact of both low adiponectin and high WC on the NIMA outcomes. Men with a low 
adiponectin and a high WC only showed increased IMT compared to the reference group, 
whereas women showed increased PWV, IMT and plaque thickness compared to the reference 
group, suggesting some interaction between the effects of adiponectin and WC on NIMA 
outcomes in women. 
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Table 4: Interaction between the effect of waist circumference and adiponectin level on the 
outcomes of the non-invasive measurements of atherosclerosis. 
MEN 
 
percentage change 
 
 
reference group A B C 
 
N=74 N=27 N=24 N=63 
 
high A, low W low A, low W high A, high W low A, high W 
Ankle-brachial index at rest 1.12 -0.2 -3.2 -3.3 
 
(1.08 ; 1.16) (-6 ; +6) (-9 ; +3) (-8 ; +1) 
Ankle-brachial index after exercise 1.09 -5.2 -6.2 -7.6 
 
(1.02 ; 1.17) (-17 ; +9) (-19 ; +8) (-17 ; +2) 
Pulse wave velocity (m/s) 9.5 -5.8 +16.9 +4.9 
 
(8.9 ; 10.1) (-16 ; +5) (+4 ; +31) (-4 ; +14) 
Augmentation index  1.2 +0.5 +3.8 +1.5 
 
(1.18 ; 1.22) (-3 ; +4) (0 ; +8) (-1 ; +4) 
Intima-media thickness (mm) 0.82 -2.5 +10.6 +11.6 
 
(0.80 ; 0.85) (-8 ; +4) (+4 ; +18) (+6 ; +17) 
Presence of plaque 28 (37.8%) +46.8 +65.2 +38.4 
  
(-6 ; +130) (+8 ; +153) (-5; +102) 
Plaque thickness (mm) 2.41 -0.8 -5.3 +0.4 
  (2.03 ; 2.87) (-23 ; +28)  (-27 ; +22) (-18 ; +23) 
     WOMEN 
 
percentage change 
 
 
 reference group A B C 
 
N=66 N=28 N=29 N=61 
 
high A, low W low A. low W high A. high W low A. high W 
Ankle-brachial index at rest 1.1 +0.1 -0.1 -1.6 
 
(1.08 ; 1.11) (-3 ; +4) (-3 ; +3) (-4 ; +1) 
Ankle-brachial index after exercise 1.12 -7.2 +1.6 -3.7 
 
(1.09 ; 1.14) (-15 ; +1) (-7 ; +11) (-10 ; +3) 
Pulse wave velocity (m/s) 8.9 -2.3 +6.5 +17.1 
 
(8.5 ; 9.4) (-12 ; +8) (-4 ; +18) (+8 ; +27) 
Augmentation index  1.3 -0.3 +1.2 +0.4 
 
(1.28 ; 1.31) (-3 ; +2) (-1 ; +4) (-2 ; +2) 
Intima-media thickness (mm) 0.81 -5.0 +3.0 +5.3 
 
(0.78 ; 0.83) (-10 ; 0) (-2 ; +9) (+1 ; +10) 
Presence of plaque 20 (30.3%) -29.3 +47.9 +24.4 
  
(-68 ; +57) (-14 ; +156) (-24 ; +103 ) 
Plaque thickness (mm) 2.08 -21.9 +14.7 +27.5 
  (1.79 ; 2.41) (-44 ; +9) (-11 ; +47) (+3 ; +58) 
Values of the non-invasive measurements are presented as geometric means followed by 95% CI. Participants with an 
adiponectin level in the top quartile and a waist circumference in the bottom quartile are used as the reference group. 
The percentage change compared to the reference group is presented for A: participants with a low adiponectin level 
(A) and low waist circumference (W); B participants with a high adiponectin level and a high waist circumference; C: 
participants with a low adiponectin level and a high waist circumference. The impact of the presence of plaque is 
presented as relative risk ratio.   
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Discussion   
 
The main finding of the present study was that a high WC was independently associated with 
subclinical atherosclerosis, as reflected by deteriorated outcomes of NIMA. Both men and 
women showed increased PWV and IMT and women showed an increased plaque thickness. 
After adjustment for other CV risk factors the same results were found in men, whereas in 
women the impact on PWV and plaque thickness declined. Participants with a low adiponectin 
level showed a decreased ABI after exercise and an increased IMT, and women also showed an 
increased PWV. However, the association of low adiponectin level with subclinical 
atherosclerosis was not independent of other major cardiovascular risk factors.   
 
The impact of waist circumference and adiponectin level on the outcomes of NIMA 
Our data showed increased subclinical atherosclerosis in both men and women with a high WC, 
as reflected by increased PWV, IMT and an increased plaque thickness in women, even after 
adjustment for other CV risk factors. These results are in line with and complementary to 
previous literature. Obesity, as measured with BMI, WHR, and/or WC, was associated with 
carotid IMT in postmenopausal Chinese women11. Visceral obesity determined by computed 
tomography has been linked to increased PWV13 in a cohort of 150 Korean women. In a 
Framingham Study of 1900 subjects (mean age 57 years) an age- and gender-adjusted odds of 56 
percent for increased maximal IMT was reported for participants with increased waist (>88 cm in 
females and >102 cm in males) compared to those with normal waist12
 
. We report an increase of 
4-7 percent in mean IMT. The larger percentage change in IMT with increasing obesity reported 
by Ingelsson et al. can partly be explained by the use of IMT as a dichotomous variable in the 
Framingham Study. Using dichotomized IMT, one should be aware that a mean percentage 
increase in IMT and the odds ratio or relative risk for a high IMT (dichotomous) are two very 
different effect measures that could be not directly compared to each other. In fact, the 
comparison is strongly dependent on the shape of the distributions of IMT across quartiles of 
waist. Even if there is perfectly normal distribution one would assume a higher percentage 
increase in the proportion of cases above a certain cut-off level (for instance the 80th percentile) 
than the percentage increase in mean IMT. Age- and gender-specific cut-off values should be 
used. Also the use of a different IMT parameter (maximal IMT in Framingham versus mean IMT 
in our study) will contribute to the difference in the size of effect of obesity on IMT. 
Furthermore, different scanning protocols were used; the maximal IMT in the Framingham study 
was a mean value of the maximal IMT in the distal common carotid artery, bulbus and in the 
internal carotid artery. The IMT in the bulbus and internal carotid artery are usually thicker than 
only using the IMT of the distal common carotid artery, which we used in our study.  
In line with our data, Lakka et al. reported a similar increase in mean IMT of 5 percent with 
increasing waist circumference, whereas the association with maximal IMT was not significant21. 
However, their follow-up data showed an increased maximal IMT with increasing obesity, 
whereas the association was not significant for mean IMT. There are some differences between 
the study of Lakka et al. and our study. Their population consisted of Finnish men aged 42 to 60 
years, living in an area known for high prevalence and incidence of atherosclerotic diseases, but 
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participants with CVD were excluded, whereas our study consisted of both men and women 
from the general population, aged 50 to 70 years old, including participants with prevalent CVD.  
Lakka et al. also reported on plaque thickness, using plaque height, defined as the difference 
between the maximal and the mean IMT, whereas in our study focal thickening of the walls were 
measured as plaques. Subsequently we divided the plaque thickness by the mean IMT and only if 
the ratio was ≥ 1.5, the thickening was marked as a plaque present and then the plaque 
thickness was made available for the analysis, as described in the Mannheim Intima-media 
thickness consensus18
 
. Lakka et al. reported no significant increase in plaque height with 
increasing obesity, whereas in our population women showed an increased plaque thickness 
with increasing waist circumference, whereas in men the increase in plaque thickness did not 
reach the level of significance. The results cannot be compared because different definitions 
were used for plaque thickness in these two studies in addition to population differences. In the 
Framingham study no data on the presence of plaques was available.  
With decreasing levels of adiponectin, participants showed a less favorable cardiovascular risk 
profile, although the difference was less definite than the differences we observed when 
participants were stratified by quartiles of WC. Despite unfavorable effects on CV risk profile, the 
impact of low adiponectin level was smaller than the impact of WC on PWV, IMT, and plaque 
thickness. However, the impact of low adiponectin level was larger on ABI after exercise and the 
presence of plaque, although the change in outcomes of NIMA due to low adiponectin levels was 
no longer significant after adjustment for other major cardiovascular risk factors. Previous 
studies in the general population reported the inverse relation between adiponectin level and 
one or two non-invasive measurements of atherosclerosis. Adiponectin was inversely correlated 
with IMT but not with presence of plaque in both men and women, in a relatively large (N=1515) 
middle-aged population at high individual risk, (participants of the Safety, tolerability, 
Pharmacokinetics and pharmacodynamic (SAPHIR) study) also after adjustment for other CV risk 
factors15. Nilsson et al. found the same association in men but not in women in a smaller middle-
aged population-based cohort and this association was attenuated after adjustment for other CV 
risk factors14.  In contrast, adiponectin level was not correlated with IMT in a healthy European 
cohort22. A few studies reported the negative association between adiponectin and PWV in the 
general population16, 23, 24. The association between adiponectin level and ABI has only been 
studied in patients with peripheral arterial disease and adiponectin level was associated with the 
severity of the disease25-27
 
.  
A high waist circumference was independently of other CV risk factors associated with 
subclinical atherosclerosis in this study, whereas the association of adiponectin with subclinical 
atherosclerosis was lost after adjustment for other CV risk factors. These results suggest that 
adiponectin is only a marker of subclinical atherosclerosis, but does not have a causal role in the 
deterioration of NIMA, but prospective studies are needed to elucidate any possible causal 
relation. A modest correlation between waist and adiponectin was found in our population, so 
colinearity might be an issue here. The analysis of interaction between waist and adiponectin 
showed that there was no significant interaction between the two variables in men. However, in 
women some interaction between the effect of WC and adiponectin was present. One could 
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argue that the group participants with a high WC and high adiponectin level may contain 
subjects who suffer from heart failure and in whom plasma adiponectin levels might be raised 
due to waisting. However, this was not apparent in our study population. 
 
In line with previous studies, the women in our study cohort showed higher levels of adiponectin 
than men, independent of obesity19, 20, 28. Nishizawa and colleagues reported that testosterone 
accounted for part of this difference29, but since these differences are already present in youth30 
and remain throughout ageing, other unknown mechanisms must be involved. The gender-
difference in correlation between adiponectin levels and CV risk factors is supported by some, 
but not all studies, as described before by Cnop et al.20. More recently, some studies reported 
similar associations of adiponectin with CV risk factors for men and women31, 32, whereas others 
described differences in these associations15
 
. In our study men had lower levels of adiponectin 
than women, but men and women showed comparable impact of adiponectin level on the 
clinical and biochemical characteristics. Furthermore, we report no difference in the impact of 
adiponectin levels on subclinical atherosclerosis between men and women. In women there 
seemed to be some interaction between the impact of waist and adiponectin on NIMA, but 
these results have to be regarded with care because of the small number of subjects in the 
interaction analysis. 
Strengths and limitations: There are a few limitations in our study. First of all this was a cross-
sectional evaluation, so we cannot argue on the possible causal role of waist circumference or 
adiponectin level on subclinical atherosclerosis. Unfortunately, we do not have data on the 
amount of visceral versus subcutaneous fat because a computed tomography scan was not 
performed in this study. Finally, the participants in our study were mainly white Caucasians aged 
50 to 70 years, and therefore the conclusions cannot simply be extrapolated to other ethnic or 
age groups. Nevertheless, we believe that our results are noteworthy. The impact of waist 
circumference versus adiponectin level on subclinical atherosclerosis has not been studied 
before in a large population-based cohort. Moreover, we studied the impact on not less than 
seven different non-invasive parameters of subclinical atherosclerosis in this large population-
based cohort, including both men and women with and without prevalent CVD, which is the 
population of interest for cardiovascular risk profiling. 
 
In summary, in our middle-aged population-based cohort, participants with a high waist 
circumference showed increased subclinical atherosclerosis, as reflected by a deterioration of 
the outcomes of NIMA, independent of other CV risk factors. In contrast, the association of 
adiponectin with subclinical atherosclerosis disappeared after adjustment for other CV risk 
factors. Prospective studies will be needed to elucidate the causal relation of a low adiponectin 
level on atherosclerosis. 
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Supplemental Material 
Materials and methods 
 
Study protocol  
All non-invasive measurements of atherosclerosis (NIMA) were performed after an overnight 
fast or in the afternoon six hours after a standardized breakfast. Participants were asked to 
abstain from caffeinated products and not to smoke for at least twelve hours before the visit. As 
published before there were no significant differences between measurements performed in the 
morning and afternoon after the measurement conditions had been standardized1. All 
measurements were taken with participants in supine position after at least 10 min rest in a 
temperature-controlled room (23-24°C)2
 
 and performed by well-trained and certified 
sonographers according to a highly standardized protocol.  
Pulse wave velocity and augmentation index  
Peripheral arterial pressure waveforms were recorded by applanation tonometry at the radial 
artery and augmentation index (AIx) was calculated, using the commercially available 
SphygmoCor system version 7.1 (Atcor Medical, Sydney. Australia) as described before3, 4. As AIx 
is influenced by heart rate5, an index normalized for heart rate of 75 beats per minute was used. 
To determine pulse wave velocity (PWV), pulse waveforms were recorded at two sites 
sequentially (right carotid artery and left femoral artery), and wave transit-time was calculated 
using the R-wave of  a simultaneously recorded ECG as a reference frame as described before4. 
All measurements had to meet the criteria of optimal quality as defined by the manufacturer. 
According to these standards, AIx was acquired in 1369 subjects (90.2%) and PWV in 1479 
subjects (97.5%). Reproducibility of the AIx and PWV was good, as has been reported in a 
previous study1
 
. The absolute difference for repeated measurements was 4.0 ± 4.0 % for AIx and 
0.63 ± 0.50 m/s for PWV. The mean ± SEM difference between the two measurements was 0.68 
± 0.86% for AIx and 0.19 ± 0.12 m/s for PWV. 
Intima-media thickness, the presence of plaque, and plaque thickness  
Carotid intima-media thickness (IMT) was determined using an AU5 Ultrasound machine (Esaote 
Biomedica, Genova, Italy) with a 7.5 MHz linear-array transducer as described before3, 6. Actual 
measurement of the IMT was performed off-line by the sonographer at the time of the 
examination, using semi-automatic edge-detection software (M’AthStd version 2.0, Metris, 
Argenteuil, France). Reproducibility of our IMT-measurements as investigated by the method of 
Bland and Altman has been reported before1.  The mean ± SEM difference was 0.003 ± 0.007 
mm. The mean IMT was calculated from the mean of all four measured segments of the distal 
common carotid artery: far wall left, near wall left, far wall right and near wall right. The mean 
far wall IMT was acquired in 1494 subjects (98.5%), and mean near wall IMT in 1478 subjects 
(97.4%).  Subsequently the presence of plaque and the thickness of plaques in the common 
carotid, internal carotid, or external carotid artery or at the carotid bulbus were measured. The 
presence of plaque was defined as focal thickening of the wall of at least 1.5 x the mean IMT, 
according to the Mannheim intima-media thickness consensus7
 
.  
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Ankle-brachial index 
The calculation of the ankle-brachial index (ABI) was performed as described before3
 
. In brief, 
resting blood pressures were measured at the left and right brachial artery and at the left and 
right posterior tibial and dorsalis pedis arteries using an 8 MHz hand-held Doppler probe 
(IMEXDOPCT+™, Biomedic Nederland B.V., Almere, The Netherlands). The highest of the two 
arm pressures was used to calculate ABI at rest for the posterior tibial and dorsalis pedis 
arteries. The lowest of the four ABIs was used in the analysis. In addition, participants were 
asked to perform a treadmill test for four minutes at a speed of 2 m/h and with an elevation of 
10%. Immediately after the exercise test blood pressures were recorded at the arm with the 
highest pressure at rest and at both ankles and ABI after exercise (ABI-ex) was calculated for 
both legs. The lowest ABI-ex was used in the analysis. In total 1502 measurements of ABI at rest 
(99.0%) and 1469 measurements of ABI-ex (96.8%) were suitable for analysis. 
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Table I: The clinical and biochemical characteristics of the participants of the NBS study. 
 
Men Women 
 
 
(N=742) (N=764) P value 
Clinical characteristics     
Age (y) 61.8 (6.0) 60.6 (5.8) < 0.001 
Pack years of smoking (y) 13.0 (17.9) 9.7 (14.5) < 0.001 
Current smokers 134 (18.1%) 140 (18.4%) 0.874 
Systolic blood pressure  (mmHg) 130.7 (14.5) 127.2 (16.0) < 0.001 
Diastolic blood pressure (mmHg) 81.0 (9.4) 75.2 (10.6) < 0.001 
Hypertension  313 (42.2) 261 (34.2) 0.001 
Anti-hypertensive  therapy 196 (26.4%) 202 (26.4%) 0.986 
Cardiovascular disease 117 (15.8%) 60 (7.9%) < 0.001 
Parameters of obesity 
  
Body mass index (kg/m2 26.9 (3.5) ) 26.5 (4.5) 0.003 
Waist circumference(cm) 99.5 (10.6) 89.4 (11.7) < 0.001 
Waist-to-hip ratio 0.95 (0.07) 0.85 (0.06) < 0.001 
Adiponectin (mg/l) 3.18 (1.54) 5.23 (2.57) < 0.001 
Lipid parameters 
  
Total cholesterol (mmol/l) 5.70 (1.04) 6.06 (1.04) < 0.001 
Triglycerides (mmol/l) 1.56 (0.94) 1.34 (0.67) < 0.001 
High-density lipoprotein-cholesterol (mmol/l) 1.27 (0.31) 1.55 (0.38) < 0.001 
Low-density lipoprotein-cholesterol (mmol/l) 3.77 (0.90) 3.94 (0.94) 0.001 
Apolipoprotein B (g/l) 1.02 (0.23) 1.02 (0.24) 0.715 
Lipid-lowering  therapy 138 (18.6%) 87 (11.4%) < 0.001 
Blood glucose and diabetes 
  
Fasting glucose (mmol/l) 5.4 (1.1) 5.1 (0.8) < 0.001 
Diabetes Mellitus type 2 53 (7.1%) 35 (4.6%) 0.009 
Continuous variables are presented as the mean followed by standard deviation (SD). Dichotomous variables are 
presented as N followed by percentage.  
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Table IIA: Non-invasive measurement of atherosclerosis by lowest and highest quartiles of waist 
circumference, including P values. 
 
reference percentage change 
   MEN group model 1 
 
model 2 
 
model 3 
 waist circumference (cm) < 93 > 104 
 
> 104 
 
> 104 
 
 
N=177 N=201 P N=201 P N=201 P 
Ankle-brachial index at rest 1.11 -1.3% 0.36 -1.0% 0.50 +0.8% 0.59 
 
(1.09 ; 1.14) (-4 ; +1) 
 
(-4 ; +2) 
 
(-2 ; +4) 
 Ankle-brachial index after exercise 1.06 -1.4% 0.72 +0.4% 0.91 +6.5% 0.13 
 
(1.01 ; 1.11) (-9 ; +6) 
 
(-7 ; +9) 
 
(-2 ; +16) 
 Pulse wave velocity (m/s) 9.3 +9.4% 0.00 +10.7% 0.00 +9.6% 0.00 
 
(9.0 ; 9.7) (+5 ; +14) 
 
(+6 ; +16) 
 
(+5 ; +15) 
 Augmentation index  1.20 +1.2% 0.09 +1.2% 0.10 +0.5% 0.51 
 
(1.19 ; 1.22) (0 ; +3) 
 
(0 ; +3) 
 
(-1 ; +2) 
 Intima-media thickness (mm) 0.82 +7.3% 0.00 +6.8% 0.00 +4.8% 0.00 
 
(0.81 ; 0.84) (+5; +10) 
 
(+4 ; +10) 
 
(+2 ; +8) 
 Presence of plaque 72 (40.7%) +3.3% 0.77 +1.8% 0.88 -9.4% 0.42 
  
(-17 ; +29) 
 
(-17 ; +32) 
 
(-29 ; +15) 
 Plaque thickness (mm) 2.33 +5.5% 0.30 +5.5% 0.31 +3.7% 0.52 
  (2.13 ; 2.55) (-5 ; +17)   (-5 ; +17)   (-7 ; +16)   
 
reference percentage change 
   WOMEN  group model 1 
 
model 2 
 
model 3 
 waist circumference (cm) < 81 > 95 
 
> 95 
 
> 95 
 
 
N=176 N= 200 P N= 200 P N= 200 P 
Ankle-brachial index at rest 1.10 -1.2% 0.16 -0.9% 0.30 -0.3% 0.74 
 
(1.09 ; 1.11) (-3 ; +1) 
 
(-3 ; +1) 
 
(-2 ; +2) 
 Ankle-brachial index after exercise 1.10 -1.6% 0.36 -0.7% 0.71 +0.3% 0.89 
 
(1.07 ; 1.14) (-5 ; +2) 
 
(-4 ; +3) 
 
(-4 ; +4) 
 Pulse wave velocity (m/s) 8.8 +8.3% 0.00 +7.4% 0.00 +3.7% 0.12 
 
(8.5 ; 9.1) (+4 ; +13) 
 
(+3 ; +12) 
 
(-1 ; +8) 
 Augmentation index  1.29 +0.6% 0.34 +0.6% 0.35 +0.6% 0.34 
 
(1.28 ; 1.31) (-1 ; +2) 
 
(-1 ; +2) 
 
(-1 ; +2) 
 Intima-media thickness (mm) 0.79 +4.3% 0.00 +4.1% 0.00 +2.8% 0.03 
 
(0.77 ; 0.80) (+2 ; +7) 
 
(+2 ; +7) 
 
(+0.3 ; +5) 
 Presence of plaque 47 (26.7%) +9.3% 0.56 +7.5% 0.65 +1.7% 0.92 
  
(-19 ; +47) 
 
(-21 ; +46) 
 
(-27 ; +41) 
 Plaque thickness (mm) 2.03 +16.6% 0.01 +13.8% 0.04 +10.1% 0.16 
  (1.83 ; 2.25) (+3 ; +32)   (+1 ; +29)   (-4 ; +26)   
Values of the non-invasive measurements are presented as geometric means followed by 95% CI. Participants with a 
waist circumference in the bottom quartile are used as the reference group. The percentage change compared to the 
reference group is presented for the participants with a waist circumference in the top quartile. The impact of the 
presence of plaque is presented as relative risk ratio. Model 1 adjusted for age. Model 2 adjusted for age and 
adiponectin. Model 3 adjusted for age, adiponectin, high-density lipoprotein-cholesterol, apolipoprotein B, and fasting 
glucose. 
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Table IIB: Non-invasive measurement of atherosclerosis by lowest and highest quartiles of 
adiponectin, including P values. 
 
reference percentage change 
   MEN group model 1 
 
model 2 
 
model 3 
 Adiponectin level (mg/l) > 3.7 < 2.2 
 
< 2.2 
 
< 2.2 
 
 
N=190  N=179 P N=179 P N=179 P 
Ankle-brachial index at rest 1.12 -2.2% 0.11 -2.2% 0.11 -0.8% 0.61 
 
(1.10 ; 1.14) (-5 ; +1) 
 
(-5 ; +1) 
 
(-4 ; +2) 
 Ankle-brachial index after exercise 1.08 -9.5% 0.01 -9.9% 0.01 -4.8% 0.24 
 
(1.03 ; 1.12) (-16 ; -2) 
 
(-17 ; -3) 
 
(-12 ; +3) 
 Pulse wave velocity (m/s) 9.9 -0.6% 0.79 -3.3% 0.16 -3.5% 0.14 
 
(9.5 ; 10.3) (-5 ; +4) 
 
(-8 ; +1) 
 
(-8 ; +1) 
 Augmentation index  1.21 +0.8% 0.23 +0.6% 0.40 +0.3% 0.69 
 
(1.20 ; 1.22) (-1 ; +2) 
 
(-1 ; +2) 
 
(-1 ; +2) 
 Intima-media thickness (mm) 0.84 +3.7% 0.01 +1.9% 0.15 +0.5% 0.73 
 
(0.83 ; 0.86) (+1 ; +6) 
 
(-1 ; +5) 
 
(-2 ; +3) 
 Presence of plaque 80 (42.1%) +10.6% 0.37 +9.4% 0.45 +5.6% 0.66 
  
(-11; +38) 
 
(-13 ; +38) 
 
(-17 ; +35) 
 Plaque thickness (mm) 2.36 +3.8% 0.47 +3.5% 0.52 +3.6% 0.55 
  (2.16 ; 2.59) (-6 ; +15)   (-7 ; +15)   (-8 ; +16)   
 
reference percentage change 
   WOMEN group model 1 
 
model 2 
 
model 3 
 Adiponectin level (mg/l) > 6.3  < 3.5  
 
< 3.5  
 
< 3.5  
 
 
N=194  N=181 P N=181 P N=181 P 
Ankle-brachial index at rest 1.1 -1.1% 0.18 -0.6% 0.50 -0.2% 0.84 
 
(1.08 ; 1.11) (-3 ; +1) 
 
(-2 ; +1) 
 
(-2 ; +2) 
 Ankle-brachial index after exercise 1.11 -3.9% 0.03 -3.6% 0.05 -3.0% 0.11 
 
(1.08 ; 1.13) (-7 ; -1) 
 
(-7 ; 0) 
 
(-7 ; +1) 
 Pulse wave velocity (m/s) 9.5 +6.8% 0.00 +4.5% 0.05 +2.2% 0.32 
 
(9.2 ; 9.8) (+2 ; +12) 
 
(0 ; +9) 
 
(-2 ; +7) 
 Augmentation index  1.31 -0.1% 0.84 -0.1% 0.85 -0.1% 0.89 
 
(1.30 ; 1.32) (-1 ; +1) 
 
(-1 ; +1) 
 
(-1 ; +1) 
 Intima-media thickness (mm) 0.8 +3.6% 0.00 +2.4% 0.05 +1.5% 0.22 
 
(0.79 ; 0.82) (+1 ; +6) 
 
(0 ; +5) 
 
(-1 ; +4) 
 Presence of plaque 58 (32.0%) +22.6% 0.17 +17.6% 0.29 +11.5% 0.52 
  
(-8 ; +64) 
 
(-13 ; +59) 
 
(-20 ; +55) 
 Plaque thickness (mm) 2.15 +10.7% 0.09 +6.4% 0.32 +3.5% 0.61 
  (1.98 ; 2.34) (-2 ; +24)   (-6 ; +20)   (-9 ; +18)   
Values of the non-invasive measurements are presented as geometric means followed by 95% CI. Participants with an 
adiponectin level in the top quartile are used as the reference group. The percentage change compared to the 
reference group is presented for the participants with an adiponectin level in the bottom quartile. The impact of the 
presence of plaque is presented as relative risk ratio. Model 1 adjusted for age. Model 2 adjusted for age and waist. 
Model 3 adjusted for age, waist, high-density lipoprotein-cholesterol, apolipoprotein B, and fasting glucose.  
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Abstract  
 
Aim: To compare apolipoprotein B (apoB), non-high-density lipoprotein-cholesterol (non-HDL-c), 
and low-density lipoprotein-cholesterol (LDL-c) in identifying individuals with a worsened 
cardiovascular (CV) risk profile, including a panel of subclinical atherosclerosis measurements 
and prevalent cardiovascular disease (CVD) in a Dutch population-based cohort.  
 
Methods & results: Clinical, biochemical, and 10 non-invasive parameters of subclinical 
atherosclerosis were determined in 1517 individuals, aged 50 to70 years. Both men and women 
with increasing levels of apoB and non-HDL-c were more obese, had higher blood pressure and 
fasting glucose levels, and a more atherogenic lipid profile. Furthermore, compared to the 
reference group (composed of those with apoB, non-HDL-c and LDL-c levels in the bottom 
quartiles), participants with high apoB and non-HDL-c showed a lower ABI at rest (-3.5% and -
3.1%) and after exercise (-6.3% and -4.7%), a thicker IMT (+5.7% and +5.3%) and more plaques 
(+54.2% and +54.3%). In addition they also showed increased stiffness parameters (e.g. PWV 
both +3.6%). Less clear differences in CV risk profile and subclinical atherosclerosis parameters 
were observed when participants were stratified by LDL-c level. Furthermore, apoB but not LDL-
c detected prevalent CVD, and non-HDL-c only detected prevalent CVD in men. The 
discriminatory power for prevalent CVD expressed as area under the ROC-curve was 0.60  for 
apoB (P <0.001), 0.57 for non-HDL-c (P =0.001), and 0.54 for LDL-c (P =0.108). 
 
Conclusion: Our data support the use of apoB, and second best non-HDL-c, over and above LDL-c 
in identifying individuals from the general population with a worsened CV phenotype. 
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Introduction 
 
Dyslipidemia is an important cardiovascular (CV) risk factor. Low-density lipoprotein-cholesterol 
(LDL-c) is used as therapeutic target in the treatment of patients with cardiovascular disease 
(CVD) and individuals at high CV risk worldwide. In the last few years the focus has shifted more 
and more towards non-high-density lipoprotein-cholesterol (non-HDL-c) and apolipoprotein B 
(apoB) as risk markers for CVD and the use of apoB and non-HDL-c have been proposed as 
therapeutic targets1. Both apoB and non-HDL-c have been shown to be superior to LDL-c in the 
prediction of CVD, but there remains controversy whether apoB or non-HDL-c is a better 
predictor of CVD and which of them should preferably be used in clinical practice. Several 
studies showed the superiority of apoB over non-HDL-c in the prediction of CVD, whereas others 
showed the contrary, as recently summarized by Lau et al.2. In a recent meta-analysis, no 
difference between non-HDL-c and apoB was reported in predicting CVD3
Individuals at risk for CVD should be detected as early as possible. Approximately 50% of the 
individuals who suffered from a CV event were not at high risk based on the current guidelines
. ApoB and non-HDL-c 
are different measures: non-HDL reflects the atherogenic cholesterol mass, whereas apoB 
provides a precise estimate of the number of atherogenic particles in the circulation.   
4. 
By measuring the early stages of the atherosclerotic process or subclinical atherosclerosis, the 
detection of patients at risk may be improved. Several measurements have been developed to 
measure subclinical atherosclerosis non-invasively, such as carotid intima-media thickness (IMT), 
ankle-brachial index (ABI), and pulse wave velocity (PWV).  In patients with dyslipidemias, 
elevated lipid parameters have been associated with increased subclinical atherosclerosis and an 
increased risk for CVD5-8. However, data on the significance of apoB and non-HDL-c on subclinical 
atherosclerosis in the general population are limited. Previous studies were performed in 
relatively small, selected patient groups or healthy cohorts and mostly only one non-invasive 
measurement of subclinical atherosclerosis has been evaluated9-14
 
. The objective was to 
compare apoB, non-HDL-c, and LDL-c in identifying individuals with a worsened CV risk profile, 
including a panel of subclinical atherosclerosis measurements and prevalent CVD in a Dutch 
population-based cohort.  
 
 
Methods 
 
Experimental protocol  
 
In total 1517 participants from the Nijmegen Biomedical Study, aged 50 to 70 years, were 
included. The NBS is a population-based survey as described before15,16. Clinical and biochemical 
parameters and 10 parameters of 4 non-invasive measurements of atherosclerosis (NIMA) were 
determined as described previously16
The Medical Ethics Committee of the Radboud University Nijmegen Medical Centre approved 
the study protocol (which is in accordance with the Declaration of Helsinki) and all participants 
provided written informed consent. 
 and a detailed description can be found in the online 
supplementary information. Non-HDL-c was calculated as total cholesterol (TC) minus high-
density lipoprotein-cholesterol (HDL-c). All lipid-lowering medication when used was 
discontinued for four weeks prior to the measurements. All NIMA were performed after an 
overnight fast or in the afternoon six hours after a standardized breakfast under highly 
standardized conditions.  
 
  
Chapter 6 
 
104 
 
Statistical analyses 
 
The clinical and biochemical characteristics of the study population are presented as top versus 
bottom quartiles of apoB, non-HDL-c , and LDL-c as means with the standard deviation(SD) for 
continuous variables and as N followed by the percentage for dichotomy variables, stratified by 
gender. P values for trends among all four quartiles were calculated.  To compare the relative 
impact of apoB, non-HDL-c, and LDL-c on all NIMA parameters, we calculated the percentage 
change (with 95%CI) in outcomes of NIMA between the top quartiles and the reference group. 
The reference group is composed of participants with apoB, non-HDL-c and LDL-c levels in the 
bottom quartiles (apoB: M:<0.85g/l; F:<0.87g/l; non-HDL-c: M:<3.73mmol/l; F:<3.80mmol/l; LDL-
c: M:<3.19mmol/l; F:<3.31mmol/l). Relative risk regression (log linear model) was used to 
determine the relative change in the presence of plaque compared to the reference group. In 
addition, the percentage change in NIMA for the top quartiles versus the reference group was 
calculated after adjustment for other major CV risk factors, including HDL-c, waist 
circumference, fasting glucose, pulse pressure, and pack years of smoking. To determine the 
discriminatory power of apoB, non-HDL-c, and LDL-c levels for prevalent CVD, the area under the 
receiver operating characteristic (ROC) curves (AUC) were determined. Relative risk regression 
(log linear model) was used to determine the relative risk for apoB, non-HDL-c, and LDL-c top 
versus bottom quartiles. P values of < 0.05 (two-sided) were considered significant. All analyses 
were performed for men and women separately or standardized for age and gender using STATA 
10.0(StataCorp LP, Texas USA).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
 
 
 
Results 
 
Clinical and biochemical characteristics 
 
Table 1 (1a men and 1b women) summarizes the clinical and biochemical characteristics of the 
study population top and bottom quartiles of ApoB, non-HDL-c, and LDL-c, including P values for 
trends among all four quartiles. Both men and women showed a worsening cardiovascular risk 
profile with increasing ApoB and non-HDL-c levels, as reflected by increasing obesity and blood 
pressure parameters and an increasing fasting glucose level. As expected, these participants also 
had an increasing atherogenic lipid profile; they showed increasing levels of total cholesterol, 
triglycerides, LDL-c, and decreasing HDL-c levels and an increasing number of participants 
received lipid-lowering therapy. Women were older and showed an increasing prevalence of 
diabetes mellitus type 2, whereas men had more pack years of smoking with increasing levels of 
apoB and non-HDL-c. In addition, both men and women with increasing apoB, but only men with 
increasing non-HDL-c showed an increased prevalence of CVD.  When participants were 
stratified by quartiles of LDL-c, less explicit deterioration in cardiovascular risk profile was 
observed among quartiles, especially in men. Men only showed increasing diastolic blood 
pressure and an increasing atherogenic lipid profile, however, no differences in HDL-c levels 
were observed. Women with increasing levels of LDL-c were characterized by an older age, 
increasing obesity parameters and fasting glucose levels, and an increasing prevalence of 
hypertension. However, no increased prevalence of CVD was observed in both men and women 
with increasing levels of LDL-c.  
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Impact of apoB, non-HDL-c, and LDL-c on the outcomes of NIMA  
 
In Table 2 the impact of apoB, non-HDL-c, and LDL-c level on age- and gender-adjusted outcomes of 
NIMA is expressed as percentage change with 95%CI for the top quartiles versus the reference group 
(crude outcomes of NIMA are available in the online supplemental information). Participants with 
apoB levels in the top quartile ( ≥1.16 g/l) showed deteriorated outcomes of all NIMA compared to 
the reference group, except for plaque thickness. They had a lower ABI at rest and after exercise        
(-3.5% and -6.3%, respectively), a thicker IMT (+5.7%), and they had 54.2% more carotid plaques 
compared to the reference group. In addition, all stiffness parameters were increased (PWV +3.6%, 
augmentation index (AIx) +1.6%, central augmented pressure (CAP) +9.9%, central systolic pressure 
(CSP) +3.2%, and central diastolic pressure (CDP) +2.8%). After adjustment for other major CV risk 
factors, including HDL-c, fasting glucose, waist circumference, pulse pressure, and pack years of 
smoking, the impact of apoB on subclinical atherosclerosis declined. 
 
Participants with non-HDL-c levels in the top quartile ( ≥5.1 mmol/l) also showed deteriorated 
outcomes of most NIMA parameters compared to the reference group, except for plaque thickness 
and CAP. They had lower ABI at rest and after exercise (-3.1% and -4.7%, respectively), a thicker IMT 
(+5.3%), and 54.3% more carotid plaques compared to the reference group. Stiffness parameters 
were also increased, except for CAP (PWV +3.6%, AIx +1.4%, CSP +3.2%, and CDP +3.9%). After 
adjustment for the other major CV risk factors, the impact of non-HDL-c on subclinical atherosclerosis 
declined. 
 
Participants with LDL-c levels in the top quartile (M: ≥4.31 mmol/l; F: ≥4.53 mmol/l) only showed a 
borderline significant lower ABI at rest (-2.7%), a thicker IMT (+4.1%), and more carotid plaques 
(+43.1%) compared to the reference group. Three out of five stiffness parameters were also 
increased (AIx +1.2%, CSP +2.9%, and CDP +4.1%). Adjustment for other major CV risk factors did not 
significantly change the results. 
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Table 2: Impact of a ApoB, non-HDL-c, and LDL-c levels in the top quartiles on the age- and gender-
adjusted outcomes of non-invasive measurements of atherosclerosis in participants of the Nijmegen 
Biomedical Study, a Dutch population-based cohort, aged 50 to 70 years. 
 
reference group 
ApoB  
(g/l) 
M & F ≥1.16 
non-HDL-c 
(mmol/l) 
M & F ≥5.1 
LDL-c (mmol/l) 
M ≥4.31; 
F≥4.53 
 
N=261 N=383 N=378 N=377 
Ankle-brachial index  at rest 1.11 -3.5% -3.1% -2.7% 
 
1.10 ; 1.13 -5.2 ; -1.5 -4.8 ; -1.3 -4.4 ; -0.01 
Adjusted model 
 
-2.4% -2.3% -2.3% 
  
-4.3 ; -0.5 -4.1 ; -0.01 -4.1 ; -0.01 
Ankle-brachial index after exercise 1.09 -6.3% -4.7% -4.0% 
 
1.06 ; 1.13 -10.9 ; -1.6 -9.0 ; -0.01 -8.4 ; +0.1 
Adjusted model 
 
-4.4% -3.7% -3.3% 
  
-9.1 ;+ 0.6 -8.2 ; +1.0 -7.7 ; +1.3 
Intima-media thickness (mm) 0.81 +5.7% +5.3% + 4.1% 
 
0.79 ; 0.82 +3.6 ; +7.7 +3.4 ; +7.3 +2.4 ; +5.8 
Adjusted model 
 
+3.6% +3.8% +3.5% 
  
+1.7 ; +5.7 +1.8 ; +5.7 +1.6 ; +5.4 
Presence of plaque  71 +54.2% +54.3% + 43.1% 
 
27.2% +24.8 ; +90.4 +25.2 ; +90.0 +15.6 ; +77.0 
Adjusted model 
 
+48.0% +48.9% +40.9% 
  
+19.4 ; +83.4 +20.8 ; +83.5 +14.3 ; +73.7 
Plaque thickness (mm) 2.26 +6.5% +2.1% -0.3% 
 
2.09 ; 2.44 -2.5 ; +16.2 -6.4 ; +11.3 -8.1 ; +8.2 
Adjusted model 
 
+3.7% -0.1% +0.4% 
  
-5.5 ; +13.7 -9.4 ; +8.3 -8.3 ; +9.7 
Pulse wave velocity (m/s) 9.3 +3.6% +3.6% +2.3% 
 
9.0 ; 9.6 +0.2 ; +7.1 +0.2 ; +7.1 -1.1 ; +5.8 
Adjusted model 
 
+1.0% +2.2% +1.3% 
  
-2.3 ; +4.5 -1.1 ; +5.6 -1.9 ; +4.6 
Augmentation index 1.25 +1.6% +1.4% +1.2% 
 
1.24 ; 1.26 +0.7 ; +2.5 +0.5 ; +2.3 +0.2 ; +2.1 
Adjusted model 
 
+1.6% +1.4% +1.1% 
  
+0.7 ; +2.6 +0.5 ; +2.3 +0.2 ; +2.1 
Central augmented pressure (mmHg) 12.5 +9.9% +4.8% +3.2% 
 
11.7 ; 13.3 +1.9 ; +18.4 -2.9 ; +13.2 -4.5 ; +11.5 
Adjusted model 
 
+7.7% +4.5% +3.1% 
  
+0.1 ; +16.1 -2.9 ; +12.6 -4.1 ; +11.0 
Central systolic pressure (mmHg) 122 +3.2% +3.2% +2.9% 
 
120.1 ; 123.9 +1.2 ; +5.2 +1.3 ; +5.1 +0.9 ; +4.8 
Adjusted model 
 
+2.1% +2.5% +2.4% 
  
+0.3 ; +3.8 +0.8 ; +4.2 +0.8 ; +4.1 
Central diastolic pressure (mmHg) 78.8 +2.8% +3.9% +4.1% 
 
77.5 ; 80.1 +0.7 ; +5.0 +1.9 ; +6.1 +2.0 ; +6.1 
Adjusted model 
 
+2.8% +3.9% +3.8% 
  
+0.5 ; +5.1 +1.7 ; +6.1 +1.8 ; +6.0 
ApoB denotes apolipoprotein B, non-HDL-c denotes non high-density lipoprotein-cholesterol; LDL-c denotes low-density 
lipoprotein-cholesterol. Values of the non-invasive measurements are presented as geometric means and 95% CI. 
Participants with apoB, non-HDL-c, and LDL-c levels in the bottom quartiles were used as the reference group. The 
percentage change in age- and gender-adjusted NIMA compared to the reference group is presented for the participants 
with apoB, non-HDL-c, and LDL-c levels in the top quartiles. The impact of the presence of plaque is presented as relative 
risk ratio. The adjusted model includes adjustment for high-density lipoprotein-cholesterol, waist circumference, fasting 
glucose, pulse pressure, and pack years of smoking.  
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ApoB, non-HDL-c, and LDL-c in relation to prevalent CVD   
 
To compare the discriminatory power of apoB, non-HDL-c and LDL-c for prevalent CVD, the AUC’s 
with 95% CI were calculated. In addition, relative risks (RR) top versus bottom quartiles were 
calculated. The results are depicted in Table 3. ApoB showed the largest AUC and the largest RR, non-
HDL-c was second best and LDL-c showed the lowest AUC and RR. After adjustment for non-HDL-c, 
the RR of apoB for prevalent CVD increased from 1.94 (1.33-2.85) to 2.04 (1.01-4.11), whereas after 
adjustment for apoB, the RR of non-HDL-c for prevalent CVD decreased from 1.70 (1.14-2.54) to 0.57 
(0.28-1.16). 
 
Table 3: Area under the Curve (AUC) and relative risk (RR) of prevalent CVD for apoB, non-HDL-c, and 
LDL-c.  
 
AUC P RR 95%CI 
Apolipoprotein B (g/l) 0.601 0.000 1.94 1.33-2.85 
Non-high-density lipoprotein-cholesterol (mmol/l)  0.574 0.001 1.70 1.14-2.54 
Low-density lipoprotein-cholesterol (mmol/l) 0.537 0.108 1.35 0.91-1.99 
AUC =Area under the Curve; RR =relative risk top versus bottom quartiles; CI=confidence intervals 
 
 
Discussion 
 
Compared to stratifying individuals by high LDL-c levels, stratifying subjects by high apoB or high non-
HDL-c levels resulted in the identification of more individuals with a worsened CV risk profile, 
including increased subclinical atherosclerosis, as reflected by deteriorated outcomes of nearly all 10 
NIMA parameters. Stratifying by high apoB identified men and women with an increased prevalence 
of CVD and non-HDL-c identified only men but not women with an increased prevalence of CVD. 
When individuals were stratified by high LDL-c no increased prevalence of CVD was detected in our 
population-based sample. These results are in line with some of the data from a meta-analysis 
recently published3. In our study the following minimal differences between apoB and non-HDL-c 
were observed. First, increasing levels of non-HDL-c did not show a significant increased prevalence 
of CVD in women, although there was a trend, whereas an increased prevalence of CVD was 
observed in both sexes with increasing apoB levels. Second, the discriminatory power for prevalent 
CVD was slightly higher for apoB than for non-HDL-c. Finally, overall, the percentage change in 
outcomes of NIMA was largest when participants were stratified by quartiles of apoB. Stratifying 
subjects by quartiles of non-HDL-c showed intermediate changes (some NIMA showed comparable 
changes compared to apoB) and when stratified by quartiles of LDL-c the smallest changes in 
outcomes of NIMA compared to the reference group were observed. These results show a slightly 
better reflection of the atherogenic influence of the number of atherogenic lipid particles (apoB) 
over the total of atherogenic cholesterol mass (non-HDL-c). After adjustment for other major CV risk 
factors the differences were less explicit. These results indicate that the accompanying other major 
CV risk factors seem to be important in the development of subclinical atherosclerosis. Early 
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detection of all CV risk factors is important and in our study apoB and non-HDL-c detected the 
individuals at increased CV risk better than LDL-c.  
These results are in contrast with other findings of the meta-analysis of the Emerging Risk Factor 
Collaboration (ERFC), who reported equal hazard ratios for non-HDL-c and LDL-c in predicting CVD3. A 
possible explanation might be that they included directly measured LDL-c in their meta-analysis 
whereas in our study LDL-c was estimated using the Friedewald method. We recognize that 
calculating LDL-c with the Friedewald method has limitations, since it cannot be applied when 
triglyceride level is higher than 4.52 mmol/l. On the other hand, the direct measurement of LDL-c 
also has its limitations. In specific patient groups, such as diabetes and kidney disease, questions 
have been raised regarding the reliability of the measurement17. The intra-assay variability of the 
direct measurement of LDL-c is also relatively large and much larger than for the apoB measurement, 
where apoB measurement is much more accurate, as recently described by Contois and collegues18. 
The fact that LDL-c was equivalent to non-HDL-c in the ERFC meta-analysis is at variance with most 
recent results and should raise concern as to the quality of the measurements. In that regard, it must 
be noted that many of the ERFC studies measured apoB using non-standardized assays. Especially 
from a practical point of view, apoB has its advantages over non-HDL-c, since the determination of 
only one parameter is preferable. Furthermore, apoB in combination with TC and TG can be used in 
clinical practice to diagnose dyslipoproteinemias19
 
.  
ApoB, non-HDL-c, and LDL-c are known to be highly correlated. In this study we have shown that 
despite this high correlation, the “predictive value” for prevalent CVD was considerably lower for 
LDL-c, which is in line with previous literature20. ApoB showed the largest relative risk, which is also in 
concordance with previous studies21,22. We report an AUC of 0.60 for apoB and 0.57 for non-HDL-c, 
both highly significant, whereas the AUC for LDL-c was 0.53 and not significant. Previous studies 
reported the same values for the AUC23-25
Our results are also in line with those reported by Simon et al. who studied the predictive value of 
apoB, non-HDL-c and LDL-c for the presence of plaque and coronary calcium score as measures of 
subclinical atherosclerosis in 723 men
.  
14. They also reported that apoB was the best predictor of 
extra-coronary plaques, non-HDL was the second best predictor and LDL-c showed the poorest 
results14. The predictive value of apoB for an increased IMT was shown before in healthy 
individuals11-13. In a French cross-sectional study among 993 randomly selected individual from the 
general population,  PWV was positively correlated with apoB26,  and in initially healthy 58-year-old 
men the apoB/apoA1 ratio was strongly associated with a low ABI27
Some limitations of the present study have to be addressed. First of all, this was a cross-
sectional analysis. Prospective data are needed to determine the predictive value of apoB, non-HDL-c 
levels, and NIMA for CVD in the general population. The participants in our Nijmegen Biomedical 
Study were mainly Caucasians and aged 50 to 70 years, so caution should be used in generalizing 
these results to other populations and age groups.  
.  
 
In conclusion, this is the first large population-based study in which the impact of apoB, non-HDL-c, 
and LDL-c on subclinical atherosclerosis, as measured with 10 parameters of NIMA was compared. 
Our data support the use of apoB, and second best non-HDL-c, over and above LDL-c in identifying 
individuals from the general population with a worsened CV phenotype.   
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Supplemental Material 
Materials and methods 
All participants filled out a questionnaire about their previous history of vascular disease, medication 
use, smoking, and exercise habits. CVD was defined as a reported myocardial infarction, transient 
ischaemic attack or stroke, peripheral arterial disease, coronary artery bypass or angioplasty in the 
past, or treated angina.  
 
Clinical evaluation and biochemical analysis 
Systolic and diastolic blood pressure was measured using an oscillometric sphygmomanometer 
(Criticon model no. 1846, Criticon Inc., Tampa, USA). Hypertension (HT) was defined when systolic 
blood pressure (SBP) was  ≥140 mmHg and/or diastolic blood pressure (DBP) was ≥ 90 mmHg or 
previously diagnosed and treated HT. Waist circumference was measured at the level of the 
umbilicus, hip circumference was measured at the level of the trochanter major and WHR was 
calculated. Weight and height were measured and BMI was calculated as body weight (in kilograms) 
divided by the square of height (in meters). Venous blood was drawn and plasma total cholesterol 
(TC), high density lipoprotein-cholesterol (HDL-c), serum triglycerides (TG) and glucose 
concentrations were determined using commercially available enzymatic reagents (AEROSET® 
System, Abbott, Chicago Illinois). Diabetes mellitus type 2 (DM 2) was defined when glucose level was 
≥ 7.0 mmol/L after an overnight fast or previously diagnosed and treated DM. Low density 
lipoprotein-cholesterol (LDL-c) levels were calculated with the Friedewald formula1. Total plasma 
apolipoprotein B (apoB) concentration was determined by immunonephelometry2
Study protocol  
.  
All NIMA measurements were performed after an overnight fast or in the afternoon six hours after a 
standardized breakfast. Participants were asked to abstain from caffeinated products and not to 
smoke for at least twelve hours before the visit. As published before there were no significant 
differences between measurements performed in the morning and afternoon after the 
measurement conditions had been standardized3. All measurements were taken with participants in 
supine position after at least 10 minutes of  rest in a temperature-controlled room (23-24° C)4
Pulse wave velocity and augmentation index  
 and 
performed by well-trained and certified sonographers according to a highly standardized protocol.  
Peripheral arterial pressure waveforms were recorded by applanation tonometry at the radial artery 
and augmentation index (AIx), central augmented pressure (CAP), central systolic pressure (CSP) and 
central diastolic pressure (CDP) were calculated, using the commercially available SphygmoCor 
system version 7.1 (Atcor Medical, Sydney, Australia) as described before5,6. As AIx is influenced by 
heart rate7, an index normalized for heart rate of 75 beats per minute was used. To determine pulse 
wave velocity (PWV), pulse waveforms were recorded at two sites sequentially (right carotid artery 
and left femoral artery), and wave transit-time was calculated using the R-wave of  a simultaneously 
recorded ECG as a reference frame as described before6. All measurements had to meet the criteria 
of optimal quality as defined by the manufacturer. According to these standards, AIx, CAP, CSP and 
CDP were acquired in 1469 subjects (96.8%) and PWV in 1476 subjects (97.3%). The reproducibility of 
the AIx and PWV technique was good, as reported in a previous study3. The absolute difference for 
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repeated measurements was 4.0 ± 4.0 % for AIx and 0.63 ± 0.50 m/s for PWV. The mean ± SEM 
difference between the two measurements was 0.68 ± 0.86% for AIx and 0.19 ± 0.12 m/s for PWV. 
Intima-media thickness, the presence of plaque, and plaque thickness  
Carotid IMT was determined using an AU5 Ultrasound machine (Esaote Biomedica, Genova, Italy) 
with a 7.5 MHz linear-array transducer as described before5,8. Actual measurement of the IMT was 
performed off-line by the sonographer at the time of the examination, using semi-automatic edge-
detection software (M’AthSTD version 2.0, Metris, Argenteuil, France). Reproducibility of our IMT-
measurements as investigated by the method of Bland and Altman has been reported before3.  The 
mean ± SEM difference was 0.003 ± 0.007 mm. The mean IMT was calculated from the mean of all 
four measured segments: far wall left, near wall left, far wall right, and near wall right of the final 
centimeter of the distal common carotid arteries. The mean far wall IMT was acquired in 1494 
subjects (98.5%), and mean near wall IMT in 1478 subjects (97.4%).  Subsequently the presence of 
plaque and the thickness of plaques in the common carotid, internal carotid, or external carotid 
artery or at the carotid bulbus were measured. The presence of plaque was defined as focal 
thickening of the wall of at least 1.5 x the mean IMT, according to the Mannheim intima-media 
thickness consensus9
Ankle-brachial index 
.  
The calculation of the ankle-brachial index was performed as described before5
 
. In brief, resting 
blood pressures were measured at the left and right brachial artery, the left and right posterior tibial 
and dorsalis pedis arteries using an 8 MHz hand-held Doppler probe (IMEXDOPCT+™, Biomedic, 
Almere, The Netherlands). The highest of the two arm pressures was used to calculate ABI at rest for 
the posterior tibial and dorsalis pedis arteries. The lowest of the four ABIs was used in the analysis. In 
addition, participants were asked to perform a treadmill test for four minutes at a speed of 2 m/h 
and with an elevation of 10%. Immediately after the exercise test blood pressures were recorded at 
the arm with the highest pressure at rest and at both ankles and ABI after exercise (ABI-ex) was 
calculated for both legs. The lowest ABI-ex was used in the analysis. In total 1502 measurements of 
ABI at rest (99.0%) and 1469 measurements of ABI-ex (96.8%) were suitable for analysis. 
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Abstract 
 
Background:  We applied a diagnostic algorithm using apolipoprotein B (apoB), triglycerides 
(TG), and total cholesterol (TC) to determine the prevalence of dyslipoproteinemias in the 
general population. We characterized the overall cardiovascular (CV) risk profiles, including 
arterial structure and function. 
 
Methods & Results: Clinical and biochemical characteristics and arterial structure and function 
were determined in 1517 individuals, aged 50 to70 years. In general, all dyslipoproteinemias 
were characterized by a worse CV risk profile and deteriorated outcomes of NIMA compared to 
those with normal apoB and TG levels (apoB < 1.2 g/l and TG < 1.5 mmol/l). The prevalence of 
hyperapoB-hyperTG was 15.1% and these individuals showed the most deteriorated atheroma-
related parameters; ankle-brachial index at rest (-3.5%) and after exercise (-9.8%), intima-media 
thickness (+5.5%), and more carotid plaques (+39.1%). The prevalence of normoapoB-hyperTG 
due to increased VLDL was 18.1% and 2.3% due to increased chylomicrons and VLDL and these 
groups normoapoB-hyperTG showed the most deteriorated stiffness parameters (e.g.pulse-
wave-velocity+7.6% and +5.2%, respectively). Adjustment for apoB affected differences in NIMA 
in the hyperapoB-hyperTG group, whereas adjustment for TG affected differences in NIMA in 
the normoapoB-hyperTG group.  
 
Conclusions: The overall prevalence of dyslipoproteinemias according to the algorithm was 
~40% in the Dutch population. The different dyslipoproteinemias showed a less favorable CV risk 
profile and deteriorated NIMA parameters, reflecting increased subclinical atherosclerosis.  
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Introduction 
 
Increased plasma cholesterol and/or triglycerides (TG) are almost always due to increased 
numbers of apolipoprotein B48 (apoB48) or apoB100 lipoprotein particles1. We recently 
demonstrated that all the major dyslipoproteinemias, with the exception of elevated lipoprotein 
(a), could be diagnosed by a simple algorithm based on the plasma levels of total cholesterol 
(TC), triglycerides (TG) and  apoB22
A variety of non-invasive measures of vascular abnormality (NIMA) have been developed. These 
address somewhat different aspects of arterial structure and function such as atherosclerosis 
versus arterial stiffness. Nevertheless, NIMA have repeatedly been shown to identify individuals 
at increased risk of cardiovascular disease (CVD)
. Correct diagnosis of the dyslipoproteinemias helps to define 
the need for lipid-lowering therapy as well as the type of therapy that is likely to succeed. 
Diagnosis may also identify dyslipoproteinemias with a genetic origin and so stimulate the 
identification of other affected family members. Finally, diagnosis provides an insight into the 
pathophysiological abnormalities so that the full range of associated changes in the plasma 
lipoproteins can be appreciated as well as other metabolic abnormalities that are known to 
commonly accompany those dyslipoproteinemias. There are no population-based estimates of 
the relative prevalence of the different dyslipoproteinemias using the algorithm.  
3-9. Moreover, there is a general presumption 
that a number of these non-invasive markers, such as carotid intima-media thickness (IMT), are 
direct markers of vascular disease and that the conventional risk factors are major determinants 
of the degree and extent of abnormalities in these non-invasive markers10-12
The objectives of the present study were to determine the prevalence of the 
dyslipoproteinemias according to the diagnostic algorithm in the general population and to 
characterize the overall cardiovascular (CV) risk profiles of participants with the various 
dyslipoproteinemias including the extent of abnormal arterial structure and function, as 
measured with a panel of non-invasive parameters.  
. Others, such as 
PWV might relate more directly to arterial stiffness and not be as directly related to the 
concentrations of the plasma lipoproteins.  
 
Materials and Methods 
Experimental protocol  
 
We included 1517 participants from the Nijmegen Biomedical Study (NBS), aged 50 to 70 years. 
The clinical and biochemical characteristics of the NBS, which is a population-based survey, have 
been described in detail previously13. Eleven participants were excluded from the analysis; 5 did 
not discontinue their lipid-lowering medication, 3 smoked and 3 had breakfast within 6 hours 
prior to the measurements. Of the remaining 1506, 49.2 percent were male. We classified 
participants according to the apoB/TC/TG diagnostic algorithm2, as depicted in Figure 1 (for a 
more detailed description see supplemental material). Any lipid-lowering medication had been 
discontinued for four weeks prior to the measurements. Pulse pressure (PP) was calculated by 
subtraction of diastolic blood pressure (DBP) from systolic blood pressure (SBP). The presence of 
the metabolic syndrome (MetS) was determined using the guidelines of the National Cholesterol 
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Education Program Adult Treatment III panel14.  Ten  NIMA parameters were measured, 
including ankle-brachial index (ABI) at rest and after exercise, carotid intima-media thickness 
(IMT), presence of plaque and plaque thickness at the distal common carotid arteries, pulse 
wave velocity (PWV), augmentation index (AIx), central augmented, systolic and diastolic 
pressure (CAP, CSP, and CDP, respectively). All measurements were performed under highly 
standardized conditions. The other methods of the clinical, biochemical and non-invasive 
measurements were described in detail recently15
Statistical analyses 
 and are available in the supplemental 
material. The Medical Ethics Committee of the Radboud University Nijmegen Medical Centre 
approved the study protocol (in accordance with the Declaration of Helsinki) and all participants 
provided written informed consent. 
 
T-test statistics were performed to determine differences in clinical and biochemical 
characteristics of the different dyslipoproteinemias compared to the reference group, composed 
of participants with normoapoB-normoTG (apoB <1.2 g/l; TG<1.5 mmol/l) and chi-square test 
was used when appropriate. To be able to compare the differences in outcomes of NIMA 
between the different dyslipoproteinemias, the percentage change in the outcomes of age-and 
gender-adjusted NIMA compared to the reference group were calculated, including 95 percent 
confidence intervals (95%CI). To correct for possible confounding effect of lipid-lowering 
therapy, these analyses were repeated after excluding participants on lipid-lowering therapy. 
The impact of apoB and TG on the NIMA outcomes was examined in the two largest groups, the 
normoapoB-hyperTG group and the hyperapoB-hyperTG group. To do so, the percentage 
changes in NIMA were calculated after adjustment for apoB and TG, respectively (model 1 and 2) 
and after adjustment for a combination of other major CV risk factors, including HDL-c, pack 
years of smoking, fasting glucose, waist circumference, and pulse pressure (model 3). Analyses 
were performed using STATA 10.0 (StataCorp LP, Texas USA).   
Fi
gu
re
 1
: T
he
 d
ia
gn
os
tic
 a
lg
or
ith
m
 fo
r 
dy
sl
ip
op
ro
te
in
em
ia
s 
ba
se
d 
on
 a
 b
as
ed
 o
n 
ap
ol
ip
op
ro
te
in
 B
, t
ri
gl
yc
er
id
es
 a
nd
 to
ta
l c
ho
le
st
er
ol
.  
Th
e 
al
go
ri
th
m
 fo
r 
dy
sl
ip
op
ro
te
in
em
ia
s 
w
as
 p
ub
lis
he
d 
be
fo
re
 in
 N
at
 C
lin
 P
ra
ct
 E
nd
oc
ri
no
l M
et
ab
.2
00
8;
 4
:6
08
-6
18
. 
N
or
m
oa
po
B 
< 
1.
2 
g/
l 
H
yp
er
ap
oB
 
≥ 
1.
2 
g/
l 
ap
oB
≥0
.7
5 
ap
oB
<0
.7
5 
Chapter 7 
 
122 
 
Results 
 
Prevalence of the dyslipoproteinemias in a sample from the general population 
 
Values for apoB, TC, and TG were available for 1501 of the 1506 study participants. A total of 894 
participants (59.6 percent) had normal apoB (<1.2 g/l) and normal TG levels (TG<1.5 mmol/l) and 
made up the reference group. Normal apoB levels in combination with increased plasma triglyceride 
levels were due to increased VLDL in 271 participants (18.1 percent) and due to increased 
chylomicrons and VLDL-remnants in 35 participants (2.3 percent). Fifteen point one percent (N=227) 
had hyperapoB-hyperTG due to increased VLDL and LDL and 4.9 percent (N=74) were hyperapoB-
normoTG due to increased LDL.   
 
Clinical and biochemical characteristics of the dyslipoproteinemias 
 
Table 1a (men) and 1b (women) detail the clinical and biochemical characteristics of the study 
population categorized by the dyslipoproteinemias.  Although the reference group had normal apoB 
and TG levels, the individuals in this group had other cardiovascular risk factors, including 
hypertension, current smoking, MetS, and diabetes mellitus, which may have contributed to the 
presence of CVD in 10.6 percent of the men and 6.3 percent of the women.  
Only 14 male subjects had normoapoB-hyperTG due to increased chylomicrons and VLDL-remnants. 
These men had more pack years of smoking, consumed more alcohol per week, and suffered more 
from hypertension compared to the reference group. In addition, 28.6 percent fulfilled the criteria of 
the MetS. Furthermore, an increased prevalence of CVD was found. Among 21 women with 
normoapoB-hyperTG due to increased chylomicrons and VLDL-remnants only an increased waist 
circumference, increased blood pressures, and an increased prevalence of the MetS was observed. 
None of these women had prevalent CVD. 
HyperapoB-normoTG due to increased LDL was observed in 30 men and 44 women. The men had 
more pack years of smoking and a sedentary life style, but otherwise were unremarkable; the 
women were older and had increased waist circumference compared to the reference group. Only 
43.3 percent of the men and 22.7 percent of the women were being treated with lipid-lowering 
medication, despite their marked abnormalities in lipid profile. 
Many participants were classified either as normoapoB-hyperTG due to increased VLDL (164 men, 
107 women) or hyperapoB-hyperTG due to increased VLDL and LDL (117 men, 110 women). Subjects 
in both groups showed a less favorable overall CV risk profile compared to the reference group. More 
were current smokers and both men and women had decreased HDL-c levels. In addition, there was 
an increased prevalence of the MetS (men over 50 percent and women over 60 percent). 
Furthermore, both men and women in both groups had an increased prevalence of CVD, although 
the difference compared to the reference group in women with normoapoB-hyperTG due to 
increased VLDL did not reach the level of significance.  
Similar results were found when participants on lipid-lowering therapy were excluded from the 
analyses (see Tables IA and IB in the supplemental information for men and women, respectively). 
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Outcomes of the non-invasive measurement of atherosclerosis in the different 
dyslipoproteinemias  
 
The percentage change in the age-and gender-adjusted outcomes of NIMA for the different 
dyslipoproteinemias compared to the reference group are depicted in Table 2. The unadjusted 
values of the NIMA for the different dyslipoproteinemias can be found in the supplemental 
information in Table IIA and IIB for men and women, respectively. 
There was evidence of deterioration of the age-and gender-adjusted NIMA in all subjects with 
dyslipoproteinemias compared to the reference group. Participants with hyperapoB-hyperTG 
due to increased VLDL and LDL showed the most deteriorated NIMA parameters that most 
directly relate to atheroma; a decreased ABI at rest (-3.5%) and after exercise (-9.8%),  a thicker 
IMT (+5.5%), and more carotid plaques (+39.1%). Participants with normoapoB-hyperTG due to 
increased VLDL showed intermediate changes in these parameters and participants with 
hyperapoB-normoTG due to increased LDL showed the smallest changes compared to the 
reference group, with only a borderline significant thicker IMT. Subjects with normoapoB-
hyperTG due to chylomicrons and VLDL did not show significant changes in atheroma-related 
NIMA parameters.  
In contrast, participants with normoapoB-hyperTG showed the largest differences in most 
parameters related to arterial stiffness. The difference in stiffness parameters compared to the 
reference group for subjects with normoapoB-hyperTG due to increased chylomicrons and VLDL-
remnants and subjects with normoapoB-hyperTG due to increased VLDL were +5.2% and +7.6% 
for PWV; +2.6% and +1.7% for AIx; +12.2% and +11.5% for CAP; +5.6% and +4.4% for CSP; and 
+7.8% and +2.4% for CDP, respectively. Participants with hyperapoB-hyperTG showed similar 
changes in PWV and CAP but smaller changes in the other stiffness parameters, whereas 
participants with hyperapoB-normoTG showed the smallest changes.  
 
Next, we determined the impact of apoB (model 1) and TG (model 2) on the outcomes of NIMA 
in the two major dyslipoproteinemias- normoapoB-hyperTG and hyperapoB-hyperTG- as well as 
the difference in outcomes of NIMA after adjustment for other major CV risk factors (model 3), 
including HDL-c, pack years of smoking, waist circumference, fasting glucose, and pulse pressure. 
The results of these adjusted models are depicted in Table 3.  In the hyperapoB-hyperTG group 
adjustment for apoB (model 1) resulted in less worse “atheroma” parameters compared to the 
reference group, whereas in the normoapoB-hyperTG group smaller effects were observed after 
adjustment for apoB. The differences in outcomes compared to the reference group after 
adjustment for apoB decreased for ABI at rest and after exercise (from -3.5% to -1.7% and -2.0% 
to -1.3%, respectively), IMT (from +5.5% to +2.6% and +3.5% to +2.8%, respectively). Also the 
increased presence of plaque in the hyperapoB-hyperTG group disappeared after adjustment for 
apoB. The difference in stiffness parameters in the normoapoB-hyperTG group compared to the 
reference group remained largely the same after adjustment for apoB, whereas in the 
hyperapoB-hyperTG group the differences in all stiffness parameters only slightly decreased, but 
all became non-significant. 
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Table 3: Percentage change in outcomes of NIMA for two largest groups of dyslipoproteinemias, 
including normoapoB-hyperTG due to increased VLDL and hyperapoB-hyperTG due to increased 
VLDL and LDL compared to participants with normoapoB-normoTG after adjustment for apoB 
(model 1), TG (model 2), and a combination of other major CV risk factors (model 3), including 
high-density lipoprotein-cholesterol, pack years of smoking, fasting glucose, waist 
circumference, and pulse pressure. 
 normoapoB hyperapoB  normoapoB hyperapoB 
 hyperTG hyperTG  hyperTG hyperTG 
Ankle-brachial index at rest -2.0%*  -3.5%* Pulse wave velocity +7.6%* +5.1%* 
 -3.4 ; -0.5 -5.0 ; -1.9  +4.5 ; +10.8 +1.9 ; +8.4 
Model 1: Apolipoprotein B -1.3% -1.7% Model 1: Apolipoprotein B +7.5%* +4.9% 
 -2.8 ; +0.3 -4.2 ; +0.8  +4.1 ; +10.9 -0.1 ; +10.1 
Model 2: Triglycerides -0.4% -1.6% Model 2: Triglycerides +1.6% -1.4% 
 -2.7 ; +1.9 -4.0 ; +0.9  -3.1 ; +6.5 -6.2 ; +3.8 
Model 3: CV risk factors -1.3% -2.6%* Model 3: CV risk factors +5.1%* +2.9% 
 -2.9 ; +0.3 -4.3 ; -1.0  +1.9 ; +8.5 -0.3 ; +6.2 
Ankle-brachial index after 
exercise -6.9%* -9.8%* 
Augmentation index 
 +1.7%* +1.5%* 
 -10.2 ; -3.6 -13.2 ; -1.9  +0.8 ; +2.5 +0.6 ; +2.5 
Model 1: apoB -6.5%* -8.5%* Model 1: Apolipoprotein B +1.4%* +0.9% 
 -9.9 ; -2.9 -14.1 ; -2.7  +0.5 ; +2.3 -0.6 ; +2.3 
Model 2: TG -6.1%* -6.5%* Model 2: Triglycerides +1.3%# +0.7% 
 -11.2 ; -0.6 -12.1 ; -0.6  0.0 ; +2.7 -0.7 ; +2.1 
Model 3: CVRF -6.3%* -8.2%* Model 3: CV risk factors +1.8%* +1.5%* 
 -9.9 ; -2.6 -12.0 ; -4.3  +0.9 ; +2.8 +0.5 ; +2.5 
Intima-media thickness +3.5%* +5.5%* Central augmented pressure +11.5%* +12.3%* 
 +2.0 ; +5.1 +3.8 ; +7.2  +4.0 ; +19.6 +4.3 ; +21.0 
Model 1: Apolipoprotein B +2.8%* +2.6%# Model 1: Apolipoprotein B +9.7%* +7.2% 
 +1.1 ; +4.4 0.0 ; +5.3  +1.8 ; +18.3 -4.8 ; +20.5 
Model 2: Triglycerides +2.1% +4.5%* Model 2: Triglycerides +4.1% +8.6% 
 -0.3 ; +4.6 +1.9 ; +7.2  -7.0 ; +16.5 -3.3 ; +21.9 
Model 3: CV risk factors +1.7%# +3.6%* Model 3: CV risk factors +11.7%* +12.1%* 
 0.0 ; +3.3 +1.8 ; +5.4  +3.9 ; +20.1 +4.1 ; +20.8 
Presence of plaque +6.1% +39.1%* Central systolic pressure +4.4%* +3.6%* 
 -10.0 ; +25.0 +18.8 ; +62.9  +2.7 ; +6.2 +1.7 ; +5.4 
Model 1: Apolipoprotein B -7.6% -1.9% Model 1: Apolipoprotein B +3.9%* +2.5% 
 -22.4 ; +10.0 -25.6 ; +29.4  +2.0 ; +5.8 -0.4 ; +5.4 
Model 2: Triglycerides -10.2% +27.5%* Model 2: Triglycerides -0.6% +2.3% 
 -30.5 ; +15.9 +2.3 ; +58.7  -3.2 ; +2.1 -0.5 ; +5.2 
Model 3: CV risk factors +0.9% +33.6%* Model 3: CV risk factors +2.9%* +2.3%* 
 -16.6 ; +22.0 +11.9 ; +59.5  +1.3 ; +4.6 +0.6 ; +4.0 
Plaque thickness -0.5% +5.1% Central diastolic pressure +3.7%* +2.4%* 
 -7.5 ; +7.0 -2.2 ; +13.0  +1.9 ; +5.6 +0.4 ; +4.4 
Model 1: Apolipoprotein B -0.8% +1.6% Model 1: Apolipoprotein B +3.2%* +2.2% 
 -0.8 ; +7.5 -10.2 ; +15.1  +1.3 ; +5.1 -0.9 ; +5.4 
Model 2: Triglycerides -4.3% +2.8% Model 2: Triglycerides -0.3% +2.5% 
 -14.8 ; +7.6 -7.9 ; +14.6  -3.1 ; +2.5 -0.5 ; +5.7 
Model 3: CV risk factors -5.6% +0.7% Model 3: CV risk factors +2.9%* +1.9% 
  -13.4 ; +2.9 -7.1 ; +9.1   +0.9 ; +5.0 -0.2 ; +4.1 
Age-and gender-adjusted NIMA are presented for the reference group (participants with apolipoprotein B levels < 1.2 g/l and 
triglycerides <1.5 mmol/l) as median with 95%CI. The percentage change in the age- and gender-adjusted outcomes of NIMA are 
presented with 95% CI compared to the reference group. Abbreviations as in Table 1. Model 1 adjusted for apolipoprotein B, model 2 
adjusted for triglycerides, model 3 adjusted for cardiovascular (CV) risk factors, including HDL-c, pack years of smoking, fasting 
glucose, waist circumference, and pulse pressure. * denotes P < 0.001, # denotes P=0.05. 
  
Chapter 7 
 
128 
 
After adjustment for TG (model 2), the difference in “atheroma” parameters in the normoapoB-
hyperTG group compared to the reference group decreased and was no longer significant for ABI 
at rest (from -2.0% to -0.4%) and IMT (+3.5% to +2.1%). However, in the hyperapoB-hyperTG 
group the difference in these “atheroma” parameters remained substantial; there was only a 
small reduction of the difference compared to the reference group. In both groups, the stiffness 
parameters were no longer significantly increased compared to the reference group after 
adjustment for TG, the impact of TG was slightly larger in the normoapoB-hyperTG group than in 
the hyperapoB-hyperTG group. 
After adjustment for the other major CV risk factors (model 3), the difference in ABI at rest, ABI 
after exercise, IMT, and the presence of plaque remained significant compared to the reference 
group in both groups, except for ABI at rest in the normoapoB-hyperTG group. The difference 
compared to the reference group was slightly reduced and larger for IMT in the normoapoB-
hyperTG group. In both groups the differences compared to the reference group in stiffness 
parameters were also slightly reduced but remained significantly different after adjustment for 
the other major CV risk factors. 
 
 
Discussion 
 
This is the first population-based study applying the diagnostic algorithm for 
dyslipoproteinemias based on apolipoprotein B, triglycerides, and total cholesterol. Previous 
surveys have been based only on lipids and not included apoB. The overall prevalence of 
dyslipoproteinemias according to the algorithm was ~40 percent. All dyslipoproteinemias were 
characterized by a less favorable CV risk profile and abnormal arterial structure and function, 
reflecting increased subclinical atherosclerosis compared to normolipidemic subjects.   
 
The prevalence of the dyslipoproteinemias in the Dutch population 
 
In our population-based cohort we report a prevalence of 2.3 percent for normoapoB-hyperTG 
due to increased chylomicrons and VLDL remnants. This represents the phenotype of familial 
dysbetalipoproteinemia and the prevalence we have observed is higher than previous studies 
that have reported a values of 0.6-1.0 percent for the hereditary familial 
dysbetalipoproteinemia16,17
The prevalence of hyperapoB-normoTG due to increased LDL in our study-population was 4.9 
percent. Moreover, only a portion of these subjects will have familial hypercholesterolemia. Our 
data confirm that isolated hypercholesterolemia is one of the most uncommon 
dyslipoproteinemias
. In our study, the most obvious secondary provoking factors were 
obesity and in men, increased alcohol intake (Figure 1 and Table 1a).  
18
By contrast, the prevalence of normoapoB-hyperTG due to increased VLDL was 18.1 percent. 
These participants showed an increased prevalence of obesity, hypertension, diabetes mellitus 
type 2, and the MetS, all known as secondary causes of an increase in VLDL. Importantly, these 
other risk factors independently increase the risk of vascular disease. This prevalence is 
comparable with the prevalence of hypertriglyceridemia in the general population reported by 
Hopkins et al. in 2003
.  
19
The prevalence of hyperapoB-hyperTG due to high VLDL and LDL was 15.1 percent. The most 
common primary cause of hyperapoB-hyperTG is familial combined hyperlipidemia, with a 
prevalence in the Western society estimated to be 5-6 percent
. 
19
An increased risk for CVD in familial combined hyperlipidemia was demonstrated in a 20-year 
follow-up study, whereas risk was not significantly increased in familial hypertriglyceridemia
. Within our group of 
hyperapoB-hyperTG, 43.6 percent reported a family history of dyslipidemia and almost fifty 
percent of this group presented with the MetS and its individual traits, which may have 
contributed as secondary causes of hyperapoB-hyperTG (Figure 1). 
20. 
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Thus, from a strictly lipoprotein perspective, hyperapoB-hyperTG poses greater risk than 
normoapoB-hyperTG. Nevertheless, the plasma lipoproteins are only one determinant, albeit a 
major one, of the total risk of vascular disease.  
Cardiovascular risk profiles and outcomes of NIMA in the different dyslipoproteinemias 
 
The different tests of NIMA measure somewhat different aspects of vascular structure and 
function. The panel of tests in this study can be broadly divided into those that are more closely 
related to atheroma- ankle-brachial index at rest and exercise, intima-media thickness, presence 
of plaque, and plaque thickness- versus those that may be more directly related to arterial 
stiffness -pulse wave velocity, augmentation index, central augmented pressure, central systolic 
pressure, and central diastolic pressure-. One has to bear in mind that this classification is 
arbitrary and some NIMA likely reflect both processes.  
In general, all dyslipoproteinemias were characterized by abnormal NIMA compared to the 
reference group, although the reference group consisted of participants with CV risk factors 
present and a prevalence of CVD of 10.6 percent in men and 6.3 percent in women. The 
hyperapoB-hyperTG group showed the largest difference in the atheroma-related NIMA 
parameters compared to the reference group. In contrast, participants with normoapoB-
hyperTG showed the largest differences in the NIMA parameters most closely related to arterial 
stiffness. Of interest, in the hyperapoB-hyperTG group, adjustment for apoB substantially 
reduced the difference in the NIMA tests that may relate most directly to atheroma whereas 
adjustment for TG had more obvious effects on these atheroma parameters in the normoapoB-
hyperTG group.  TG also had more effect on the NIMA tests that relate to arterial stiffness, albeit 
slightly more in the normoapoB-hyperTG group than in the hyperapoB-hyperTG group. These 
results suggest there may be different effects of different CV risk factors on the arterial wall, and 
the effects can differ in different patient groups. The observed relationship between TG and the 
stiffness parameters may be due to colinearity with other major CV risk factors present in the 
groups with dyslipoproteinemias, since elevated TG levels have been associated with obesity and 
the MetS21
 
. However, we emphasize these are only hypotheses that must be tested in future 
studies designed to elucidate the determinants of the different NIMA parameters. 
In summary, this study reports for the first time the frequency of the different 
dyslipoproteinemias according to the diagnostic algorithm based on apoB, TG, and TC in a 
population-based sample. Furthermore, we report that participants with a dyslipoproteinemia 
showed a worse cardiovascular risk profile compared to normolipidemic participants, including 
deteriorated outcomes of NIMA, reflecting increased subclinical atherosclerosis. The NIMA 
parameters used in this study reflect different aspects of the atherosclerotic process and further 
studies are needed to determine which CV risk factors cause deteriorated outcomes of the 
individual NIMA parameters.  
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Supplemental Material  
Materials and methods 
 
Clinical evaluation and biochemical analysis 
Systolic and diastolic blood pressure was measured using an oscillometric sphygmomanometer 
(Criticon model no. 1846, Criticon Inc., Tampa, USA). Hypertension (HT) was defined when 
systolic blood pressure was ≥ 140 mmHg and/or diastolic blood press ure was ≥ 90 mmHg or 
previously diagnosed and treated HT. Waist circumference was measured at the level of the 
umbilicus, hip circumference was measured at the level of the trochanter major and waist-to-hip 
ratio was calculated. Weight and height were measured and body mass index was calculated as 
body weight (in kilograms) divided by the square of height (in meters). Venous blood was drawn 
and plasma total cholesterol (TC), high density lipoprotein-cholesterol, serum triglycerides (TG), 
and fasting glucose concentrations were determined using commercially available enzymatic 
reagents (AEROSET® System, Abbott, Chicago Illinois). Diabetes mellitus type 2 (DM 2) was 
defined when glucose level was ≥ 7.0 mmol/l after an overnight fast or previously diagnosed and 
treated DM. Low-density lipoprotein-cholesterol levels were calculated with the Friedewald 
formula1. Total plasma apolipoprotein B (apoB) concentration was determined by 
immunonephelometry2
 
. Plasma concentration of adiponectin was determined using enzyme-
linked immunosorbent assays (Elisa development System, Duoset®, R&D Systems, Minneapolis). 
All lipid-lowering medication when used was discontinued for four weeks prior to the 
measurements. All participants filled out a questionnaire about their previous history of vascular 
disease, medicine use, smoking, and exercise habits. Cardiovascular disease (CVD) was defined 
as a reported myocardial infarction, transient ischaemic attack or stroke, peripheral arterial 
disease, coronary artery bypass or angioplasty in the past, or treated angina.  
Categorizing participants according to the diagnostic algorithm  
Participants were first categorized by apoB level (below versus equal or higher than 1.2 g/l). 
Participants with a low apoB were subsequently divided in those with a normal TG (<1.5mmol/l) 
and those with hyperTG levels ( ≥ 1.5 mmol/l).  Participants with normal apoB and normal TG 
levels were defined as normal (reference group). Those with low apoB but high TG were further 
divided in participants with a TG/apoB ratio above or below 10. No participants in our study 
population had a TG/apoB ratio equal or above 10. The participants with low apoB, high TG and 
TG/apoB ratio below 10 were further split based on the TC/apoB ratio. When TC/apoB ratio was 
equal or above 6.2, participants were classified to have high chylomicrons and very low-density 
lipoprotein remnants (VLDL-R) and this group is referred to as the normoapoB-hyperTG due to 
chylomicrons and VLDL-R. Those with a TC/apoB ratio below 6.2 have increased TG levels due to 
increased VLDL (normoapoB-hyperTG due to VLDL group). 
When participants had a high apoB, they were divided according to the TG level; a TG < 1.5 
mmol/l was normal and ≥1.5 mmol/l was defined as a hyperTG. Those with low TG levels are 
referred to as the hyperapoB-normoTG due to LDL and those with both high apoB and high TG 
are referred to as the hyperapoB-hyperTG due to VLDL and LDL. 
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Study protocol  
All NIMA measurements were performed after an overnight fast or in the afternoon six hours 
after a standardized breakfast. Participants were asked to abstain from caffeinated products and 
not to smoke for at least twelve hours before the visit. As published before there were no 
significant differences between measurements performed in the morning and afternoon after 
the measurement conditions had been standardized3. All measurements were taken with 
participants in supine position after at least 10 minutes of  rest in a temperature-controlled 
room (23-24°C)4
Pulse wave velocity and augmentation index 
 and performed by well-trained and certified sonographers according to a highly 
standardized protocol.  
Peripheral arterial pressure waveforms were recorded by applanation tonometry at the radial 
artery. Pulse wave analysis (PWA) was performed and augmentation index (AIx), central 
augmented pressure, central systolic pressure, and central diastolic pressure were calculated, 
using the commercially available SphygmoCor system version 7.1 (Atcor Medical, Sydney, 
Australia) as described before5. As AIx is influenced by heart rate6, an index normalized for heart 
rate of 75 beats per minute was used. To determine pulse wave velocity (PWV), pulse 
waveforms were recorded at two sites sequentially (right carotid artery and left femoral artery), 
and wave transit-time was calculated using the R-wave of  a simultaneously recorded 
electrocardiogram as a reference frame as described before7. All measurements had to meet the 
criteria of optimal quality as defined by the manufacturer. According to these standards, PWA 
was acquired in 1469 subjects (96.8%) and PWV in 1476 subjects (97.3%). The reproducibility of 
the AIx and PWV was good, as reported in a previous study3
 
. The absolute difference for 
repeated measurements was 4.0 ± 4.0 % for AIx and 0.63 ± 0.50 m/s for PWV. The mean ± SEM 
difference between the two measurements was 0.68 ± 0.86% for AIx and 0.19 ± 0.12 m/s for 
PWV. 
Intima-media thickness, the presence of plaque, and plaque thickness 
Carotid intima-media thickness (IMT) was determined using an AU5 Ultrasound machine (Esaote 
Biomedica, Genova, Italy) with a 7.5 MHz linear-array transducer as described before5,8. Actual 
measurement of the IMT of the distal common carotid artery was performed off-line by the 
sonographer at the time of the examination, using semi-automatic edge-detection software 
(M’AthSTD version 2.0, Metris, Argenteuil, France). Reproducibility of our IMT-measurements 
as investigated by the method of Bland and Altman has been reported before3. The mean ± SEM 
difference was 0.003 ± 0.007 mm. The mean IMT was calculated from the mean of all four 
measured segments: far wall left, near wall left, far wall right, and near wall right of the final 
centimeter of the distal common carotid artery. The mean far wall IMT was acquired in 1494 
subjects (98.5%), and mean near wall IMT in 1478 subjects (97.4%). Subsequently the presence 
of plaque and the thickness of plaques in the common carotid, internal carotid, or external 
carotid artery or at the carotid bulbus were measured. The presence of plaque was defined as 
focal thickening of the wall of at least 1.5 x the mean IMT, according to the Mannheim intima-
media thickness consensus9.   
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Ankle-brachial index 
The calculation of the ankle-brachial index (ABI) was performed as described before5
 
. In brief, 
resting blood pressures were measured at the left and right brachial artery, the left and right 
posterior tibial and dorsalis pedis arteries using an 8 MHz hand-held Doppler probe 
(IMEXDOPCT+™, Biomedic, Almere, The Netherlands). The highest of the two arm pressures was 
used to calculate ABI at rest for the posterior tibial and dorsalis pedis arteries. The lowest of the 
four ABIs was used in the analysis. In addition, participants were asked to perform a treadmill 
test for four minutes at a speed of 2 m/h and with an elevation of 10%. Immediately after the 
exercise test blood pressures were recorded at the arm with the highest pressure at rest and at 
both ankles and ABI after exercise (ABI-ex) was calculated for both legs. The lowest ABI-ex was 
used in the analysis. In total 1502 measurements of ABI at rest (99.0%) and 1469 measurements 
of ABI-ex (96.8%) were suitable for analysis. 
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Abstract 
 
Introduction: Familial combined hyperlipidemia (FCH) is characterized by dyslipidemia, visceral 
obesity, and insulin resistance, and is associated with an increased risk of cardiovascular disease. 
In the present study, we investigated whether FCH is associated with early functional vascular 
wall changes, as represented by endothelial dysfunction. Furthermore, we determined for a 
broad variety of cardiovascular risk factors whether they contribute independently to 
endothelial function in FCH, and, if so, whether this is dependent on the extent of the 
morphological vascular wall changes present.  
 
Methods: In 98 patients with FCH and 230 unaffected relatives, venous blood was drawn in the 
fasting state after discontinuation of lipid-lowering drugs (if used), and endothelial function was 
assessed both by flow-mediated dilation (FMD) and by measurement of plasma concentrations 
of various soluble adhesion molecules, including s-ICAM-1, s-VCAM-1 and sE-selectin.  
 
Results: There were no significant differences between FCH patients and their unaffected 
relatives in FMD (2.9 [2.3-3.6]% vs. 2.8 [2.5-3.2]%), and in plasma concentrations of s-VCAM-1 
(312 [298-326] vs. 328 [317-340] ng/ml), s-ICAM-1 (147 [138-155] vs. 134 [129-140] ng/ml) and 
sE-selectin (32 [29-34] vs. 28 [27-30] ng/ml). In both FCH patients and unaffected relatives with 
advanced morphological vascular wall changes (carotid artery plaques), IMT was the best 
predictor of FMD in multivariate analysis (respectively β= -18.12, p=0.038 and β= -11.10, 
p=0.009). In subjects without carotid artery plaques, male gender was the most important 
predictor of FMD, and IMT was not an independent predictor of FMD. 
 
Conclusion: FCH patients have no impaired endothelial function when compared to their 
unaffected relatives. IMT is an important predictor of FMD when carotid artery plaques are 
present, irrespective of FCH diagnosis. Our results question the use of FMD as an independent 
tool to predict CVD in high-risk populations. 
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Introduction 
 
Familial combined hyperlipidemia (FCH) is the most common form of heritable lipid disorder, 
with a prevalence of approximately 5% in the general population, and 10-20% in survivors of 
myocardial infarction1,2. The FCH  phenotype is  characterized by  elevated levels of plasma total 
cholesterol (TC), triglycerides (TG) and/or apolipoprotein B (apoB), decreased plasma levels of 
high-density lipoprotein-cholesterol (HDL-c), the presence of small dense low-density lipoprotein 
particles (sdLDL), a decreased insulin sensitivity, and the presence of visceral obesity3,4. As a 
result of all metabolic disturbances, FCH patients have a 2-fold increased risk for cardiovascular 
diseases (CVD)5. However, not only the prevalence of clinically overt CVD is increased in FCH, but 
also the amount of subclinical morphological changes of the vascular wall that precede CVD; in a 
recent study, we showed that FCH patients have an increased intima media thickness (IMT) when 
compared to their unaffected relatives6
In the last two decades, it has become increasingly clear that endothelial dysfunction represents 
early and reversible stages in the atherosclerotic process. It comprises a pro-inflammatory and 
pro-coagulant state, which is thought to be initiated by the up-regulation of the expression of 
various adhesion molecules
. Because of their increased risk on CVD and the presence of 
morphological vascular wall changes, it may be of great benefit to FCH patients to detect any 
vascular wall changes at an early stage of the atherosclerotic process. 
7. Besides, endothelial dysfunction is characterized by a reduction in the 
bioavailability of vasodilator substances, in particular nitric oxide (NO), leading to an impairment of 
flow-mediated dilation (FMD). Close correlations between FMD and various important clinical and 
biochemical cardiovascular risk factors have been demonstrated8
Despite the high prevalence of FCH in Western society and the increased risk of FCH patients on 
CVD, so far little is known about endothelial function and its determinants in FCH. Although 
endothelial function measurements hypothetically provide an excellent tool to detect early 
atherosclerotic changes in FCH, the increased amount of morphological vascular wall damage in 
these patients might be an important confounder of endothelial function measurements, since 
several studies have related FMD to the amount of structural vascular wall changes as 
represented by IMT 
.  
9-11
Therefore, the objectives of the present study are (i) to investigate whether endothelial function 
is disturbed in FCH patients, and (ii) to elucidate whether endothelial function in FCH is related 
to any of the cardiovascular risk factors associated with the FCH phenotype, or to the (increased) 
amount of morphological vascular wall changes, as measured by IMT. 
. 
Methods 
 
Study population 
The study population consisted of 32 families, comprising 343 subjects. These families were 
ascertained in the past through probands exhibiting a combined hyperlipidemia, with both 
plasma TC and TG concentrations above the 90th percentile, adjusted for age and gender12. At 
least one relative of the proband had to have a multiple type hyperlipidemia with elevated levels 
of TG and/or TC, and at least one of the first-degree relatives should have premature CVD 
(before the age of 60 years), as described previously13. The current FCH diagnosis was based on 
absolute apoB levels in combination with plasma TG and TC levels, adjusted for age and gender, 
using our recently published nomogram13.  Individuals with secondary causes of hyperlipidemia 
(diabetes, renal or hepatic insufficiency, hypothyroidism, and/or medication), with the presence 
of the apo E2/E2 genotype, or the presence of tendon xanthomas, were excluded. This resulted 
in a total of 328 eligible subjects of which 98 subjects were diagnosed as FCH and 230 as 
unaffected relatives. The mean (range) number of subjects recruited per family was 3.9 (1-15) 
for the group of 98 FCH patients and 7.7 (1-34) for the group of 230 unaffected relatives. The 
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Medical Ethics Committee of the Radboud University Nijmegen Medical Centre approved the 
study protocol, and all participants provided written informed consent.  
 
Clinical measurements 
All subjects filled out a lifestyle questionnaire about their smoking habits, previous medical 
history, and their medication use, with special attention to the use of vasoactive medication, 
defined as the use of one or more of the following drug-classes on a regular, daily basis: ACE-
inhibitors, angiotensin II-inhibitors, nitrates, calcium-channel blockers, diuretics or β-blockers. 
Systolic (SBP) and diastolic (DBP) blood pressures were measured, using an oscillometric 
sphygmomanometer (Critikon model no.1846, Critikon inc., Tampa, USA). The waist 
circumference was measured 
 
at the level of the umbilicus. Venous blood was drawn after an 
overnight fast, and after discontinuation of all lipid-lowering medication for at least four weeks. 
Biochemical analyses 
Plasma lipid and apolipoprotein concentrations were determined as previously described6. 
Plasma concentrations of soluble vascular cell adhesion molecule (sVCAM) were determined in 
duplicate by commercial ELISA assay (R&D, Minneapolis, USA), and soluble intercellular cell 
adhesion molecule (sICAM) and sE-selectin were determined by ELISA by the method of 
Leeuwenberg et al.14. Plasma glucose was determined by a commercially available glucose 
oxidation method (GOD-PAP, Hitachi 747; Roche Molecular Biochemicals, Indianapolis, IN). 
Serum insulin concentration was assessed by means of an in house radioimmunoassay (inter-
assay coefficient of variation (CV), 10.3%). Insulin resistance was assessed by the Homeostasis 
model assessment (HOMA). The HOMA-index was calculated from the fasting concentration of 
insulin and glucose as described previously15
 
. 
Experimental procedures  
For all measurements, patients abstained from caffeine-containing beverages and alcohol for at 
least 12 hours16
 
, and did not smoke for at least 6 hours before the measurements. Experiments 
were performed in the morning after an overnight fast with the patients supine in a quiet 
temperature-controlled room (23-24°C). 
FMD measurements 
Vasodilator responses were measured non-invasively by recording flow-mediated dilation (FMD) 
of the brachial artery, using a 7.5 MHz linear-array transducer of an AU5 ultrasound system 
(Esaote Biomedica, Genova, Italy), connected to a computer with a data acquisition board. For 
image optimization we used a stereo static arm with a holder for the probe and a water bath to 
prevent compression of the artery. Dedicated software (Wall Track System 2.0; Pie Medical, 
Maastricht, the Netherlands and AIM-WTS software, University Hospital Groningen, the 
Netherlands) was used to measure and analyze changes in vessel diameter. All measurements 
were performed by trained technicians, and analyzed off-line by an independent technician. 
FMD was measured by the method of Celermajer and collegues17. First, basal vessel diameter 
was measured. Subsequently, a pneumatic tourniquet, placed around the forearm was inflated 
to 50 mmHg above systolic blood pressure for 4 minutes. After deflation, vessel diameter was 
recorded continuously in four-second frames every 15 seconds for at least 4 minutes to detect 
changes in vessel diameter (endothelium-dependent vasodilation). There-after, fifteen minutes 
were allowed for vessel recovery, and a second baseline vessel diameter was measured. 
Sublingual nitroglycerin spray (Nitrolingual 400µg per dose, G. Pohl-Boskamp GmbH&Co. KG, 
Germany) was administered, and from 2 until 10 min after administration, endothelium-
independent nitroglycerin-mediated dilation (NMD) was measured by the last series of scans. 
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FMD was calculated as the difference between the maximum diameter post-occlusion and the 
average baseline diameter, relative to the average baseline diameter, and expressed as a 
percentage. Reproducibility of our FMD18 was in line with the recommendations of the 
International Brachial Artery Reactivity Task Force19
IMT measurements 
. In total, FMD could be calculated for, 
respectively, 89% of the FCH patients and for 86% of the unaffected relatives (P= NS). NMD 
could be determined in 90% of the FCH patients and in 90% of the unaffected relatives (P= NS). 
In 9% of the subjects FMD and/or NMD could not be determined due to technical problems. 
Fifteen subjects (4%) were unwilling to take nitroglycerin, and therefore NMD could not be 
determined. 
Carotid intima-media thickness (IMT) was determined using an AU5 Ultrasound machine (Esaote 
Biomedica, Genova, Italy) with a 7.5 MHz linear-array transducer, as has been described 
extensively before18. All measurements were carried out in end-diastole, using the R-wave of a 
simultaneously recorded ECG as a reference frame. The outcome variable was defined as the 
mean IMT of all four measured segments of the common carotid artery (CCA): far wall left, near 
wall left, far wall right and near wall right. The CCA, the carotid bifurcation and the internal 
carotid artery (ICA) were visualized both longitudinally and transversely over a length as large as 
possible to assess the occurrence of plaques. A plaque was defined as a focal thickening of the 
vessel wall of >50%  relative to adjacent segments, with protrusion into the lumen (as judged 
visually), composed of calcified or no calcified components20
 
. 
Statistical analyses 
Variables with a skewed distribution, including TG, the VLDL-c/TG ratio, and the HOMA-index, 
were logarithmically transformed before analysis. Differences between FCH patients and their 
unaffected relatives were tested by χ2-
VLDL-c/TG ratio, the TC/HDL-c ratio and SBP were chosen as representatives of the pertinent 
parameters. As a result, smoking [yes/no], waist, SBP, apoB, TC/HDL-c ratio, VLDL-c/TG-ratio, 
HOMA-index and IMT were entered as independent variables, and age and gender were forced 
into the final regression models. Probability values <0.05 were considered statistically 
significant. Bonferroni corrections were applied to correct P-values for multiple testing in 
correlation and regression analysis.  All statistical analyses were performed using SPSS 12.0.1 for 
Windows statistical package (SPSS Inc., Chicago Illinois, USA). 
test (categorical variables) or by general linear model 
(GLM) with age, gender and (in case of flow-related parameters) vasoactive medication use as 
covariates. Family number was entered as a random factor in order to correct for the lack of 
genetic independence of the subjects. Correlations between FMD and continuous clinical or 
biochemical variables were analyzed using Pearson’s correlation coefficients. Stepwise multiple 
regression analysis with FMD as the dependent variable was carried out to test whether any of 
these cardiovascular risk factors or the amount of morphological vascular changes (represented 
by IMT) was independently related to FMD. To avoid problems with multi-colinearity, the  
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Results 
 
Subjects characteristics 
Table 1 shows the clinical and biochemical characteristics for FCH patients and their unaffected 
relatives. Patients with FCH were on average 7 years older than their unaffected relatives. The 
ratio men/women was not significantly different between the two groups, nor was the 
percentage subjects reporting any past/present smoking. However, significantly more subjects 
with FCH used one or more vasoactive drugs (33.7% versus 11.3%, p <0.0001, Table 1).  
 
Table 1. Clinical and biochemical characteristics of patients with familial combined 
hyperlipidemia (FCH) and their unaffected relatives. 
 
Unaffected FCH 
  (n=230) (n=98) P 
Gender (M/F) 112/118 42/56 NS 
Age (y) 44 [42-46] 51 [48-54] <0.001 
Smoking (%) 21.7 24.5 NS 
Vasoactive drugs (%)* 11.3 33.7 <0.001 
Waist circumference (cm) 89 [88-90] 97 [95-100] 0.002 
HOMA-index 1.76 [1.62-1.89] 2.57 [2.25-2.87] 0.001 
Systolic blood pressure (mmHg) 132 [130-135] 140 [136-144] NS 
Diastolic blood pressure (mmHg) 74 [72-75] 77 [75-79] NS 
Total cholesterol (mmol/l) 5.25 [5.12-5.37] 6.87 [6.63-7.11] <0.001 
Triglycerides (mmol/l) 1.30 [1.22-1.37] 3.36 [2.93-3.79] <0.001 
High-density lipoprotein-cholesterol (mmol/l) 1.31 [1.27-1.35] 1.16 [1.11-1.21] 0.001 
Low-density lipoprotein-cholesterol (mmol/l) 3.51 [3.40-3.63] 4.22 [3.98-4.46] 0.001 
Apolipoprotein B (g/l) 0.92 [0.93-0.99] 1.37 [1.32-1.42] <0.001 
TC/HDL-c ratio 4.22 [4.07-4.37] 6.23 [5.86-6.59] <0.001 
VLDL-c/TG ratio 0.30 [0.29-0.32] 0.41 [0.39-0.44] <0.001 
Intima-media thickness (mm) 0.73[0.72-0.74] 0.77 [0.74-0.80] 0.04 
Data are presented as unadjusted mean [95% CI]. M/F indicates male/female; HOMA, homeostasis model assessment, 
VLDL-c, very low-density lipoprotein-cholesterol; NS, not significant. * Unaffected relatives: ACE inhibitors (n=10), 
Angiotensin II inhibitors (n=2), diuretics (n=9),  β-blockers (n=13), calcium antagonists (n=7). FCH patients: ACE 
inhibitors (n=11), angiotensin II inhibitors (n=9), diuretics (n=13),  β-blockers (n=15), calcium antagonists (n=8) and 
nitrates (n=3) 
 
As by definition, FCH-patients were characterized by an adverse lipid profile, with increased 
levels of TC, TG, LDL-c, and apoB, an increased VLDL-c/TG ratio (reflecting an increased amount 
of remnant lipoproteins), and a decreased HDL-c level. They were also more obese (as reflected 
by a high waist circumference), and more insulin resistant (as reflected by a higher HOMA-index) 
than their unaffected relatives. The SBP and DBP were not significantly different between both 
groups, but this could have been the result of the higher number of subjects using vasoactive 
medication in the FCH group (Table1). Finally, the amount of morphological vascular wall 
damage, as represented by the IMT, was significantly higher in subjects with FCH. 
 
 
Endothelial function  
Characteristics of endothelial function in FCH patients and unaffected relatives are depicted in 
Table 2. Basal brachial artery diameter, endothelium-dependent vasodilation (FMD) and 
endothelium-independent vasodilation (NMD) were not significantly different in patients with 
FCH compared to their unaffected relatives when tested with age, gender, and vasoactive 
medication use as covariates. In addition, concentrations of the various adhesion molecules 
were not significantly elevated in the patients with FCH. Subgroup analysis of the subjects not 
using vasoactive medication yielded comparable results (data not shown). 
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Table 2. Flow-mediated dilation, nitroglycerin-mediated dilation and plasma concentrations of 
various adhesion molecules as characteristics of endothelial function in FCH patients and their 
unaffected relatives.  
  
Unaffected FCH 
 
 
N (n=230) (n=98) P 
Basal vessel diameter (µm) 319 4685 [4569-4796] 4799 [4650-4949] NS 
Flow-mediated dilation (%) 296 2.8 [2.5-3.2] 2.9 [2.3-3.6] NS 
Nitroglycerin-mediated dilation (%) 304 15.0 [14.2-15.9] 13.6 [12.3-15.0] NS 
sVCAM-1 (ng/ml) 328 328 [317-340] 312 [298-326] NS 
sICAM-1 (ng/ml) 328 134 [129-140] 147 [138-155] NS 
sE-selectin (ng/ml) 327 28 [27-30] 32 [29-34] NS 
Data are presented as mean [95% CI]. N denotes the number of subjects in whom endothelial function was measured 
and included in the analyses. sVCAM-1, soluble vascular cell adhesion molecule-1; sICAM-1, soluble intracellular 
adhesion molecule 1, sE-selectin, soluble E-selectin. NS indicates not significant. 
 
Univariate correlations of endothelial function with cardiovascular risk factors and IMT 
None of the individual clinical and biochemical cardiovascular risk factors were significantly 
correlated to FMD in univariate correlation analysis in patients with FCH. In the unaffected 
relatives, the only cardiovascular risk factors significantly correlated to FMD were ‘male gender’, 
‘waist’, and ‘HOMA index’ (Table 3). In both FCH patients and their unaffected relatives, 
concentrations of the various adhesion molecules (as alternative measures of endothelial 
function) and IMT (as a measure of morphological vascular wall damage) were not significantly 
correlated to FMD (Table 3). 
 
Table 3. Univariate Pearson correlation coefficients of FMD with clinical and biochemical 
characteristics of patients with FCH and their unaffected relatives. 
 Non affected FCH 
(n=230) (n=98) 
Male gender  0.26*  0.16 
Age (y) -0.02 -0.10 
Smoking (%) -0.01 -0.06 
Waist circumference (cm) -0.15* -0.16 
HOMA-index -0.14* -0.04 
Systolic blood pressure (mmHg) -0.09 -0.01 
Diastolic blood pressure (mmHg) -0.06 -0.12 
Total cholesterol (mmol/l) 0.04 -0.01 
Triglycerides (mmol/l) -0.06 -0.03 
High-density lipoprotein-cholesterol (mmol/l) 0.07 0.02 
Low-density lipoprotein-cholesterol (mmol/l) 0.06 -0.01 
Apolipoprotein B (g/l) -0.02 -0.04 
TC/HDL-c ratio -0.05 -0.07 
VLDL-c/TG ratio -0.03 0.04 
Intima-media thickness (mm) -0.07 -0.19 
Abbreviations as in table 1. * denotes p<0.05 
 
However, since we anticipated the amount of morphological vascular wall changes actually 
present to be a confounder of the latter non-significant correlation, we repeated univariate 
correlation analysis after stratification of the subjects in the presence of carotid artery plaques 
(representing an increased amount of morphological vascular wall changes). We found a strong 
univariate correlation between IMT and FMD in subjects with carotid artery plaques (r =−0.44, 
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P= 0.012, Fig. 1a), whereas this relation was absent in subjects without carotid plaques (r = 
−0.05, P= NS, Fig. 1b). However, when the subjects with carotid plaques were subdivided in a 
subgroup FCH patients and a subgroup of unaffected relatives, FMD and IMT were no longer 
significantly correlated (respectively, r= −0.51, P= 0.12 and r= −0.43, P= 0.20), which might be 
explained by the lower power to detect a significant correlation due to smaller sample sizes. 
 
Figure 1. Association between mean carotid IMT and FMD in subjects with (A) and without (B) 
carotid artery plaques. 
 
 
 
 
 
 
 
 
 
   A      B 
 
A. FMD (%) as a function of IMT in subjects with carotid artery plaques. Solid black line denotes regression line for all 
subjects (r=-0.44, p=0.006). Solid grey line denotes regression line for subjects with FCH (      , r=-0.51, p=0.03). Dashed 
black line denotes regression line for subjects not affected by FCH (     , r= -0.43, p=0.05). 
 
B. FMD (%) as a function of IMT in subjects without carotid artery plaques. Solid black line denotes regression line for 
all subjects (r=-0.05, p=NS). Solid grey line denotes regression line for subjects with FCH (      , r=-0.13, p=NS). Dashed 
black line denotes regression line for subjects not affected by FCH (     , r= -0.005, p=NS) 
 
 
Multivariate analysis 
 
Multivariate linear regression analysis was carried out to investigate whether IMT was still a 
predictor of FMD in subjects with carotid artery plaques when the effects of age, gender and 
cardiovascular risk factors were taken into account. The final model is shown in Table 4. In 
subjects with carotid artery plaques, IMT turned out to be an independent predictor of FMD, 
explaining 19.7% of its variation, whereas it was not an independent predictor in subjects 
without carotid artery plaques. Similar multivariate models were also constructed with sICAM, 
sVCAM or sE-selectin as the dependent variables. For none of these variables was IMT an 
independent predictor of the respective plasma concentrations, neither in subjects with carotid 
artery plaques, nor in subjects without carotid artery plaques (data not shown). 
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Discussion 
 
In this study, we report that patients with FCH do not have an impaired endothelial function 
compared to their unaffected relatives. Furthermore, we show that IMT is the best independent 
predictor of FMD when more advanced morphological vascular wall changes are present.  
We demonstrated that FMD was not impaired in FCH patients compared to their unaffected 
relatives, which is in sharp contrast to previous reports of Stroes et al.21, de Michelle et al.22, and 
Karasek et al.23 who demonstrated endothelium-dependent vasodilation to be impaired in FCH 
patients. However, sample sizes in these studies were rather small (n=12, n=30 and n=43, 
respectively), they did not use the newly developed nomogram13
molecules pointed out that endothelial function was not impaired in FCH subjects compared to 
their relatives, both markers of endothelial function were not significantly correlated in our 
population. 
 to diagnose FCH, and in the 
study of Stroes et al. a different technique to assess NO-dependent vasodilation was used. 
Instead of using high-resolution ultrasound of the brachial artery to obtain FMD, they 
determined the amount of serotonin-induced changes in forearm blood flow (FBF). Both 
methods represent endothelial function of a different vascular bed (large conduit arteries versus 
small resistance arteries), and may therefore yield different results. Our study not only provides 
by far the largest FCH population in which endothelial function has ever been studied, it is also 
the only study that has investigated endothelial function in FCH patients both by measurement 
of NO-availability and by measurement of plasma concentrations of the various adhesion 
molecules. We could not demonstrate a statistically significant difference in sVCAM, sICAM or 
sE-selectin plasma concentration between the FCH patients and their unaffected relatives. 
Although both FMD and plasma concentration adhesion 
 
Previous studies also reported an absence of correlation between endothelial function as 
measured by FMD and by plasma concentrations of the various adhesion molecules24. This may 
result from the fact that both are independent predictors of CVD, and therefore not necessarily 
etiologically related25. The lack of a difference in endothelial function between FCH patients and 
their unaffected relatives seems paradoxical, since previous studies have shown that when 
cardiovascular risk factors are present, the endothelium may adopt a phenotype that facilitates 
inflammation, thrombosis, and vasoconstriction, regardless of the measurement technique26
 
. In 
the present study the expression of several cardiovascular risk factors was more profound in FCH 
patients compared to their unaffected relatives, and therefore a difference in endothelial 
function between the two groups was anticipated. The lack of significant differences in 
endothelial function was not the result of the observed difference in the use of vasoactive 
medication between FCH patients and their unaffected relatives, since vasoactive medication 
use (yes/no) was entered as a covariate in ANOVA. Nor was it the result of a type 2 statistical 
error; based on the FMD and the SD within our study population, our study had a statistical 
power to detect a difference in FMD of 1.05% at an 80% power. So we would have been able to 
record a difference in vessel diameter in response to occlusion between the two groups of only 
47 μm, if present.  
However, there are three potential other explanations for the absence of a difference in 
endothelial function between FCH patients and their unaffected relatives. First, traditional 
cardiovascular risk factors are not the only determinants of endothelial function. Previous 
studies showed that individuals with a normal endothelial function and patients with endothelial 
dysfunction do not necessarily differ in their risk factor profiles27,28
Genetic predisposition and/or yet-unknown risk factors might as well play a pivotal role 
explaining the inter-individual variation in endothelial susceptibility to risk factors. Second, it is 
questionable to what extent the diagnostic cornerstones of FCH (elevated levels of TC, TG and 
.  
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apoB) contribute to the development of endothelial dysfunction. For TC, significant negative 
associations with endothelial function have been reported29. However, many of these 
observational studies are performed in patients with FH, a disorder characterized by very high 
levels of TC. Since TC concentrations in our FCH patients were only moderately elevated, no 
major effect of TC on FMD could have been anticipated. This is supported by a recently 
published extensive meta-regression analysis of all studies with FMD as an endpoint in which 
cholesterol was measured between 1992 and 200130. In this study, Bots et al. reported that TC 
explains only 1% of the variation in FMD on top of the already explained variation by 
methodological aspects and non-modifiable/reversible risk factors as age, gender, coronary 
heart disease and diabetes. Literature on the effect of apoB on endothelial function is sparse, 
but recently Lind et al31 reported that the apoB/A1 ratio was not related to FMD in 1016 
population-based elderly subjects. Whether the plasma TG concentration, being the third 
cornerstone of FCH diagnosis, is related to endothelial function remains controversial, but most 
evidence points towards a limited effect of plasma TG concentrations on endothelial function8. 
The third and last reason for the lack of a significant difference in endothelial function between 
FCH patients and their unaffected relatives are the marginal differences in blood pressure and 
smoking habits between the two groups. Although both blood pressure and smoking are 
indisputably important determinants of endothelial function8, differences between FCH patients 
and their unaffected relatives for both parameters were not significant and too small to induce 
significant differences in FMD or concentrations of adhesion molecules. Previous studies have 
reported a significant correlation between IMT and FMD in a number of high risk populations9,11
 
.  
However, in two large prospective studies performed in healthy subjects with a low 
cardiovascular risk, the correlation between FMD and IMT was only very weak10 or even 
nonexistent32.  Although in the present study we did not stratify our subjects on cardiovascular 
risk, our findings are in line with these previous reports, since we showed that IMT is an 
important independent predictor of FMD in subjects with carotid artery plaques, but not in 
subjects without carotid artery plaques. Thereby, our study is the first to demonstrate in a 
single, well-defined population, that the association between IMT and FMD is dependent on the 
extent of the morphological vascular wall changes present, as reflected by carotid artery 
plaques. This is an important finding, since it provides an answer to the opposing findings 
regarding the relation of FMD with IMT in populations with a low and a high cardiovascular risk.  
Furthermore, it provides a pathophysiological base for the marginal abilities of FMD to predict 
CVD that have recently been reported in two large scale prospective studies33,34. Based on these 
findings, and based on the relatively high intra-individual variability of FMD due to either 
biological factors and measurement-related factors35,36
 
, we question the (additive) value of FMD 
measurements compared to (or besides) the measurement of morphological vascular wall 
damage (IMT) for the purpose of cardiovascular risk prediction, especially in populations where 
a high prevalence of advanced morphological wall changes is anticipated.  
Our study has limitations. First, we compared endothelial function of FCH patients and their 
unaffected relatives only, and did not include a (second) control group of unrelated subjects. 
Although Benjamin et al.37
Apart from the heritability of FMD, our control group of unaffected relatives may also contain 
subjects who are ‘latent patients’. Because of this, the mean FMD of our control group is 
probably lower than the mean FMD of a group of age-and gender matched unrelated control 
subjects would be
 recently demonstrated that the heritability of FMD is low, we cannot 
completely rule out a common (genetic) factor determining endothelial function in FCH patients 
and relatives as a cause of the lack of difference between the two groups.  
23. Therefore, we may only compare the FMD of the FCH patients to the FMD 
of their unaffected relatives, and we cannot extrapolate our results to other groups. A second 
potential limitation of our study is that our subjects were stratified based on the presence of 
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carotid artery plaques. Since no consensus about plaque definition exists, various different 
plaque definitions are used in literature. Although the currently used definition was used by 
other groups as well20
 
, using an alternative definition could have affected our results to a certain 
extent. A third limitation of our study is the cross-sectional design. Although we found a 
significant association between FMD and IMT in subjects with carotid artery plaques, we cannot 
draw any conclusions regarding the nature of this association. Although it is generally assumed 
that the correlation between FMD and IMT in high-risk populations is the result of the fact that 
both IMT and FMD are representatives of the same atherosclerotic process, we cannot exclude 
the existence of a reciprocal (causal) effect of IMT on FMD. Therefore, future studies have to be 
performed to relate endothelial function of FCH patients to unrelated subjects, and to reveal the 
nature of the relation between morphological vascular wall changes and FMD, and to determine 
the independent predictive ability of FMD for CVD in high-risk populations in a prospective 
setting.  
In conclusion, the results of our study show that FCH patients do not have an impaired 
endothelial function, as measured both by FMD and by plasma concentrations of soluble 
adhesion molecules, compared to their unaffected relatives. IMT is an important predictor of 
FMD when advanced morphological vascular wall changes are present. This questions the value 
of FMD measurements for cardiovascular risk stratification in populations with an anticipated 
high cardiovascular risk. 
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Abstract 
 
Background: In the present cross-sectional study we investigated whether familial combined 
hyperlipidemia (FCH) is associated with increased arterial wall stiffness, and whether measures 
of arterial wall stiffness in FCH family members could contribute to cardiovascular risk 
stratification.  
 
Methods: Ninety-eight subjects with FCH and 230 unaffected relatives filled out a questionnaire 
about their smoking habits, medical history, and medication use. Fasting venous blood was 
drawn after discontinuation of any lipid-lowering medication. Pulse wave velocity (PWV) and 
augmentation index (AIx) were determined by applanation tonometry as surrogate markers of 
arterial stiffness.  
 
Results: Patients with FCH had a significantly increased PWV compared to their unaffected 
relatives (9.07 ± 2.75 vs. 8.28 ± 2.62 m/s, p=0.005), whereas AIx was not increased (21.6 ± 12.7 
vs.15.6 ± 14.1, p=0.96). Age- and gender-adjusted PWV was an equally good predictor of the 
presence of cardiovascular disease (CVD) in FCH family members as the most predictive 
combination of age- and gender-adjusted clinical and biochemical risk factors, including total 
cholesterol, high-density lipoprotein-cholesterol and systolic blood pressure (area under the 
receiver operating curve (ROC) [AUC] 0.83 [0.76-0.90] versus AUC 0.84 [0.78-0.91], p=0.83). 
Addition of PWV to the multivariable prognostic model, including these age- and gender-
adjusted traditional risk factors, did not increase the predictive ability for CVD (AUC 0.84 [0.79-
0.89]). 
 
Conclusion: Patients with FCH are characterized by an increased arterial stiffness. The PWV 
predicts the presence of CVD equally well as any combination of clinical and traditional 
biochemical risk factors, but PWV has no additional value besides traditional risk factor 
screening in FCH families.  
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Introduction 
 
Familial combined hyperlipidemia (FCH) is the most common form of heritable lipid disorder, 
with a prevalence of up to 5% in the general population, and 10-20% in survivors of myocardial 
infarction1,2. It is characterized by several phenotypes, including elevated plasma levels of total 
cholesterol (TC), triglycerides (TG) and/or apolipoprotein B (apoB). Other characteristics of FCH 
are decreased plasma levels of high-density lipoprotein cholesterol levels (HDL-c), the presence 
of small dense low-density lipoprotein particles (sdLDL), a decreased insulin sensitivity, and the 
presence of visceral obesity3-5. All these clinical and biochemical characteristics may contribute 
to the observed increased risk of cardiovascular disease (CVD) in subjects with FCH6
However, FCH is a heterogeneous disorder with a highly variable phenotypic expression between 
subjects. Phenotypic expression varies even within subjects over time
.  
7. Because of the variability 
in expression, quantification of a subset of cardiovascular risk factors (as usually happens in 
clinical practice) might result in suboptimal prediction of CVD risk in an individual. Another major 
problem in clinical medicine is that at every level of traditional risk factor exposure, there is a 
large inter-individual variation in the amount of atherosclerosis and the development of CVD. 
Therefore, an indicator which directly reflects the presence of atherosclerosis in the vessel wall 
(and thereby the overall effect of all potential risk factors) is expected to yield a better risk 
prediction. Pulse wave velocity (PWV) and augmentation index (AIx) are attractive candidate 
representatives of such an overall effect. AIx is a marker of pressure wave reflection, whereas 
PWV is a surrogate measure of arterial wall stiffness. An increased arterial wall stiffness has 
been associated with both the severity of coronary artery disease8 and carotid artery disease9. 
Furthermore, increased arterial wall stiffness has been associated with coronary risk scores in 
healthy subjects10, and, more importantly, it has been shown to predict future morbidity and 
mortality in hypertensive and diabetic populations11,12. Very recently,  it was shown that PWV is 
an independent predictor of coronary heart disease and stroke in apparently healthy 
subjects13,14
 
.  In the present cross-sectional study we investigated whether PWV and/or AIx, as 
determined with applanation tonometry, were disturbed in patients with FCH compared to their 
normolipidemic relatives. Furthermore, we investigated whether PWV and AIx can be used to 
stratify CVD risk in FCH family members with additional power beyond traditional risk factor 
screening. 
 
Methods 
 
Study population 
The study population consisted of 32 families, comprising 343 subjects. These families were 
ascertained through probands exhibiting a combined hyperlipidemia, as described 
previously7,15,16. FCH diagnosis was based on absolute apoB levels in combination with plasma TG 
and TC levels, adjusted for age and gender, using our recently published nomogram16. In total 98 
subjects were diagnosed as FCH and 230 as unaffected relatives. CVD was defined by stroke, 
myocardial infarction (MI), angina pectoris (AP), peripheral vascular disease or revascularization 
procedure. When the presence of CVD was suspected by the clinical investigator, further details 
were sought from the patients’ general practitioner or from any relevant hospital records. In 
total, 43 subjects were diagnosed with CVD, including 4 subjects with stroke, 12 subjects with 
previous MI, 14 subjects with AP, 6 subjects with peripheral vascular disease and 12 subjects 
with a revascularization procedure. Twenty-six % (n = 11) of these subjects were diagnosed CVD 
based on the presence of two or more manifestations of CVD. All individuals with secondary 
causes of hyperlipidemia (diabetes, renal or hepatic insufficiency, hypothyroidism, and/or 
medication), with the apo E2/E2 genotype, or tendon xanthomas were excluded. The Medical 
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Ethics Committee of the Radboud University Nijmegen Medical Centre approved the study 
protocol, and all participants provided written informed consent. 
 
Clinical measurements 
All subjects filled out a lifestyle questionnaire about their previous medical history, and their 
medication use, with special attention to the use of vasoactive medication, defined as the use of 
one or more of the following drug-classes on a regular, daily basis: ACE-inhibitors, angiotensin II-
inhibitors, nitrates, calcium-channel blockers, diuretics or β-blockers. Waist circumference was 
measured at the level of the umbilicus. Systolic (SBP) and diastolic (DBP) blood pressures were 
measured at the brachial artery using an oscillometric sphygmomanometer (Critikon model 
no.1846, Critikon inc., Tampa, USA), and MAP was calculated as: DBP + 0.33 (SBP-DBP). 
 
Biochemical analyses 
Venous blood was drawn after an overnight fast, and plasma TC and TG concentrations were 
determined using commercially available enzymatic reagents (Hitachi 747, Roche, Almere, The 
Netherlands).VLDL-cholesterol (VLDL-c) was isolated from whole plasma by ultracentrifugation 
at density (d)=1.019 g/ml for 16 h at 36,000 rpm in a fixed angle rotor. High-density lipoprotein-
cholesterol (HDL-c) was determined by the polyethylene glycol 6000 method17. Low-density 
lipoprotein-cholesterol (LDL-c) was calculated by subtraction of VLDL-c and HDL-c from plasma 
TC. Total plasma apoB concentration was determined by immunonephelometry18. Both hsCRP 
(Dako, Glastrup, Denmark) and plasma oxLDL (Mercodia, Uppsala, Sweden) were determined by 
ELISA. Plasma glucose was determined by a commercially available glucose oxidation method 
(GOD-PAP, Hitachi 747; Roche Molecular Biochemicals, Indianapolis, IN). Serum insulin 
concentration was assessed by means of an in house radioimmunoassay (interassay coefficient 
of variation: 10.3%)19. Insulin resistance was assessed by the Homeostasis model assessment 
(HOMA)20
 
. 
AIx and PWV measurement 
All measurements were taken in the supine position in a temperature-controlled room (23-24°C) 
after a brief period (at least 5 min) of rest21. Peripheral arterial pressure waveforms were 
recorded by applanation tonometry at the radial artery, using the commercially available 
SphygmoCor system version 7.1 (Atcor Medical, Sydney, Australia). The corresponding central 
waveform was then derived by applying a validated integral transfer function on the average 
peripheral waveform22,23, and subjected to further analyses to determine AIx, defined as the 
difference between the first and second peak of the central arterial waveform, expressed as a 
percentage of the pulse pressure. As AIx is influenced by heart rate24, an index normalized for 
heart rate of 75 beats per minute was used. To determine PWV, pulse waveforms were recorded 
at two sites sequentially (right carotid artery and left femoral artery), and wave transit-time was 
calculated using the R-wave of a simultaneously recorded ECG as a reference frame. Surface 
distance between the two recording sites was measured parallel to the plane of the examination 
table, and the distance between the carotid artery site and the manubrium was subtracted from 
the total distance, allowing PWV to be calculated. All measurements had to meet the criteria of 
optimal quality as defined by the manufacturer. According to these standards, AIx was acquired 
in 306 subjects (93%) and PWV in 311 subjects (94%). The reproducibility of the AIx and PWV 
measurements was good, as has been reported in a previous study25
 
. The mean difference ± 
repeatability coefficient for repeated measurements by the same observer was 0.68 ± 4.87% for 
AIx and 0.19 ±0.52 m/s for PWV.  
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Statistics 
Variables with a skewed distribution were logarithmically transformed before analysis. 
Comparisons between FCH patients and their unaffected relatives for PWV and AIx  were 
performed by general linear model (GLM) with age, gender, MAP, “vasoactive medication use”  
and body height (AIx only) as covariates, and family number as a random factor. MAP was used 
as a covariate (and not SBP or DBP) since it had the strongest correlation with PWV in 
multivariate analysis with adjustment for age and gender (Standardized β resp. 0.34, 0.33 and 
0.28). Univariate logistic regression was used to evaluate the prognostic ability of the variables 
separately to discriminate between subjects affected by FCH and their unaffected relatives. 
Because most variables were expected to be nonlinearly related in the logistic model, 
reasonable cut-off values for these variables to discriminate between affected subjects and their 
unaffected relatives were constructed. At this point, the condition of equal "costs" of 
misclassification of cases and non-cases was used. Subsequently, multivariate logistic regression 
analysis with backward selection procedure was used to determine which age- and gender-
adjusted clinical and biochemical variables contributed independently to the prediction of CVD. 
Next, with the multivariable prognostic model, a boundary value of probability to be affected by 
CVD was derived for the most predictive combination of age- and gender-adjusted clinical and 
biochemical variables as derived from multivariate logistic regression analysis, again under the 
condition of equal costs of misclassification. Finally, the prognostic ability of this boundary value 
was compared to the optimal cut-off points for age- and gender-adjusted PWV and AIx to predict 
CVD, using receiver-operating curve characteristics. A p-value <0.05 was considered statistically 
significant. Statistical analyses were performed using SPSS 12.0.1 for Windows statistical 
package (SPSS Inc., Chicago Illinois, USA) and STATA 8.0 software. 
 
 
Results 
 
Clinical and biochemical characteristics of FCH families 
 
Table 1 shows the clinical and biochemical characteristics for FCH patients and their unaffected 
relatives. Patients with FCH were on average 7 years older than their unaffected relatives and 
used significantly more often vasoactive medication. In addition, FCH patients had a higher waist 
circumference, were more insulin resistant (as reflected by a higher HOMA index), and had a less 
favorable lipid profile and a higher plasma level of hsCRP compared to their unaffected relatives. 
Although both SBP, DBP, and MAP tended to be higher in FCH patients, the differences with 
their unaffected relatives did not reach statistical significance. The number of subjects affected 
by any past or present CVD was significantly higher amongst FCH patients. As expected, FCH 
patients with a history of prevalent CVD exhibited a more unfavorable risk factor profile than 
FCH patients without CVD, although differences did not reach statistical significance for most 
parameters, most probably due to the relatively small  number of subjects with FCH and CVD 
(n=21, data not shown).  
 
Pulse wave analysis in FCH families 
 
A general linear model with adjustment for age, gender, MAP, use of vasoactive medication, and 
family number revealed that the PWV of patients with FCH was significantly higher compared to 
the PWV of unaffected controls (9.07 ± 2.75 vs. 8.28 ± 2.62 m/s, p=0.005, Table 1). After 
adjustment for covariates, the AIx adjusted for a heart-rate of 75 b.p.m. was not significantly 
different in subjects with FCH compared to their unaffected relatives (21.6 ± 12.7 vs. 15.6 ± 14.1, 
p=0.96) 
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Table 1. Clinical and biochemical characteristics and representatives of arterial wall stiffness 
stratified by FCH diagnosis.  
 Unaffected FCH  
 (n=230) (n=98) P 
Age (y) 44 ± 14 51 ± 14 <0.001 
Gender (%male) 48.7 42.9 NS  
Vasoactive medication use (%)* 11.3 33.7 <0.001 
Past or present smoking (%) 21.7 24.5 NS  
Past or present CVD (%) 9.5 21.4 0.004 
Waist circumference (cm) 89 ± 12 97 ± 11     <0.001 
Systolic blood pressure (mmHg) 132 ± 18 140 ± 20 NS  
Diastolic blood pressure (mmHg) 74 ± 12 77 ± 12 NS  
Mean arterial pressure (mmHg) 94 ± 13 99 ± 11 NS 
Heart rate (b.p.m.) 62 ± 10 65 ± 11 NS 
Total cholesterol (mmol/l) 5.25 ± 0.95 6.87 ± 1.17 <0.001 
Triglycerides (mmol/l) 1.30 ± 0.58 3.36 ± 2.13 <0.001 
High-density lipoprotein-cholesterol (mmol/l) 1.31 ± 0.33 1.16 ± 0.25 0.001  
Low-density lipoprotein-cholesterol (mmol/l) 3.51 ± 0.87 4.22 ± 1.19 0.001 
VLDL-c/TG ratio 0.30 ± 0.10 0.41 ± 0.11 <0.001 
HOMA-index 1.76 ± 0.97 2.57 ± 1.33 0.002 
hsCRP (mg/l) 2.43 ± 7.10 3.61 ± 3.44 <0.001 
OxLDL/apoB ratio 0.067 ± 0.009 0.065 ± 0.010 NS 
Pulse wave velocity (m/s) 8.28 ± 2.62 9.07 ± 2.75 0.005 
Augmentation index (%) 15.6 ± 14.1 21.6 ± 12.73 NS  
Data are presented as mean ± SD. Statistical comparisons between FCH patients and unaffected family members were 
made by the χ2
* Unaffected relatives: ACE inhibitors (n=10), Angiotensin II inhibitors (n=2), diuretics (n=9),  β-blockers (n=13), 
calcium antagonists (n=7). FCH patients: ACE inhibitors (n=11), angiotensin II inhibitors (n=9), diuretics (n=13),  β-
blockers (n=15), calcium antagonists (n=8) and nitrates (n=3) 
-test for dichotomous variables, and for continuous variables by general linear model (GLM) with age, 
gender (all variables), MAP, vasoactive medication use (AIx and PWV), and body height (AIx) as covariates and family 
number (all variables) as a random factor. ApoB, apolipoprotein B; VLDL-c/TG ratio, ratio of very low-density 
lipoprotein-cholesterol/ TG; HOMA, homeostasis model assessment; hsCRP, high-sensitive C-reactive protein; 
oxLDL/apoB ratio, ratio of oxidized low-density lipoprotein to apoB;  
 
 
Cardiovascular risk factors and pulse wave analysis as predictors of the presence of CVD 
 
Crude univariate odds ratios (OR) for the optimal cut-off values of clinical and biochemical 
variables and stiffness parameters to predict past or present CVD are indicated in Table 2. Age 
was the best predictor of CVD, with an age above 53 years being equivalent to a 15.7-fold [6.9-
35.6] increased risk of CVD. Of the modifiable clinical and biochemical risk factors included in 
traditional CVD risk factor screening, TC, waist circumference, and apoB best predicted CVD (OR 
for optimal cut-off points respectively 6.4 [3.1-13.2], 3.7 [1.9-7.4] and 3.4 [1.7-6.5]). Compared 
to these separate clinical and biochemical risk factors, PWV was a better predictor of CVD: a 
value above the cut-off point of 8.85 m/s was equivalent to a 7.2 [3.3-15.5] -fold increased risk 
of CVD. In agreement with this, the area under the curve (AUC; as a measure of predictive 
ability) in receiver operating curve (ROC) analysis was larger for PWV (77%) than it was for TC 
(AUC 70%), waist (AUC 68%), or apoB (AUC 62%).  The predictive ability of PWV for the presence 
of CVD extended beyond simple BP measurements, as the AUC for PWV (77%) was significantly 
higher than AUCs for MAP (60%), SBP (62%), and DBP (56%) (all p<0.01).  
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Table 2: Crude OR of cardiovascular risk factors to predict the presence of CVD in FCH family 
members with univariate logistic regression. 
 
Cut-off 
value OR       95%CI   R2 AUC(%)  (%) 
Age (y) 53 15.7 6.9-35.6 30 79 
Male gender - 1.5 0.8-2.9 0.9 55 
Apolipoprotein B (g/l) 1150 3.4 1.7-6.5 7.3 62 
Total cholesterol (mmol/l) 6.00 6.4 3.1-13.2 15.6 70 
Triglycerides (mmol/l) 1.44 2.0 1.0-3.8 2.3 60 
High-density lipoprotein-cholesterol (mmol/l) 1.19 2.5 1.3-4.9 4.1 64 
Low-density lipoprotein-cholesterol (mmol/l) 3.93 3.3 1.7-6.5 7.1 65 
VLDL-c/TG ratio 0.35 2.4 1.2-4.6 3.8 62 
HsCRP (mg/l) 1.57 1.1 0.6-2.1 <0.1 52 
OxLDL/apoB ratio 0.070 0.8 0.4-1.5 0.75 43 
HOMA-index 2.10 3.0 1.5-5.8 6.0 59 
Waist circumference (cm) 96 3.7 1.9-7.4 8.4 68 
Systolic blood pressure (mmHg) 136 3.2 1.6-6.3 6.7 62 
Diastolic blood pressure (mmHg) 75 1.5 0.8-2.9 0.9 56 
Mean arterial pressure (mmHg) 95 2.3 1.2-4.3 3.4 60 
Pulse wave velocity (m/s) 8.85 7.2 3.3-15.5 17.0 77 
Augmentation index (%) 23.5 2.5 1.3-5.0 4.2 60 
OR, odds ratio; CI, confidence interval; R2, percentage explained variance; AUC, area under the Receiver Operating 
Curve as a measure of predictive discrimination (i.e. 50% is equivalent to random guessing and 100% is perfect 
prediction). OR, R2
 
, and AUC are calculated for the optimal cut-off value presented in this table. Other abbreviations 
as in table 1. 
Next, we aimed to compare the CVD risk prediction ability of PWV and AIx measurements 
relative to the CVD risk prediction based on traditional risk factor screening. Because traditional 
risk factor screening includes multiple risk factors instead of separate risk factors, and also takes 
into account the modifier effect of “age” on all these risk factors, we compared the predictive 
ability of age- and gender-adjusted PWV and AIx with the most predictive combination of age- 
and gender-adjusted clinical and biochemical risk factors. Multivariate logistic regression analysis 
revealed that, of the age-and gender-adjusted traditional risk factors, a combination of TC, HDL-c 
and SBP best predicted the presence of CVD in our population, with a R2
Figure 1 shows that the combined predictive ability of these risk factors for the presence of CVD 
was comparable to the predictive ability of PWV: the area under the ROC-curve was 0.83 [0.76-
0.90] for PWV and 0.84 [0.78-0.91] for the combined clinical and biochemical risk factors (p= 
0.83). The AUC for AIx (0.78 [0.70-0.86]), however, was considerably lower when compared to 
the AUCs of both PWV (p=0.04) and the combined clinical and biochemical risk factors (p=0.02).  
 of 33%.  
 
By logistic regression analysis, the probability of classification affected CVD based on the optimal 
cut-off point for the combined clinical and biochemical risk factors was assessed at 37%. This is 
about equal to the 36% probability for the optimal cut-off point of age-and gender-adjusted 
PWV to predict CVD. In line with this, sensitivity and specificity for the prediction of CVD are of 
the same magnitude for PWV and for the combined clinical and biochemical risk factors 
(sensitivity 81% and 78% and specificity 79% and 86%, respectively). However, for age-and 
gender-adjusted AIx, the probability of classification affected CVD based on the optimal cut-off 
point was only 24%, and sensitivity (70%) and specificity (69%) for the prediction of CVD were 
lower than for PWV and the combined clinical and biochemical risk factors. 
Although the predictive ability of PWV for the presence of CVD was comparable to the predictive 
ability of the combined clinical and biochemical risk factors (TC, HDL-c, and SBP), addition of 
PWV to the multivariable prognostic model including these age- and gender-adjusted traditional 
risk factors, did not increase the predictive ability for CVD ( AUC 0.84 [0.79-0.89]). 
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Figure 1:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Receiver operating curves of PWV, AIx, and a combination of clinical-and biochemical risk factors to predict the 
presence of CVD in a cohort of 330 subjects from FCH-families. TC denotes total cholesterol; HDL-c, high-density 
lipoprotein-cholesterol; AIx@75, augmentation index normalized for a heart rate of 75 b.p.m; PWV, pulse wave 
velocity. 
 
 
 
Discussion 
 
In the present study we found that arterial wall stiffness, as reflected by PWV, was increased in 
subjects with FCH as compared to their unaffected relatives. In addition, in patients with FCH 
and their unaffected relatives, PWV was a good predictor of the presence of CVD, although PWV 
had no additional predictive value when added to traditional risk factor screening.  
Although previous studies have reported an increased arterial stiffness in patients with familial 
hypercholesterolemia (FH)26, this is the first study to show that in FCH vascular wall stiffness is 
also markedly increased, despite the fact that mean plasma total cholesterol levels are 
considerably lower than in FH. Even when age, gender, MAP, and the use of vasoactive 
medication were taken into account, patients with FCH had a significantly increased PWV 
compared to their unaffected relatives. This was not the case for AIx since no significant 
difference could be demonstrated in AIx between FCH patients and their unaffected relatives. 
The larger difference in PWV between the two groups may be explained by the different 
vascular beds represented by these parameters. Whereas PWV represents the arterial stiffness 
of large conduit arteries, AIx is a marker of arterial wave reflection, which is dependent on the 
vascular resistance of small resistance vessels27
As in all other major cohorts, “age” was the best univariate predictor of CVD. Considering the 
modifiable clinical and biochemical risk factors waist circumference, systolic blood pressure, and 
plasma concentrations of TC, apoB and LDL-c were the best predictors of CVD in univariate 
, on PWV, and on the distance of the reflection 
point to the heart.  
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analysis, whereas only TC and SBP together with HDL-c remained independent predictors of CVD 
in the multivariate model with adjustment for age and gender. Although unadjusted plasma 
concentrations of hsCRP and oxLDL have been shown to predict CVD in  healthy subjects28,29
Most interestingly, age- and gender-adjusted PWV was as predictive for the presence of CVD as 
the most predictive combination of independent age- and gender-adjusted clinical and 
biochemical risk factors (TC, HDL-c, and SBP). Sensitivity for the prediction of CVD was 
comparable for PWV and for the combination of clinical and biochemical risk factors, whereas 
specificity was slightly lower for PWV.  Recently, Willum-Hansen et al.
, the 
predictive ability of both parameters in the current FCH population, was minor compared to the 
traditional biochemical and clinical risk factors and also compared to AIx and PWV.  
14
 
 showed that PWV was a 
significant predictor of future cardiovascular complications, above and beyond other risk factors 
in a large, population-based group of middle-aged subjects. However, in their study they 
excluded individuals with a previous history of myocardial infarction and stroke. In the present 
study we show that, even in a population with an increased prevalence of CVD and the presence 
of multiple cardiovascular risk factors, PWV is a good predictor of the presence of CVD, although 
we could not demonstrate that PWV predicts the presence of CVD “above and beyond” the 
traditional risk factors in our high-risk FCH population.  
The predictive ability of AIx in our population was considerably lower than the predictive abilities 
of both PWV and the combined clinical and biochemical risk factors. The inferior sensitivity and 
specificity of AIx for the prediction of CVD may be explained by the fact that the relative 
importance of small vessel changes in the atherosclerotic process is larger in the early 
(subclinical) stages of the atherosclerotic process. Progression of advanced subclinical 
atherosclerosis to manifest clinical CVD is related to alterations in larger conduit vessels that are 
not represented by AIx.  
With a sensitivity of 81% and a specificity of 79%, the cut-off value of 9.5 m/s for age- and 
gender-adjusted PWV may be used as a reasonable screening tool to detect the presence of CVD 
in subjects from FCH families, although it should be noted that this cut-off value (and thereby 
sensitivity and specificity) may vary depending on the method used to measure the travelled 
distance of the pulse.  
However, PWV had no contribution in the prediction of prevalent CVD in addition to 
conventional risk factor screening in our present study. This might be related to the relatively 
limited sample size and/or the cross-sectional design of our study. With larger sample sizes, 
derivation of age- and gender-group specific cut-off values may augment sensitivity and 
specificity of PWV as a screening instrument of CVD. Prospective studies have to be performed 
to investigate whether PWV is not only a good marker of the presence of CVD in FCH 
populations, but also of the development of CVD, and if so, whether the predictive ability of 
PWV adds to traditional risk factor screening. Not until the results of these prospective studies 
are available, the additive value of PWV measurements besides (or instead) of traditional risk 
factor screening remains questionable.  
 
In conclusion: Patients with FCH have an increased PWV compared to their unaffected relatives. 
In this cross-sectional study, PWV predicts the presence of CVD equally well as any combination 
of clinical and traditional biochemical risk factors, but it has no additional value besides 
traditional risk factor screening.  
 
 
  
Chapter 9 
 
164 
 
References 
 
 (1)  Brunzell JD, Schrott HG, Motulsky AG, Bierman EL. Myocardial infarction in the familial forms of 
hypertriglyceridemia. MetabC lin Exp 1976;25(3):313-320. 
 (2)  Hopkins PN, Heiss G, Ellison RC, Province MA, Pankow JS, Eckfeldt JH, Hunt SC. Coronary artery 
disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: A case-control 
comparison from the National Heart, Lung, and Blood Institute Family Heart study. Circulation 
2003;108(5):519-523. 
 (3)  Bredie SJH, Tack CJJ, Smits P, Stalenhoef AFH. Nonobese patients with familial combined 
hyperlipidemia are insulin resistant compared with their nonaffected relatives. Arterioscler 
Thromb Vasc Biol 1997;17(7):1465-1471. 
 (4)  De Graaf J, Veerkamp MJ, Stalenhoef AFH. Metabolic pathogenesis of familial combined 
hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty 
acids. J R Soc Med Suppl 2002;95(42):46-53. 
 (5)  Keulen ETP, Voors-Pette C, De Bruin TWA. Familial dyslipidemic hypertension syndrome: Familial 
combined hyperlipidemia, and the role of abdominal fat mass. Am J Hypertens 2001;14(4 I):357-
363. 
 (6)  Austin MA, McKnight B, Edwards KL, Bradley CM, McNeely MJ, Psaty BM, Brunzell JD, Motulsky 
AG. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year 
prospective study. Circulation 2000;101(24):2777-2782. 
 (7)  Veerkamp MJ, De Graaf J, Bredie SJH, Hendriks JCM, Demacker PNM, Stalenhoef AFH. Diagnosis 
of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: Results 
of a 5-year follow-up study. Arterioscler Thromb Vasc Biol 2002;22(2):274-282. 
 (8)  Gatzka CD, Cameron JD, Kingwell BA, Dart AM. Relation between coronary artery disease, aortic 
stiffness, and left ventricular structure in a population sample. Hypertension 1998;32(3):575-578. 
 (9)  Saba PS, Roman MJ, Pini R, Spitzer M, Ganau A, Devereux RB. Relation of arterial pressure 
waveform to left ventricular and carotid anatomy in normotensive subjects. J Am Coll Cardiol 
1993;22(7):1873-1880. 
 (10)  Nürnberger J, Keflioglu-Scheiber A, Opazo Saez AM, Wenzel RR, Philipp T, Schäfers RF. 
Augmentation index is associated with cardiovascular risk. J Hypertens 2002;20(12):2407-2414. 
 (11)  Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, Laurent S. Aortic stiffness is 
an independent predictor of primary coronary events in hypertensive patients: A longitudinal 
study. Hypertension 2002;39(1):10-15. 
 (12)  Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity 
and its relationship to mortality in diabetes and glucose intolerance: An integrated index of 
vascular function? Circulation 2002;106(16):2085-2090. 
 (13)  Mattace-Raso FUS, Van Der Cammen TJM, Hofman A, Van Popele NM, Bos ML, Schalekamp 
MADH, Asmar R, Reneman RS, Hoeks APG, Breteler MMB, Witteman JCM. Arterial stiffness and 
risk of coronary heart disease and stroke: The Rotterdam Study. Circulation 2006;113(5):657-663. 
 (14)  Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. 
Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general 
population. Circulation 2006 February 7;113(5):664-670. 
 (15)  Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to 
incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol; 
1992;70(7):733-737. 
 (16)  Veerkamp MJ, De Graaf J, Hendriks JCM, Demacker PNM, Stalenhoef AFH. Nomogram to 
diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. 
Circulation 2004;109(24):2980-2985. 
 (17)  Demacker PNM, Hijmans AGM, Vos-Janssen HE. A study of the use of polyethylene glycol in 
estimating cholesterol in high-density lipoprotein. Clin Chem 1980;26(13):1775-1779. 
 (18)  Demacker PNM, Veerkamp MJ, Bredie SJH, Marcovina SM, De Graaf J, Stalenhoef AFH. 
Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for 
estimation of coronary heart disease risk: A study in familial combined hyperlipidemia. 
Atherosclerosis 2000;153(2):483-490. 
 (19)  De Galan BE, Tack CJ, Lenders JW, Pasman JW, Elving LD, Russel FG, Lutterman JA, Smits P. 
Theophylline improves hypoglycemia unawareness in type 1 diabetes. Diabetes 2002;51(3):790-
796. 
Pulse wave velocity in FCH 
 
165 
 
 (20)  Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: Insulin resistance and 
beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 
1985;28(7):412-419. 
 (21)  Van Bortel LM, Duprez D, Starmans-Kool MJ, Safar ME, Giannattasio C, Cockcroft J, Kaiser DR, 
Thuillez C. Clinical applications of arterial stiffness, task force III: Recommendations for user 
procedures. Am J Hypertens 2002;15(5):445-452. 
 (22)  Chen CH, Nevo E, Fetics B, Pak PH, Yin FCP, Maughan WL, Kass DA. Estimation of Central aortic 
pressure waveform by mathematical transformation of radial tonometry pressure: Validation of 
generalized transfer function. Circulation 1997;95(7):1827-1836. 
 (23)  Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending 
aortic pressure from the radial artery pressure waveform. Hypertension 2001;38(4):932-937. 
 (24)  Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate 
on augmentation index and central arterial pressure in humans. J Physiol 2000;525(1):263-270. 
 (25)  Ter Avest E, Holewijn S, Stalenhoef AFH, De Graaf J. Variation in non-invasive measurements of 
vascular function in healthy volunteers during daytime. Clin Sci 2005;108(5):425-431. 
 (26)  Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. 
Arterioscler Thromb Vasc Biol 2003;23(4):554-566. 
 (27)  Giannattasio C, Mangoni AA, Failla M, Carugo S, Stella ML, Stefanoni P, Grassi G, Vergani C, 
Mancia G. Impaired radial artery compliance in normotensive subjects with familial 
hypercholesterolemia. Atherosclerosis 1996;124(2):249-260. 
 (28)  Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density 
lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, 
middle-aged men from the general population. Circulation 2005;112(5):651-657. 
 (29)  Ridker PM, Cook N. Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein 
Across the Full Range of Framingham Risk Scores. Circulation 2004;109(16):1955-1959. 
 
 
  
 
 
 
Chapter 10 
 
 
 
 
Remnant particles are the major determinant of an increased intima-
media thickness in patients with familial combined hyperlipidemia 
(FCH) 
 
 
 
Ewoud ter Avest 
Suzanne Holewijn 
Sebastian J.H. Bredie 
Anton F.H. Stalenhoef 
Jacqueline de Graaf  
 
 
 
 
Atherosclerosis,
 
 2007: 191(1):220-6 
  
Chapter 10 
 
168 
 
Abstract 
 
Introduction: Familial combined hyperlipidemia (FCH) is characterized by several phenotypes, 
including an atherogenic lipoprotein profile, low-grade inflammation, visceral obesity, insulin 
resistance, and hypertension. In this study, we investigated which of the clinical and biochemical 
characteristics of FCH patients contributes most to their increased risk of cardiovascular disease, 
by determining the association of a broad variety cardiovascular risk factors with the intima-
media thickness (IMT) of the common carotid artery (CCA) in 94 FCH patients and 216 
unaffected relatives. 
 
Methods: All subjects filled out a questionnaire about their smoking and drinking habits, medical 
history and medication use, and venous blood was drawn in the fasting state after 
discontinuation of lipid-lowering medication (if used). IMT of the far wall and near wall of both 
common carotid arteries was measured by high-resolution B-mode ultrasound. 
 
Results: The mean IMT in FCH patients (adjusted for age and gender) was 33 µm thicker when 
compared to their unaffected relatives (p=0.006). In multivariate analysis, waist-to-hip ratio, 
apolipoprotein B concentration, and pulse pressure were significant and independent predictors 
of IMT in both FCH patients and their normolipidemic relatives. The most important 
independent predictor of IMT in FCH patients however, was the VLDL-c/TG-ratio, explaining 
32.8% of the variation in age- and gender-adjusted IMT, whereas this ratio was not an 
independent predictor of IMT at all in their unaffected relatives.  
 
Conclusion: Abdominal obesity, a higher blood pressure and dyslipidemia characterized by both 
an increased number of atherogenic particles and the presence of highly atherogenic remnant 
lipoproteins play an important role in the development of cardiovascular disease in FCH-
patients. 
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Introduction 
 
Familial combined hyperlipidemia (FCH) is the most common form of heritable lipid disorder, 
with a prevalence of 5.7% in the general population, and 10-20% in survivors of myocardial 
infarction1,2. It is characterized by several phenotypes, including elevated plasma levels of total 
cholesterol (TC), triglycerides (TG) and/or apolipoprotein B (apoB). Other characteristics of FCH 
are decreased plasma levels of high density lipoprotein-cholesterol-levels (HDL-c), the presence 
of small dense low density lipoprotein particles (sdLDL), a decreased insulin sensitivity, the 
presence of visceral obesity, an increased blood pressure, and an increased low-grade 
inflammation3-6. All these clinical and biochemical characteristics may contribute to the observed 
increased risk of cardiovascular disease (CVD) in FCH-subjects, as has been reported before7,8
However, the development of atherosclerosis is a gradual process, starting long before clinical 
events occur. Measurement of intima-media thickness (IMT) of the common carotid artery (CCA) 
by high resolution B-mode ultrasound is a widely used way of quantifying pre-clinical disease. 
Several prospective studies have shown that an increased IMT confers risk of future coronary 
heart disease and stroke
.  
9, and close associations have been demonstrated between IMT and 
age, gender, and many cardiovascular risk factors, both in healthy subjects and in patients with 
dyslipidemia10,11
 
.  In this study, we aim to investigate which of the modifiable clinical and 
biochemical characteristics of FCH patients contribute to the increased cardiovascular risk, by 
determining the association between IMT and a broad variety of cardiovascular risk factors in a 
large cohort of FCH patients (n=94) and their unaffected relatives (n=216).  
Methods 
 
Study population 
The study population existed of 30 families, comprising 310 subjects, of whom 94 were 
diagnosed as FCH-patients and 216 as normolipidemic relatives. Patients and relatives were 
ascertained in the past through probands exhibiting combined hyperlipidemia, with both plasma 
TC and TG concentrations above the 90th percentile, adjusted for age and gender12. At least one 
relative of the proband had to have a multiple type hyperlipidemia with elevated levels of TG 
and/or TC, and at least one of the first-degree relatives should have premature CVD before the 
age of 60 years. Present FCH-diagnosis was based on absolute apoB levels in combination with 
plasma TG and TC levels, adjusted for age and gender, using our recently published nomogram6
 
.  
Individuals with secondary causes of hyperlipidemia (diabetes, renal or hepatic insufficiency, 
hypothyroidism, and/or medication), with the presence of the apo E2/E2 genotype, or the 
presence of tendon xanthomas were excluded. The Medical Ethics Committee of the Radboud 
University Nijmegen Medical Centre approved the study protocol, and all participants provided 
written informed consent.  
Clinical measurements 
All subjects filled out a questionnaire about their previous medical history, especially about their 
cardiovascular history, medication use, and smoking and drinking habits. CVD was defined by 
stroke, transient ischaemic attack, myocardial infarction, angina pectoris or peripheral vascular 
disease. Systolic (SBP) and diastolic (DBP) blood pressures were measured, using an oscillometric 
sphygmomanometer (Critikon model no.1846, Critikon inc., Tampa, USA). Pulse pressure was 
calculated as the difference between the SBP and the DBP. Hypertension was defined as a 
systolic tension ≥140 mmHg and/or a diastolic tension ≥90 mmHg or the use of anti-
hypertensive medication. The waist circumference was measured at the level of the umbilicus, 
the hip circumference was measured at the level of the trochanter major, and the waist-to-hip 
ratio (WHR) was calculated. Weight and height were measured, and body mass index (BMI) was 
calculated as body weight (in kilograms) divided by the square of height (in meters). 
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Biochemical analysis 
Venous blood was drawn after an overnight fast and after withdrawal of lipid-lowering 
medication (if used) for 4 weeks. Plasma TC and TG concentrations were determined using 
commercially available enzymatic reagents (Hitachi 747, Roche, Almere, The Netherlands).VLDL-
cholesterol (VLDL-c) was isolated from whole plasma by ultracentrifugation at density (d)=1.006 
g/ml for 16 h at 36,000 rpm in a fixed angle rotor (TFT 45.6 rotor, Kontron), in a Beckman L7-55 
ultracentrifuge. High-density lipoprotein-cholesterol (HDL-c) was determined by the 
polyethylene glycol 6000 method13. Low-density lipoprotein-cholesterol (LDL-c) was calculated 
by subtraction of VLDL-c and HDL-c from plasma TC. Total plasma apoB concentration was 
determined by immunonephelometry14. Both hsCRP (Imtec Immun-diagnostica, Berlin, 
Germany) and plasma oxLDL (Mercodia, Uppsala, Sweden) were determined by ELISA. Plasma 
glucose was determined by a commercially available glucose oxidation method (GOD-PAP, 
Hitachi 747; Roche Molecular Biochemicals, Indianapolis, IN). Plasma insulin concentrations 
were assessed by means of radioimmunoassay (in-house RIA [interassay coefficient of variation 
(CV), 10.3%])15. Insulin resistance was assessed by the Homeostasis model assessment (HOMA). 
The HOMA-index was calculated from the fasting concentrations of insulin and glucose using the 
following formula: HOMA-index =fasting serum insulin (mU/l) x fasting plasma glucose 
(mmol/l)/22.516
 
.  
IMT measurements  
Carotid IMT was determined using an AU5 Ultrasound machine (Esaote Biomedica, Genova, 
Italy) with a 7.5 MHz linear-array transducer. Longitudinal images of the distal-most 10 mm of 
both the far wall and the near wall of both common carotid arteries (CCA) were obtained in the 
optimal projection. Actual measurement of the IMT was performed off-line by the sonographer 
at the time of the examination, using semi-automatic edge-detection software (M’AthStd 
version 2.0, Metris, Argenteuil, France). All measurements were carried out in end-diastole, 
using the R-wave of a simultaneously recorded ECG as a reference frame. Reproducibility of our 
IMT-measurements as investigated by the method of Bland and Altman has been reported 
before17
 
: the mean (± SEM) difference for repeated measurements by the same observer was 
0.003 ± 0.007 mm, and the mean (± SEM) inter-observer-difference was 0.012 ±0.009 mm. IMT-
segments in which mean IMT could not be determined in more than 50% (i.e.5 mm) of the last 
distal 10 mm of the CCA were excluded from analysis (n=28), as were measurements of 
segments were a plaque was present in the last distal 10 mm of the CCA (n=7). According to 
these standards, mean far wall IMT was acquired in 298 subjects (96%), and mean near wall IMT 
in 290 subjects (94%). The primary outcome variable was defined as the mean IMT of all four 
measured segments: far wall left, near wall left, far wall right and near wall right. Secondary 
outcome variables were the mean far wall IMT and the mean near wall IMT. 
Statistical analyses 
Variables with a skewed distribution, including TG, VLDL-c, VLDL-TG, glucose, insulin, HOMA-
index, and hsCRP, were logarithmically transformed before analysis. As it has been documented 
that IMT is age and sex dependent, IMT data were adjusted for age and sex prior to all analysis, 
using linear regression analysis. Statistical comparisons for continuous variables between 
subjects with FCH and their unaffected relatives were performed by 2-way ANOVA with age as a 
covariate, and family number as a random factor in order to correct for the lack of genetic 
independence of the subjects. The frequency distribution of the categorical variables between 
the two groups was compared using the χ2-test. Correlations between age- and gender-adjusted 
IMT and continuous clinical or biochemical variables were analyzed using Pearson’s correlation 
coefficients. Associations between dichotomous variables and quartiles of IMT were established 
by one-way ANOVA with post-hoc multiple comparisons (Tukey Kramer). Forward stepwise 
multiple linear regression analysis with IMT as the dependent variable was carried out to test 
Intima-media thickness in FCH 
 
171 
 
whether variables had an independent effect on IMT. All variables with at least a moderate 
univariate correlation (r >0.20) were considered for multivariate analysis. The following variables 
were selected for the multivariate model: apoB, WHR, TC/HDL-c ratio, VLDL-c/TG-ratio, pulse 
pressure, and (log) HOMA-index. To avoid problems with (multi)colinearity, WHR, TC/HDL-c 
ratio, VLDL-c/TG ratio and pulse pressure were chosen as representatives of the pertinent 
parameters. Family number was entered into the model to correct for the lack of genetic 
independence of the subjects. Probability values <0.05 were considered statistically significant. 
All statistical analyses were performed using SPSS 12.0.1 for Windows statistical package (SPSS 
Inc., Chicago Illinois, USA). 
 
 
Results 
 
Subject characteristics 
Table 1 shows the clinical and biochemical characteristics for FCH patients and their unaffected 
relatives. Patients with FCH were on average 7 years older than their unaffected relatives. The 
ratio women/men was not significantly different between the groups. FCH patients were more 
obese, as reflected by their higher BMI and their higher WHR, although the latter difference did 
not reach statistical significance. The percentage subjects drinking >2 alcoholic beverages/day 
did not differ significantly between the two groups (p= 0.13), nor did the percentage 
past/present smokers (p=0.6). Significantly more FCH patients were diagnosed to have 
hypertension compared to their unaffected relatives (odds ratio 4.33 [2.38-7.88], p<0.001), and 
there was especially a trend toward higher systolic blood pressures and pulse pressures. Fifteen 
out of 94 subjects (16%) in the FCH group were diagnosed with cardiovascular diseases, and this 
percentage was significantly higher than it was in the group of unaffected family-members (8%) 
(Odds ratio 2.09 [1.00-4.35], p=0.045). As expected, the number of subjects on lipid-lowering 
medication (prior to the 4-week wash out period of the present study) was significantly higher 
amongst the patients with FCH when compared to their unaffected relatives (40.4% vs. 10.2%, 
p<0.0001). By definition, plasma levels of apoB, TG, and TC were higher in the patients with FCH 
as compared to their unaffected relatives (Table 1). The more atherogenic lipoprotein profile of 
these patients was further characterized by higher LDL-c, VLDL-c, and VLDL-TG levels, and a 
higher VLDL-c/ TG ratio. The latter is indicative of a higher concentration of remnant-particles. 
Furthermore, FCH patients had lower HDL-c concentrations, and their TC/HDL-c ratio was 
significantly decreased as compared to their unaffected relatives. FCH patients were also more 
insulin resistant, reflected by higher fasting glucose and insulin concentrations and (as a result) a 
higher mean HOMA-index. Finally, patients with FCH had significantly higher plasma levels of 
hsCRP and oxLDL as compared to their unaffected relatives. The increased oxLDL levels however, 
might be the result of their concomitantly higher LDL-c levels, since there was no difference in 
the oxLDL/apoB ratio between both groups.   
 
Intima-media thickness 
The results of the IMT measurements are depicted in Table 2. Both the far wall and the near wall 
of the CCA were thicker in FCH patients compared to their unaffected relatives, although 
statistical significance was only reached for the far wall. Most importantly however, there was a 
significant difference between the two groups considering the primary endpoint of the study 
(the mean IMT of all four measured segments), with an absolute difference in IMT between 
affected and unaffected subjects of 33 µm.  
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Table 1: Clinical and biochemical characteristics of patients with FCH (n=94) and their unaffected 
relatives (n=216) 
 FCH (n=94) Unaffected (n=216) P 
Gender (M/F) 40/54 107/109 0.26 
Age (y) 50.4 [47.4-53.5] 43.4 [41.5-45.4] 0.022 
Body mass index (kg/m2 28.2 [27.4-29.1] ) 25.1[24.6-25.5] <0.001 
Waist-to-hip ratio 0.91[ 0.89-0.92] 0.87 [0.86-0.88] 0.114 
Systolic blood pressure (mmHg) 139 [135-144] 132 [130-134] 0.079 
Diastolic blood pressure (mmHg) 77 [75-80] 74 [72-76] 0.544 
Pulse pressure (mmHg) 62[ 59-65] 58[ 56-60] 0.083 
Total cholesterol (mmol/l) 6.76[6.52-6.99] 5.24 [5.11-5.38] <0.001 
Triglycerides (mmol/l) 3.33 [2.90-3.76] 1.29 [1.20-1.37] <0.001 
Apolipoprotein B (g/l) 1.33 [1.29-1.38] 0.95 [0.92-0.98] <0.001 
High-density lipoprotein-cholesterol (mmol/l) 1.15 [1.09-1.20] 1.33 [1.28-1.37] 0.001 
Low-density lipoprotein-cholesterol (mmol/l) 4.13 [3.88-4.38] 3.50 [3.37-3.63] <0.001 
VLDL-c (mmol/l) 1.51 [1.23-1.79] 0.42 [0.38-0.47] <0.001 
VLDL-TG (mmol/l) 2.60 [2.18-3.01] 0.78 [0.70-0.85] <0.001 
VLDL-c/ TG ratio 0.41 [0.39-0.44] 0.30 [0.29-0.31] <0.001 
TC/ HDL-c ratio 4.17 [4.02-4.33] 6.22 [5.81-6.62] <0.001 
Fasting glucose (mmol/l) 5.2 [5.0-5.3] 4.8 [4.7-4.9] 0.007 
Insulin (mU/l) 11.7 [10.8-12.7] 8.4 [7.9-8.9] <0.001 
HOMA-index 2.72 [2.46-2.99] 1.81 [1.69-1.93] 0.001 
hsCRP (mg/l) 3.72 [2.92-4.52] 2.39 [1.93-2.84] <0.001 
oxLDL (U/l) 87 [83-91] 64 [62-66] <0.001 
oxLDL/apoB ratio 0.065 [0.063-0.067] 0.067 [0.066-0.069] 0.627 
Data are presented as mean [95% CI]. M/F indicates male/female, VLDL-c, very low density lipoprotein-cholesterol; 
VLDL-TG, very low density lipoprotein-triglycerides; HOMA, homeostasis model assessment, hsCRP, high-sensitive C-
reactive protein; oxLDL, oxidized low density lipoprotein-cholesterol 
 
 
Table 2: Age-and gender-adjusted intima-media thickness of patients with FCH (n=94) and their 
unaffected relatives (n=216) 
 N  FCH   Unaffected P 
FW-IMT CCA (mm) 298 0.741 [0.721-0.761] 0.707 [0.695-0.719] 0.001 
NW-IMT CCA (mm) 290 0.799 [0.777-0.821] 0.764 [0.751-0.777] 0.088 
Mean IMT CCA (mm)  279 0.769 [0.749-0.789] 0.736 [0.724-0.748] 0.047 
FW-IMT is the average of the mean far-wall IMT of the left and right common carotid artery. NW-IMT is the average of 
near-wall IMT of the left and right common carotid artery. Mean IMT is the average IMT of all four measured 
segments in one subject. n denotes the number of subjects in whom IMT was measured and included in the analyses. 
 
 
Association of IMT with cardiovascular risk factors 
Most biochemical and clinical cardiovascular risk factors, including plasma levels of TC, LDL-c, 
VLDL-c, VLDL-TG, apoB, oxLDL, as well as the VLDL-c/TG ratio, the TC/HDL-c ratio, HOMA-index, 
BMI, WHR, SBP, DBP, and pulse-pressure were significantly positively correlated with mean age-
and gender-adjusted IMT in univariate correlation analysis (Table 3). Plasma levels of HDL-c 
correlated inversely with mean age-and gender-adjusted IMT. HsCRP and the amount of oxLDL 
per apoB were not significantly associated with mean age-and gender-adjusted IMT. 
Furthermore, the age-and gender-adjusted mean IMT was significantly associated with the 
prevalence of cardiovascular diseases when IMT was analyzed in quartiles (ANOVA, p<0.001): 
The subjects with the highest quartile IMT (mean IMT: 0.865 mm) had a significantly higher 
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prevalence of CVD when compared to subjects in the lower three quartiles (mean IMT, 
respectively 0.637 mm, 0.710mm and 0.768mm, all p<0.001 vs. highest quartile). Age-and 
gender-adjusted IMT was also associated with the prevalence of hypertension (ANOVA, 
p<0.001): subjects with the highest quartile IMT had significantly more often hypertension 
compared to subjects in the first (p<0.001) second (p=0.001) and third quartile (p=0.024). No 
significant association was found between IMT and smoking [past or present smoking yes/no] 
(ANOVA, p=0.37) or use of alcohol [use of >2IE alcohol/day yes/no] (ANOVA, p=0.24). 
 
 
Table 3: Univariate correlations of age- and gender-adjusted IMT with clinical and biochemical 
characteristics in FCH-families (n=279) 
 r P a 
Body mass index (kg/m2 0.25 ) <0.001 
Waist-to-hip ratio 0.49 <0.001 
Systolic blood pressure (mmHg) 0.56 <0.001 
Diastolic blood pressure (mmHg) 0.44 <0.001 
Pulse pressure (mmHg) 0.37 <0.001 
Total cholesterol (mmol/l) 0.52 <0.001 
Triglycerides (mmol/l) 0.38 <0.001 
Apolipoprotein B (g/l)  0.53 <0.001 
High-density lipoprotein-cholesterol (mmol/l) -0.19 0.002 
Low-density lipoprotein-cholesterol (mmol/l) 0.42 <0.001 
VLDL-c  0.38 <0.001 
VLDL-TG  0.34 <0.001 
VLDL-c/ TG ratio 0.36 <0.001 
TC/ HDL-c ratio 0.45 <0.001 
HOMA-index 0.16 0.007 
hsCRP (mg/l) 0.05 NS 
oxLDL/apoB ratio -0.07 NS 
Abbreviations as in table 1. a
 
 Pearson’s correlation coefficients of age- and gender-adjusted IMT with the selected 
variables. NS indicates non-significant 
 
Multivariate analysis 
Multiple linear regression analysis was used to investigate whether one or more of the 
univariate correlated factors were independent predictors of age-and gender-adjusted IMT. The 
final model is shown in Table 4, and explained 51.4% of the variation in age-and gender-adjusted 
IMT in FCH-patients, and 51.8% in their unaffected relatives. WHR, pulse pressure, and apoB 
were independent predictors of IMT, both in FCH-subjects as in their unaffected relatives. In 
addition, in the FCH-patients but not in their unaffected relatives, the VLDL-c/TG-ratio turned 
out to be an independent predictor too. With 32.8% explained variation in IMT, it was even the 
most important predictor of the age-and gender-adjusted IMT in patients with FCH. Family 
number, forced into the multivariate regression model to correct (partially) for the non-
independence of the study subjects) had no significant contribution to the R2
 
. 
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Table 4: Multivariate model of mean age- and gender-adjusted IMT of patients with FCH (n=78) 
and their unaffected relatives (n=201) 
  
FCH  
  
Unaffected 
(N=201) 
 
(N=78) 
 
Std.β p rel. R Std.β 2a p rel. R
Waist-to-hip ratio 
2a 
0.28 0.003 0.063 0.29 <0.001 0.053 
VLDL-c/TG ratio 0.39 <0.001 0.328 NE 
  Apolipoprotein B 0.24 0.009 0.093 0.46 <0.001 0.355 
Pulse pressure 0.20 0.023 0.03 0.36 <0.001 0.107 
Abbreviations as in Table 1. Adjusted multiple R2 of the model is 0.514 for FCH patients and 0.518 for unaffected 
relatives. Family number was forced into the regression model to correct for non-independence of the study subjects, 
but had no significant contribution to the R2. Std. denotes standardized; NE, does not enter the final model; a denotes 
absolute increase in adjusted R2
 
 when entered in the model.   
 
  
Discussion 
 
Mean age- and gender-adjusted IMT was 33 µm thicker in FCH patients compared to their 
unaffected relatives. This increased IMT could (at least partially) be attributed to the presence of 
visceral obesity, a higher blood pressure and dyslipidemia characterized by both an increased 
number of atherogenic particles and an altered (VLDL) particle composition. 
Former studies on IMT in patients with FCH yielded opposing results, possibly as a result of their 
relatively small sample sizes. Keulen et al.18 reported a slightly larger difference in IMT between 
FCH patients and age-matched controls than we did. This difference could be explained by the 
fact that their control subjects were population-based volunteers and spouses with a variety of 
genetic and socio-economic backgrounds instead of unaffected family members, as in our study. 
Ylitalo et al.19 on the other hand, reported no difference in IMT between FCH patients and their 
unaffected relatives. The contrast with our findings could be explained by the exclusion of 
subjects with CVD in the study of Ylitalo et al. Exclusion of subjects with CVD in the present study 
was expected to result in a smaller IMT in FCH patients, since CVD was much more prevalent in 
patients with FCH when compared to their unaffected relatives. Although the difference in IMT 
between patients with FCH and their unaffected relatives was still significant after exclusion of 
all subjects with CVD (p=0.036), the absolute difference in mean IMT decreased to 25µm (data 
not shown). Although it has been proved that CVD is associated with IMT-thickening20, CVD is 
rather the result of IMT-thickening, than being an independent risk factor for IMT-thickening. 
Therefore, subjects with CVD were not excluded from analysis in the present study. Even more, 
the difference in IMT of 33µm in the current study might be an underestimation of the true 
difference, since the number of subjects taking statins was significantly higher in the FCH 
patients, and statins have been shown to slow down progression of IMT or even revert it21
Previous studies have extensively reported the important effect of age and gender on IMT
.  
11. 
However, since age and gender are not modifiable, all IMT data were standardized for these 
parameters prior to analysis. After standardization, the most important cardiovascular risk 
factors responsible for the increased IMT in patients with FCH were an elevated blood pressure, 
the presence of visceral obesity (reflected by an increased WHR), an increased number of 
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atherogenic lipoprotein particles (reflected by an increased plasma apoB-concentration), and the 
presence of remnant particles (reflected by the increased VLDL-c/TG-ratio). 
In concordance with previous reports addressing the effect of systolic blood pressure on IMT22
Univariate correlations with IMT for waist and WHR were higher than for BMI. This is in line with 
the current perception that waist circumference and WHR are better predictors of 
cardiovascular risk than BMI
, 
pulse pressure was an independent predictor of IMT in the multivariate model, both in FCH 
patients and in the normolipidemic relatives. This could explain (in part) the increased 
prevalence of cardiovascular disease in FCH patients, since there was a trend towards a higher 
SBP and a higher pulse pressure in patients with FCH, and the percentage subjects with 
hypertension was significantly higher when compared to their normolipidemic relatives. 
23. WHR was also an independent predictor of IMT in the 
multivariate regression model, explaining 5.3% (unaffected subjects) to 6.3% (FCH patients) of 
variation in IMT when entered in the model. The difference in body composition between FCH 
patients and their unaffected relatives might therefore, with time, be an important contributor 
to the observed increased cardiovascular risk of patients with FCH. This is in line with recent 
reports of elevated leptin levels24 and decreased adiponectin levels25
 
 in patients with FCH, 
confirming a possible role of the adipose tissue in the pathogenesis of FCH. 
Surprisingly, we found no association of smoking [past/present smoking, yes/no] with IMT, 
although the existence of such an association has been reported in prior studies. This lack of 
association could be due to the confounding effect of therapeutic lifestyle-counseling, since FCH 
patients were seen regularly by their physicians, as opposed to their unaffected relatives. 
Suboptimal data collection with regard to smoking habits could also have been a contributing 
factor, since smoking habits were reported on the inquiry-form dichotomously [yes/no] instead 
of continuously [pack years of smoking]. 
 
Almost all plasma lipid and (apo)lipoprotein concentrations determined in this study (including 
increased plasma concentrations of TC, TG, apoB, LDL-c, TG, VLDL-c, and decreased HDL-c), were 
significantly associated with the age-and gender-adjusted IMT in univariate correlation analysis. 
Although elevated levels of hsCRP  have been shown to be a strong independent risk factor for 
cardiovascular disease26, the concentration of hsCRP was no major determinant of  IMT in the 
current population. This is in line with recent findings of Sander et al.27
 
, who showed that hsCRP 
was not an independent predictor of IMT in a large prospective, population-based study 
conducted in 3534 subjects.  
In multivariate analysis, apoB was independently associated with IMT, both in FCH patients and 
in their unaffected relatives, stressing the relative importance of the number of atherogenic 
lipoprotein particles in the development of cardiovascular diseases. However, not only particle 
number plays a role; particle composition might be of equal importance. Patients with FCH had a 
significantly higher VLDL-c/TG ratio, reflecting the relative enrichment of their VLDL particles 
with cholesterol. This might be the result of a combination of an increased production of VLDL 
particles together with disturbances in their lipoprotein-catabolism, like a decreased LPL-
activity4. As a result, triglyceride-rich lipoproteins have an increased residence-time in the 
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arterial wall. The resulting, partially hydrolyzed triglyceride-rich remnant-particles, are more 
atherogenic than larger (newly secreted) triglyceride-rich lipoprotein-particles since the particles 
are smaller and thereby able to penetrate the endothelial barrier more easily28
 
. This explains 
why the VLDL-c/TG ratio turned out to be a significant and independent predictor of IMT in 
subjects with FCH. The VLDL-c/TG ratio was superior to the TG concentration in predicting IMT: 
The amount of explained variation in IMT decreased from 32.8% for the VLDL-c/TG ratio to only 
5.9% for TG, when the VLDL-c/TG ratio was replaced by TG in the regression model (data not 
shown). So quantifying the amount of remnant particles in patients with FCH is of additional 
value in determining their cardiovascular risk compared to determining the total plasma 
triglyceride-concentration reflecting the combined effect of all TG-rich lipoproteins. Since in 
healthy subjects remnant lipoproteins are (almost) absent in the fasting state, the VLDL-c/TG-
ratio was not an independent predictor of IMT in the unaffected relatives. 
In conclusion: FCH patients have a significantly increased age- and gender-adjusted IMT when 
compared to their normolipidemic relatives. WHR, pulse pressure, plasma apoB-concentration, 
and the VLDL-c/TG-ratio turned out to be independent predictors of their IMT. The VLDL-c/TG 
ratio was associated with IMT only in the patients with FCH and not in their unaffected relatives. 
Therefore, we conclude that the presence of highly atherogenic remnant lipoproteins probably 
plays an important role in the pathogenesis of cardiovascular diseases in FCH. 
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1. General discussion on the non-invasive measurements of atherosclerosis  
 
Although most of the non-invasive measurements of atherosclerosis (NIMA) described in this 
thesis are used for research purposes worldwide, none of these measurements made its way 
into clinical practice yet, except for the ankle-brachial index (ABI). Some NIMA are 
recommended to be included in cardiovascular risk stratification; ABI, intima-media thickness 
(IMT), and pulse wave velocity (PWV) are recommended to determine subclinical organ damage 
in the guidelines for the management of arterial hypertension, and in the guidelines for 
cardiovascular (CV) screening in the asymptomatic at-risk population1,2
 
. The NIMA will be 
discussed in the sections below, including their current status and possible evidence for 
introduction of these NIMA into clinical practice. At the end of the chapter future perspectives of 
NIMA in relation to cardiovascular research will be discussed. 
 
1.1 Endothelial (dys)function 
 
1.1.1 Flow-mediated dilation 
 
In both our middle-aged low- and high-risk population, flow-mediated dilation (FMD) was not 
related to the traditional CV risk factors or prevalent cardiovascular disease (CVD). In contrast, 
several papers published that the FMD measurements could be a useful tool in CV risk 
stratification and prediction, especially in young populations3-8, although prospective studies are 
needed to prove this concept. Endothelial dysfunction is a measure of early atherosclerosis and 
will therefore be present in older populations where multiple risk factors are present for many 
years.  Very recently, Yeboah and colleagues showed that FMD was a predictor of CVD in a large 
sample from the general population, although FMD did not improve the prediction of CVD over 
the Framingham Risk Score. However, adding FMD to risk stratification based on the 
Framingham Risk Score made many individuals shift from risk category8. Individuals with a 
normal FMD shifted towards a lower risk category. They concluded that FMD might help in CV 
risk stratification to select those who seemed to be at risk based on Framingham Risk Score, but 
based on a normal FMD seem to be at lower CV risk8
Numerous factors, such as biological and technical factors, contribute to the variability 
of FMD as recently summarized by Moens and co-workers
.  In our opinion the conclusions have to be 
regarded with care, since the variability of FMD is quite large, as also reported by these authors.  
9. Many efforts have been made to 
reduce  measurement variability, such as the introduction of monitoring software10-12. Intra-
observer coefficients of variation of 1.8 to 23.0 % were previously reported, but when expressed 
as a percentage, coefficients of variation increased to 28-33%12. Other authors calculated 
already in 1995,  that a mean improvement of FMD over 2% is necessary to detect a treatment 
benefit and that for any individual a difference of 4-8% is necessary to account for natural 
variability13.  Therefore, we performed a power analysis; based on detecting a difference of 0.5% 
in the prevalence of CVD, over 14.000 FMD measurements are needed. Furthermore, it is a time-
consuming measurement that is relatively uncomfortable for the patient. Finally, in our opinion 
there has been an under-reporting of negative studies, as previously mentioned by other 
authors14
After all these years of research on FMD, there is still no clarity on its possible potential to be 
a screening tool in CV risk stratification, and no uniform results have been reported. Therefore, 
the use of FMD in clinical practice is questionable. After performing and analyzing many FMD 
measurements, based on the above described facts, and looking back on the results in our two 
populations, which showed very poor relation between CV risk factors and FMD in both low and 
high-risk populations, we conclude that time for FMD to be applied in clinical practice is still far 
.  
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away. Further research might focus on the possible role of FMD in CV risk stratification in 
younger populations, using standardized methods for FMD in standardized conditions. 
 
1.1.2 Brachial artery diameter 
 
In contrast to FMD, brachial artery diameter (BAD) was related to cardiovascular risk factors and 
other measurements of subclinical atherosclerosis in our population-based sample, which was 
also recently published by others15,16. The diameter of the brachial artery might be a reflection of 
systemic vasodilation, as a compensation in reaction to narrowing of the arterial lumen17
 
. In our 
opinion the BAD could be a potential tool in CV risk stratification when combined with other 
measurements of atherosclerosis; however, this has to be investigated in prospective data.  
 
1.2 Arterial stiffness 
 
1.2.1 Pulse wave velocity  
 
Due to ageing and atherosclerosis arteries become stiffer. Due to the different composition of 
central and peripheral arteries, not all arteries stiffen to the same extent. The stiffening of 
central arteries is larger than the stiffening of the peripheral arteries. The clinical consequences 
of arterial stiffness are an increased risk of stroke as a result of increased systolic blood pressure, 
the development of left ventricular hypertrophy as a result of increased cardiac after load, and a 
decrease in coronary perfusion and heart failure due to the decrease in diastolic blood pressure. 
At the start of our study in 2004, the predictive value of PWV for CVD was unknown. However, 
recently, several studies showed that PWV was an independent predictor of CVD both in low and 
high-risk populations. Some studies in the general population even showed that PWV provided 
incremental information on cardiovascular risk over and above traditional risk factors18,19. 
Nowadays, PWV is the “gold standard” measurement for arterial stiffness20. Reference values 
have been provided by several authors2,21-23
In our study in FCH (Familial Combined Hyperlipidemia) patients, PWV was increased compared 
to their unaffected relatives. PWV did predict the presence of CVD equally well as a combination 
of traditional risk factors, but did not have additive value over and above the traditional risk 
factors in this high-risk population. This might be due to the relatively small sample size and the 
cross-sectional analyses. In our population-based cohort, PWV was associated with the 
metabolic syndrome and its individual traits. We also observed increased PWV in all 
dyslipoproteinemias based on the algorithm using apoB, TG and TC. 
;  in healthy adults the PWV generally ranges from 5 
to 7 m/sec.  
In conclusion, PWV is a well established measure of arterial stiffness and is a very promising tool 
to be included in CV risk stratification in clinical practice. The additive value of PWV over and 
above traditional CV risk factors has to be confirmed, especially in combination with other NIMA.    
 
1.2.2 Pulse wave analysis 
 
Another surrogate measure of arterial stiffness currently used in research is the augmentation 
index (AIx). Very recently the use of other central blood pressure parameters regained interest. 
Central blood pressure can be measured invasively, but non-invasive measures would be 
preferred and more widely applicable in clinical practice. New devices have been developed that 
calculate these central blood pressures from the measured pressure wave at the radial or 
carotid artery. The main problem of these non-invasively obtained central pressure parameters 
is that they are derived from peripheral waveforms using a transfer function. The transfer 
function has only been validated in selected patients groups24,25, and therefore care must be 
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taken by the interpretation of the data in other populations. Furthermore, there is doubt about 
the formula used to calculate the AIx26. Despite these mathematical difficulties, the use of 
central blood pressure parameters has regained interest due to the results of the Conduit Artery 
Functional Endpoint (CAFÉ) study. That study showed that central blood pressure but not 
peripheral blood pressure was lowered by one of the drugs administered in that study27. Since 
then, many studies incorporated the central pressure measurements in their studies and many 
results are yet to be published. However, very recently the authors of the CAFÉ study published 
additional analyses of their study and concluded that the difference in central pressure reported 
before, was mainly the result of the heart rate reduction with beta-blockers. This appeared to be 
the major mechanism accounting for less effective central aortic pressure reduction per unit 
change in brachial pressure28. Besides the CAFÉ study, the Cardiovascular Health Study also 
showed interesting results with regard to non-invasively obtained central pressure parameters. 
They reported that central pressure was more strongly related to (subclinical) atherosclerosis 
and CV events than brachial blood pressure29
 
.  
In our study in FCH patients, no difference in augmentation index was observed compared to 
their unaffected relatives, whereas PWV was increased. This discrepancy might be explained by 
the fact that the age-related changes in PWV and AIx follow different patterns; changes in AIx 
are more dominant in younger subjects (<50 years) and changes in PWV are more marked in 
older individuals (>50 years)30
In our population-based cohort, AIx was associated with the Metabolic Syndrome and its 
individual traits, although the association was stronger in men than in women.  However, no 
clear association between high waist circumference and AIx was observed.  In the study in which 
we applied the algorithm for dyslipoproteinemias based on apoB, triglycerides (TG) and total 
cholesterol (TC) to the low-risk population, all stiffness parameters, including central pressure 
parameters, were increased in the different dyslipoproteinemias.    
.  
Whether AIx is associated with cardiovascular risk in the general population is not known and 
studies in selected patient groups showed conflicting results23,31,32
 
. Further research is needed to 
determine whether AIx and other derived central pressure parameters are real reflections of 
central pressure and can be useful in CV risk assessment, especially in younger populations.  
 
1.3 Thickness of the arterial wall 
 
1.3.1 Intima-media thickness 
 
IMT is a measure of structural changes in the arterial wall.  IMT is a well established measure of 
(subclinical) atherosclerosis and has shown to predict CVD, as well in patients as in 
asymptomatic individuals33-41
Numerous studies reported that IMT can be measured in a reliable and reproducible manner, 
although different protocols are used in different studies
. In line with these data, we showed that IMT was strongly 
associated with traditional CV risk factors in both participants from the Nijmegen Biomedical 
Study (NBS) and in FCH families. IMT was increased in FCH patients, in individuals with the 
Metabolic Syndrome, and in different dyslipoproteinemias.  
42. Measurement variability is typically 
introduced from several resources: ultrasound scanning equipment, sonographers, reading 
equipment, readers of the scans, scanning protocol, and thickness of the intima-media 
complex43-46. Since automatic devices were introduced to measure IMT, variability decreased 
substantially9,47-52. At higher ages, the variability in IMT between subjects is larger44 . The 
thickness of the wall also varies during the heart cycle, as demonstrated in Figure 1. In the 
diastolic phase, the IMT is thicker than in the systolic phase. Therefore the measurements have 
to be performed at the same time in the heart cycle in every person.  
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Figure 1: Variation in IMT of the artery during the cardiac cycle. The dotted area represents the lumen of the artery 
and the fat black line represents the intima of the arterial wall.  
 
Several authors already extensively discussed the different methods used to measure IMT and 
international recommendations have been done for standardized IMT measurements46. In 
studies evaluating the effect of drugs in which IMT is the primary end point, very small 
differences have to be detected, demanding a very precise IMT measurement. However, in our 
study IMT is used as a screening tool; the measurement needed to be simple, quick, but reliable 
and we decided to measure the near and far walls of both the common carotid arteries42,46,53,54
At the start of our study in 2004, the predictive value of IMT over and above traditional risk was 
unknown. However, evidence has been accumulating last few years that IMT has additive value 
over and above traditional CV risk factors in the prediction of CVD, although not all studies could 
confirm the additive value of IMT
.  
55,56. The guidelines for the management of arterial 
hypertension and the guidelines for cardiovascular screening in the asymptomatic at-risk 
population included an IMT value > 0.9 mm or the presence of plaque as a sign of target organ 
damage1,2
In summary, IMT is a well established surrogate marker of atherosclerosis and is a very 
promising tool to be included in CV risk stratification in clinical practice. Before IMT will make its 
way into clinical practice, the additive value of IMT over and above traditional CV risk factors has 
to be confirmed in prospective trials.  
. However, IMT is not yet widely introduced in clinical practice for CV risk stratification. 
 
1.3.2 The presence of plaque and plaque thickness 
 
The presence of plaque and plaque thickness are measures of advanced atherosclerosis. Not 
many studies measured these parameters, and many different methods are used to measure 
these quantities. As described in the previous section, the presence of plaque showed predictive 
value for CVD and is included in some guidelines2.  In 2004 a consensus document was published 
with recommendations on how to define the presence of plaque57. However, data on plaque 
thickness are scarce and even more diverse methods are used. The predictive value of plaque 
thickness in CV risk stratification and the additive value of the presence of plaque in different 
populations needs to be evaluated in prospective studies, taking into account the measuring 
method.  
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1.4 Peripheral flow 
 
1.4.1 Ankle-brachial index at rest 
 
The ankle-brachial index (ABI) at rest is a measure of more advanced stages of atherosclerosis 
and is used in clinical practice for years now to determine whether a patient suffers from 
peripheral arterial disease. We applied the method commonly used in clinical practice, namely 
one measurement of ABI at a single time point and by one single observer. This method was also 
the method applied by Price et al who established the cut-off value of ABI in a very large 
population-based cohort58. The ABI at rest is a simple, noninvasive and inexpensive test that can 
be used to identify individuals who are at high risk of developing CVD59
The measurement found its way into clinical practice rather easily, since not many studies have 
been done to determine the reproducibility of the measurement. The first publication on the 
reproducibility dates from 1981
.  
59. The authors recommended performing the measurement 
more than once and a difference in subsequent measures from 15 mmHg could be regarded as 
clinical relevant. Some studies reported on reproducibility of the ABI in selected patients groups 
and all concluded that the measurement was reliable when performed by trained technicians60-
66.  An ABI at rest below 0.9 is widely considered to be abnormal1,2,58. Several  studies reported  
that a low ABI at rest had predictive value for CVD in patients with CVD and in low-risk 
populations59,67-82
Further studies need to provide insight in the predictive value of the ABI at rest for CVD in low-
risk populations over and above traditional risk factor stratification.  
. In our study in a sample from the general population, a decreased ABI at rest 
was associated with the Metabolic Syndrome and with the individual traits. A decreased ABI was 
also associated with different dyslipoproteinemias.   
 
1.4.2 Ankle-brachial index after exercise 
 
In clinical practice the exercise test is performed to confirm that a diminished arterial flow is the 
cause of the walking disability. A decreased ABI after exercise can also detect atherosclerotic 
lesions that do not cause a drop in blood pressure at rest yet. When more oxygen is needed 
during exercise, the obstruction might prevent an increase in oxygen supply, which causes a 
drop in the pressure at the lower limb resulting in a lower ABI after exercise. ABI after exercise 
might therefore be considered as a measure of subclinical atherosclerosis. However, data on the 
predictive value of the ABI after exercise for CVD are lacking.   
In our study in the general population we showed that individuals with the Metabolic Syndrome 
had a decreased ABI after exercise. ABI after exercise was also associated with the individual 
traits of the Metabolic Syndrome and with an increased apoB level. We also reported decreased 
ABI after exercise in the different dyslipoproteinemias. Also larger differences in ABI after 
exercise than in ABI at rest were observed in different sub studies evaluating different CV risk 
factors.  
Further studies are warranted to determine the predictive value of ABI after exercise for CVD 
and its additive value over and beyond traditional CV risk factors, especially in low-risk 
populations.  
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2. Predictive value of combinations of NIMA 
 
The individual predictive value of PWV, IMT, and ABI at rest has been established. Several 
studies also focused on the additive value of these NIMA in CV risk stratification over and above 
traditional risk factor screening and are included into the guidelines as measures of target organ 
damage2
 
.  However, each NIMA reflects a different characteristic of the atherosclerotic process, 
involving functional and/or morphological changes in the vessel wall. Furthermore, the extent of 
atherosclerosis differs along the arterial tree. In different populations at risk of atherosclerosis, 
different characteristics of the atherosclerotic process may be present or accelerated. Therefore, 
simultaneous measurements of different NIMA could theoretically enhance the power to 
improve CV risk assessment, however, up to now no studies have been published in which the 
predictive value for CVD for different combinations of NIMA was evaluated prospectively. 
 
3. Determinants of NIMA 
 
The progression rate of atherosclerosis differs among individuals. This might be due to different 
impact of known and unknown CV risk factors and/or differences in time exposure to these risk 
factors, and/or genetic predisposition. NIMA measure the extent of atherosclerosis, and the 
hypothesis is that the amount of atherosclerosis reflects the impact of these different CV risk 
factors.   
Previous studies demonstrated that the predictive power of NIMA for cardiovascular events is 
independent of the conventional risk factors18,19,35,81,83-85
In our study in FCH families, the percentage explained variance in IMT by traditional CV risk 
factors was ± 50%, as well in FCH patients as in the unaffected relatives, leaving the other half of 
the variance unexplained. These results are in line with other studies in high-risk populations. In 
general, the reported percentage explained variance in NIMA  is larger in high-risk populations 
than in low-risk populations
, although a large proportion 
(approximately 70%) of the variance in NIMA and prevalent CVD remained unexplained. 
86-94
Because a large proportion of NIMA and prevalent CVD remain unexplained by known CV risk 
factors, future studies are needed to identify other main determinants of NIMA, including 
exploring potential new CV risk factors, i.e. inflammation parameters. Therefore, repeated 
measurements of NIMA might help unraveling the impact of ageing, time of exposure to known 
and unknown CV risk factors, and/or genetic susceptibility.   
.  
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4. Future perspectives 
 
As noted in the previous section, a major problem in clinical practice is that at every level of risk 
factor exposure, there is large inter-individual variation in the amount of atherosclerosis and the 
development of CVD. By measuring atherosclerosis directly in the arterial wall, the damage 
caused by ageing and clinical, biochemical, and genetic risk factors can be evaluated. This 
provides the opportunity to measure atherosclerosis before symptomatic CVD develops. Thus, 
subclinical disease measurements (NIMA), representing the final result of risk exposure, may be 
useful for improving CV risk prediction, therapeutic strategies and evaluation of risk factor 
modification. However, in the general population only ±20-30% and in high-risk populations 
approximately 50% of the variance of NIMA can be explained by known CV risk factors, so the 
major pathophysiological determinants of NIMA are unknown. Furthermore, follow-up data on 
the panel of NIMA are lacking and therefore the relevance of NIMA in clinical practice for the 
individual patient is unclear. So, measuring changes in a panel of NIMA values after for instance 
5 years of follow-up, measured in both a low and a high-risk population, in relation to changes in 
traditional and new CV risk factors and incidence of CVD will:  
 
 Unravel the major pathophysiological determinants of NIMA, including aging, time of 
risk factor exposure, and genetic risk factors.  
 Unravel the impact of time of exposure to these CV risk factors on the development and 
progression of (subclinical) atherosclerosis (as measured by NIMA) and CVD (as 
measured by clinical endpoints).  
 Provide evidence based protocol for NIMA to improve cardiovascular risk stratification 
for the individual patient in clinical practice.  
 Provide the power of baseline versus repeated NIMA in CVD risk prediction, over and 
beyond CV risk factors. 
 Identify the combination of NIMA that will improve CV risk stratification in a low and a 
high-risk population in a cost-effective way, allowing earlier and more effective (new) 
preventive therapy.  
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Summary 
 
Cardiovascular disease (CVD) has been a major cause of death for years now. Atherosclerosis is 
the underlying disease causing CVD. Many risk factors causing atherosclerosis and its 
progression are known, such as increased blood pressure, increased lipid levels, smoking, 
obesity, and diabetes mellitus.  In clinical practice, it appears that not all individuals with the 
same risk factors develop the same extent of atherosclerosis. It is possible that an individual with 
only increased lipid levels already develops CVD at an early age, whereas another smoking 
individual with increased blood pressure and obesity develops CVD at the age of 80.  
Atherosclerosis develops gradually and causes changes in the arteries. The function of the 
endothelial layer, a monolayer of cells on the inner layer of the arteries, deteriorates, the 
arterial wall thickens, and the arterial wall becomes stiffer. To be able to prevent CVD, it is 
important to measure the extent of atherosclerosis as early as possible so that treatment can be 
started to reduce the progression of atherosclerosis and the development of CVD. The extent of 
atherosclerosis in the arterial wall can be measured by several techniques that measure the 
quality of the arteries non-invasively, such as ultrasound and tonometry. The non-invasive 
measurements of atherosclerosis (NIMA) based on these techniques are relatively cheap, 
painless, friendly for the patient, and can reliably be measured. Some individuals do have 
atherosclerosis but did not (yet) develop CVD and this is subclinical atherosclerosis. So, 
individuals with deteriorated NIMA but without CVD have subclinical atherosclerosis. 
The 4 NIMA which reflect subclinical atherosclerosis measured in the studies include: (Figure 2, 
chapter 1) 
1. Endothelial (dys) function as measured by flow-mediated dilation (FMD; Figure 3, chapter 1). 
The function of the endothelium can be determined by measuring the dilation of an artery in 
reaction to a stimulus, such as the lack of oxygen of the administration of a vasodilator 
(nitroglycerin).  
2. Arterial stiffness as measured by pulse wave velocity (PWV) using tonometry (Figure 6, chapter 
1). By measuring the arrival of the pulse wave generated by the heart at two sites sequentially 
(the neck and the groin), the speed of the pulse wave can be calculated. By registration of the 
waveform, the augmentation index (AIx) and other central pressure parameters can be 
calculated.  
3. Thickness of the arterial wall as measured by intima-media thickness (IMT) (Figure 7-9, chapter 
1). Using ultrasound, the carotid artery in the neck can be visualized, including the different 
layers of the arterial wall. The thickness of the arterial wall can be measured and subsequently 
the carotid arteries are also checked for the presence of plaques and thickness of the plaques is 
measured. 
4. Peripheral flow as measured by the ankle-brachial index (ABI) at rest and after exercise (Figure 
10, Chapter 1). 
 
This thesis covers only partially the data gathered in the large prospective non-invasive 
measurement of atherosclerosis (NIMA) study. The main objective of the studies described in 
this thesis was to determine the association between cardiovascular (CV) risk factors, the 
presence of cardiovascular disease (CVD), and subclinical atherosclerosis, as measured with 4 
NIMA. In part I we described these associations in a low-risk population (50-70 years old), the 
Nijmegen Biomedical Study (NBS) and in Part II the associations between NIMA and CV risk 
factors and prevalent CVD were investigated in a high-risk population, a cohort of families with 
Familial Combined Hyperlipidemia (FCH).  
 
The first step in our project was to validate new techniques for non-invasive measurements of 
atherosclerosis in our Department of Vascular Diagnostics. Furthermore, a large number of 
subjects were to be measured, and to shorten the time frame in which this could be finished, in 
chapter 2 we studied whether the values of NIMA performed in the morning differed from the 
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outcomes of NIMA performed in the afternoon, under standardized conditions. We 
demonstrated that, when exogenous variables (including food intake, caffeine intake, smoking, 
alcohol intake, medication use, room temperature and moment in the menstrual cycle) were 
carefully controlled for, the outcomes of NIMA were not confounded by variation in the exact 
time of the measurement. The mean ± SEM difference between the morning and afternoon 
measurements was 0.009 ± 0.005 mm for IMT; 0.95 ± 1.68% for augmentation index AIx; -0.37 ± 
0.23 m/s for PWV; and -0.71 ± 1.18% for FMD. We also showed that, IMT, PWV, and FMD could 
be performed reproducibly in 19 healthy volunteers. The mean ± SEM difference was 0.003 ± 
0.007 mm for IMT; 0.68 ± 0.86% for AIx; 0.19 ± 0.12 m/s for PWV; and -1.05 ± 1.12% for FMD.  
 
 
Part I: Non-invasive measurements of atherosclerosis in relation to cardiovascular risk factors 
and prevalent CVD in the Nijmegen Biomedical Study, a population-based study. 
 
One of the first signs of the process of atherosclerosis is endothelial dysfunction. In chapter 3 we 
determined whether FMD, BAD, and NMD were related to CV risk factors and IMT in the NBS 
population. We showed that FMD and NMD were not related to known CV risk factors and 
prevalent CVD, and FMD was not correlated with IMT (r=0.04; p=0.625), a surrogate marker of 
atherosclerosis. Most intriguingly, the BAD was significantly correlated with some CV risk factors, 
prevalent CVD and IMT (r=0.25; p < 0.001). So, BAD might be a potential valuable tool in CV risk 
prediction in middle-aged low-risk populations, whereas FMD is not. 
The clustering of certain CV risk factors might play an important role in the development and 
progression of atherosclerosis; this clustering is known as the Metabolic Syndrome (MetS). Many 
different definitions have been developed the last few years, and most of them include central 
obesity, dyslipidemia, increased blood pressure, and insulin resistance or glucose intolerance. In 
chapter 4 we aimed to determine the impact of the MetS and its individual traits on subclinical 
atherosclerosis, as measured with NIMA. We showed that both men and women with the MetS, 
regardless which definition was used, were characterized by increased subclinical 
atherosclerosis, as reflected by less favourable outcomes of all six parameters of subclinical 
atherosclerosis, derived from the 4 NIMA. Subjects with the MetS showed lower ABI at rest (M:-
5.2%; F:-3.1%) and after exercise (M:-7.7%; F:-6.6%), higher AIx (M:+4.8%; F:+1.9%), increased 
PWV (M:+22.8%; F:+20.5%), increased IMT (M:+9.3%; F:+6.9%), and thicker plaques (M:+17.6%; 
F:+26.6%) compared to those without the MetS. Most intriguingly, the number of traits was 
strongly associated with the severity of subclinical atherosclerosis, as all NIMA gradually 
deteriorated with increasing number of traits present. NIMA were already deteriorated when 
one or two traits were present and further deteriorated when 4 or 5 traits of the MetS were 
present. Therefore, it seems more important to identify the presence of the individual traits and 
the number of traits of the MetS than to diagnose the presence of the MetS. 
 
Obesity, especially abdominal obesity, is a known risk factor for CVD and can easily be measured 
with a measuring tape. Recently, adiponectin has been identified as a new biochemical marker 
of obesity. A low adiponectin level has been associated with an increased CV risk and has been 
proposed to be the missing link between obesity and CVD. The objective of the study described 
in chapter 5 was to compare the impact of waist circumference versus adiponectin level on 
subclinical atherosclerosis, and to determine which of these obesity markers showed the 
strongest associations with subclinical atherosclerosis. Both men and women with a high waist 
(M>104cm; F>95cm) showed an increased PWV (M:+9.4%; F:+8.3%) and a larger IMT (M:+7.3%; 
F:+4.3%) and women also showed an increased plaque thickness (+16.6%). After adjustment for 
other CV risk factors both men and women with a high waist showed an increased IMT 
(M:+4.8%;  F:+2.8%) and men showed an increased PWV (+9.6%). The main determinants of IMT 
were pulse pressure and waist circumference. Both men and women with a low adiponectin 
Chapter 12 
 
196 
 
level (M<2.2 mg/l; F< 3.5 mg/l) showed a decreased ABI after exercise (M:-9.5%; F:-3.9%) and an 
increased IMT (M:+3.7%; F:+3.6%) and women also showed an increased PWV (+6.8%), but after 
adjustment for other CV risk factors low adiponectin level was no longer associated with 
deteriorated outcomes of NIMA. So, waist circumference showed independent associations with 
subclinical atherosclerosis, whereas the association of adiponectin level with subclinical 
atherosclerosis was not independent of other CV risk factors. The atherogenic effect of a low 
adiponectin level seemed to be mediated by other CV risk factors and not by low adiponectin 
level intrinsically.  
 
A high level of low-density lipoprotein-cholesterol (LDL-c) contributes to an increased CV risk. 
Many studies already showed that apolipoprotein B (apoB) and non-high-density lipoprotein-
cholesterol (non-HDL-c) were superior to LDL-c in CV risk prediction. In chapter 6 we compared 
apoB, non-HDL-c and LDL-c in identifying individuals at increased CV risk based on their CV risk 
profile, including the presence of subclinical atherosclerosis.  Both men and women with 
increasing levels of apoB and non-HDL-c were more obese, had higher blood pressure and 
fasting glucose levels, and a more atherogenic lipid profile. Furthermore, compared to the 
reference group (composed of those with apoB, non-HDL-c, and LDL-c levels in the bottom 
quartiles), participants with high apoB and non-HDL-c (top quartiles) showed a lower ABI at rest 
(-3.5% and -3.1%) and after exercise (-6.3% and -4.7%), a larger IMT (+5.7% and +5.3%) and more 
plaques (+54.2% and +54.3%). In addition they also showed increased stiffness parameters (e.g. 
PWV both +3.6%). Less clear differences in CV risk profile and subclinical atherosclerosis 
parameters were observed when participants were stratified by LDL-c level. Furthermore, ApoB 
but not LDL-c detected prevalent CVD, and non-HDL-c only detected prevalent CVD in men. The 
discriminatory power for prevalent CVD expressed as area under the ROC-curve was 0.60  for 
ApoB (P <0.001), 0.57 for non-HDL-c (P =0.001), and 0.54 for LDL-c (P =0.108). Our data support 
the use of apoB, and second-best non-HDL-c, over and above LDL-c in identifying individuals 
from the general population with a less favorable CV phenotype. 
Recently an algorithm was developed to distinguish between different types of dyslipidemia, 
incorporating total cholesterol, triglycerides (TG), and apoB. In chapter 7 we applied this 
algorithm to the NBS population to determine the prevalence of the different dyslipidemias in a 
sample from the general population and to determine the CV risk profiles, including the extent 
of subclinical atherosclerosis as measured with NIMA. The overall prevalence of 
dyslipoproteinemias was ~ 40% in the general Dutch population. In general, all 
dyslipoproteinemias were characterized by a worse CV risk profile and deteriorated outcomes of 
NIMA compared to those with normal apoB and TG levels (reference group; apoB < 1.2 g/l and 
TG < 1.5 mmol/l). The prevalence of dyslipoproteinemia characterized by hyperapoB-hyperTG 
(apoB ≥ 1.2 g/l and TG ≥ 1.5 mmol/l) was 15.1% and these individuals showed the most 
deteriorated atheroma-related NIMA parameters; ABI at rest (-3.5%) and after exercise (-9.8%), 
IMT (+5.5%), and the presence of plaque (+39.1%). The prevalence of normoapoB-hyperTG due 
to increased VLDL was 18.1% and due to increased chylomicrons and VLDL 2.3%. Both groups 
with normoapoB-hyperTG showed the worst stiffness-related NIMA parameters (e.g.PWV+7.6% 
and +5.2%, respectively) compared to the reference group. Various effects of apoB, TG and 
other major CV risk factors on different NIMA parameters were observed. The NIMA parameters 
used in this study reflect different aspects of the atherosclerotic process, as reflected by 
atheroma-related and stiffness-related parameters. Further studies are needed to evaluate the 
main determinants of NIMA and which CV risk factors contribute most to the deteriorated 
outcomes of the individual NIMA parameters.  
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Part II: Non-invasive measurements of atherosclerosis in relation to cardiovascular risk factors 
and prevalent CVD in patients with Familial Combined Hyperlipidemia (FCH) 
 
FCH is characterized by dyslipidemia, obesity, and insulin resistance and is associated with a 2-5 
fold increased CV risk. In chapter 8 we investigated whether FCH was associated with early 
functional vascular wall changes, as represented by endothelial dysfunction and we determined 
the independent predictors of endothelial function. FCH patients (N=98) had no impaired 
endothelial function when compared to their unaffected relatives (N=230).We reported a FMD 
in FCH patients of 2.9% (2.3-3.6%) and a FMD of 2.8% (2.5-3.2%) in their unaffected relatives. 
IMT is an important predictor of FMD when carotid artery plaques are present, irrespective of 
FCH diagnosis. Our results question the use of FMD as an independent tool to predict CVD in 
high-risk populations. 
 
In chapter 9 we investigated whether FCH was associated with increased arterial stiffness, and 
whether measures of arterial wall stiffness in FCH family members could contribute to 
cardiovascular risk stratification. Patients with FCH were characterized by increased PWV 
compared to their unaffected relatives (9.1 ± 2.8 m/s versus 8.3 ± 2.6 m/s; p=0.005). However, 
no difference in AIx was observed (21.6 ± 12.7% versus 15.6 ± 14.1%; p=0.96). PWV predicted 
the presence of CVD equally well as a combination of clinical- and traditional biochemical risk 
factors, including TC, HDL-c, and SBP. The area under the receiver operating curve (AUC) for 
PWV was 0.83 (0.76-0.90) versus 0.84 (0.78-0.91) for the combination of CV risk factors (p=0.83), 
but PWV had no additional value besides traditional risk factor screening in FCH families.   
 
In chapter 10 we investigated which of the clinical and biochemical characteristics of FCH 
patients contributed most to their increased risk of cardiovascular disease, by determining the 
association of a broad variety cardiovascular risk factors with the IMT of the common carotid 
artery. FCH-patients had a significantly increased age- and gender-adjusted IMT when compared 
to their normo-lipidemic relatives (0.77 mm (0.75-0.79mm) versus 0.74 mm (0.72-0.75mm); 
p=0.047). Waist-to-hip ratio, pulse pressure, plasma apoB-concentration, and the ratio of very-
low-density lipoprotein-cholesterol and TG (VLDL-c/TG-ratio) turned out to be independent 
predictors of their IMT. The VLDL-c/TG-ratio was associated with IMT only in the patients with 
FCH but not in their unaffected relatives. Therefore, we conclude that the presence of highly 
atherogenic remnant lipoproteins might play an important role in the pathogenesis of 
cardiovascular diseases in FCH. 
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Conclusions: 
 
1. In both a low- and high-risk population, endothelial dysfunction as measured by flow-
mediated dilation is not related to cardiovascular (CV) risk factors, prevalent 
cardiovascular disease (CVD), or other measurements of subclinical atherosclerosis.  
2. In both a low- and high-risk population, arterial stiffness as measured by pulse wave 
velocity (PWV) is related to CV risk factors. In FCH patients, PWV is an equally good 
predictor of prevalent CVD as a combination of traditional CV risk factors. However, 
arterial stiffness as measured by augmentation index (AIx) is not increased in FCH 
patients and is not associated with cardiovascular risk factors in the Nijmegen 
Biomedical Study.  
3. Intima-media thickness (IMT) is related to CV risk factors and prevalent CVD in both a 
low- and high-risk population. In FCH patients atherogenic remnant particles are the 
main determinant of IMT. In the general population waist circumference and pulse 
pressure are the main determinants of IMT. 
4. With increasing number of CV risk factors, subclinical atherosclerosis increases in a low-
risk population, as measured by deteriorated outcomes of NIMA. To evaluate the extent 
of subclinical atherosclerosis to determine the cardiovascular risk, it is more important 
to evaluate the number of risk factors than diagnosing individuals with the Metabolic 
Syndrome, a clustering of specific risk factors. 
5. Independent of other major CV risk factors, a high waist circumference is associated 
with increased subclinical atherosclerosis, as reflected by deteriorated outcomes of 
nearly all NIMA parameters, whereas low adiponectin level is not.   
6. Compared to stratifying subjects by low-density lipoprotein-cholesterol (LDL-c), 
stratifying subjects by high apolipoprotein B (apoB) and non-high-density lipoprotein-
cholesterol (non-HDL-c) levels resulted in the identification of more individuals with a 
less favorable CV risk profile, including increased subclinical atherosclerosis, as reflected 
by deteriorated outcomes of nearly all 10 NIMA parameters. ApoB but not LDL-c 
detected prevalent CVD. Non-HDL-c was second best, identifying only men but not 
women with an increased prevalence of CVD. Our data support the use of apoB, and 
second best non-HDL-c, over and above LDL-c in identifying individuals from the general 
population with a less favorable CV phenotype and prevalent CVD.  
7. Applying the newly proposed diagnostic algorithm to distinguish between different 
dyslipoproteinemias based on apoB, triglycerides, and total cholesterol showed that the 
overall prevalence of dyslipoproteinemias was ~ 40% in the general Dutch population. 
Different dyslipoproteinemias as distinguished by the algorithm showed a less favorable 
CV risk profile and deteriorated NIMA parameters. Furthermore, various effects of apoB, 
triglycerides and other major CV risk factors on different NIMA parameters were 
observed. 
8. Dyslipoproteinemias characterized by hyperapoB-hyperTG show most deteriorated 
atheroma-related NIMA parameters, including ankle-brachial index, IMT, and the 
presence of plaques, whereas dyslipoproteinemias characterized by normoapoB-
hyperTG show most deteriorated stiffness-related NIMA parameters, including PWV, AIx 
and central pressure parameters. 
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Samenvatting 
 
Hart- en vaatziekten (HVZ) zijn al jaren doodsoorzaak nummer één. Atherosclerose 
(“Aderverkalking”) is de onderliggende ziekte die hart- en vaatziekten veroorzaakt. We kennen 
vele risicofactoren die het ontstaan en de mate van atherosclerose verergeren, zoals een hoge 
bloeddruk, een hoog cholesterolgehalte in het bloed, roken, overgewicht, en suikerziekte. In de 
praktijk blijkt echter dat niet alle mensen met dezelfde hoeveelheid aan risicofactoren, dezelfde 
mate van atherosclerose ontwikkelen. Zo kan het zijn dat een persoon met alleen een hoog 
cholesterolgehalte al op jonge leeftijd HVZ ontwikkelt terwijl een ander met een hoge 
bloeddruk, overgewicht, die ook nog eens rookt pas op latere leeftijd HVZ ontwikkelt.  
Atherosclerose is een geleidelijk proces dat leidt tot veranderingen in de slagaders. De functie 
van de binnenbekleding van de vaatwand verslechtert en de wand van de slagaders wordt dikker 
en stijver. Om HVZ te voorkomen, moet je in een zo vroeg mogelijk stadium de mate van 
atherosclerose meten, zodat zo vroeg mogelijk behandeld kan worden om de mate van 
atherosclerose en de ontwikkeling van HVZ te verminderen. De mate van atherosclerose in de 
vaatwand kan worden gemeten met behulp van verschillende technieken die vanaf de 
buitenkant van het lichaam de kwaliteit van de bloedvaten bepalen, zoals echografie en 
tonometrie. De niet-invasieve metingen van atherosclerose (NIMA) op basis van deze technieken 
zijn relatief goedkoop, pijnloos, patiëntvriendelijk, en kunnen op een betrouwbare manier 
uitgevoerd worden. Sommige personen hebben wel atherosclerose hebben maar nog geen HVZ 
ontwikkeld zoals een hartinfarct, en in dat geval spreken we van subklinische atherosclerose. 
Dus personen met afwijkende NIMA maar zonder HVZ hebben subklinische atherosclerose.  
 
De NIMA die we gebruikt hebben in de studies beschreven in dit proefschrift zijn: (Figuur 2, 
hoofdstuk 1) 
 1. De meting van endotheel-dysfunctie met behulp van endotheel-afhankelijke flow-
gemedieerde dilatatie (FMD) (Figuur 3, hoofdstuk 1). De functie van het endotheel kan bepaald 
worden aan de hand van de mate waarin een bloedvat in staat is zich te verwijden in reactie op 
een prikkel, zoals zuurstoftekort het of het toedienen van een vaatverwijdende stof 
(nitroglycerine). 
2. Meting van de stijfheid van de slagaders met een tonometer aan de hand van polsgolfsnelheid 
(pulse wave velocity: PWV; Figuur 6, hoofdstuk 1). Door zowel in de hals als in de lies te meten 
wanneer de bloedgolf die gegenereerd wordt door het hart aankomt, kan je de snelheid van de 
bloedstroom bepalen. Tevens kunnen door het registreren van de vorm van de polsgolf en de 
bloeddruk gemeten aan de arm, de augmentatie index (AIx) en andere berekende centrale 
bloeddruk-parameters berekend worden.  
3. De dikte van de vaatwand met behulp van de intima-media dikte meting met echografie (IMT) 
(Figuur 7 t/m 9, hoofdstuk 1). Met behulp van echografie wordt de halsslagader in beeld gebracht. 
De verschillende lagen van de vaatwand kunnen zo zichtbaar gemaakt worden en de dikte van 
de vaatwand kan worden gemeten. Tevens wordt gekeken of er verdikkingen van de wand 
aanwezig zijn, die worden plaques genoemd en daarvan wordt de dikte gemeten.  
4. Meting van de perifere doorbloeding met behulp van de enkel-arm index (ABI) in rust en na 
inspanning (Figuur 10, hoofdstuk 1). De bloeddruk gemeten aan de enkels wordt gedeeld door de 
bloeddruk gemeten aan de arm. Indien er sprake is van een vernauwing van de bloedvaten in de 
benen wordt de bloeddruk aan de enkels lager en daalt daardoor de enkel-arm index. Bij een 
index < 0.9 is er sprake van een verminderde doorbloeding en spreken we van perifeer vaatlijden 
(Figuur 10, hoofdstuk 1). 
 
Dit proefschrift beschrijft slechts een deel van de verzamelde gegevens in de grotere 
prospectieve niet-invasieve metingen van atherosclerose (NIMA) studie. Het doel van de studies 
die beschreven staan in dit proefschrift, was te onderzoeken of de NIMA gerelateerd waren aan 
de bekende risicofactoren voor HVZ. In deel I bestudeerden wij deze relaties in een laagrisico 
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groep, de Nijmegen Biomedische Studie (NBS), een steekproef uit de algemene bevolking (50-70 
jaar). In deel II bestudeerden wij deze relaties in een hoogrisico groep, een cohort van families 
met familiaire gecombineerde hyperlipidemie (FCH), waarvan bekend is dat zij een 2 to 5 keer 
verhoogd risico hebben om HVZ te ontwikkelen.  
 
De eerste stap in ons project was het valideren van nieuwe NIMA technieken op onze afdeling 
Vasculaire Diagnostiek. Om zoveel mogelijk deelnemers in zo kort mogelijke tijd te kunnen 
meten, onderzochten we in hoofdstuk 2 tevens of de metingen op verschillende tijdstippen van 
de dag dezelfde uitkomsten gaven. We lieten zien dat, zolang condities die van invloed zouden 
kunnen zijn op de metingen (zoals het nuttigen van voedsel, cafeïne of alcohol, het gebruik van 
medicatie, de kamertemperatuur en het moment in de menstruele cyclus) zorgvuldig worden 
gestandaardiseerd, het tijdstip van meten geen invloed heeft op de uitkomst van de metingen. 
Het gemiddelde verschil ± SEM tussen de metingen in de ochtend en de middag was 0.009 ± 
0.005 mm voor IMT; 0.95 ± 1.68% voor AIx; -0.37 ± 0.23 m/s voor PWV; en -0.71 ± 1.18% voor 
FMD. Ook lieten we zien dat de IMT, AIx, PWV, en de FMD reproduceerbaar gemeten kon 
worden in 19 gezonde vrijwilligers. Het gemiddelde verschil ± SEM tussen de herhaalde 
metingen op de ochtend was 0.003 ± 0.007 mm voor IMT; 0.68 ± 0.86% voor AIx; 0.19 ± 0.12 m/s 
voor PWV; en -1.05 ± 1.12% voor FMD.  
 
 
 
Deel I: Niet-invasieve metingen van atherosclerose in relatie tot cardiovasculaire risicofactoren 
en hart- en vaatziekten in de Nijmegen Biomedische Studie, een studie in de algemene 
bevolking.  
 
Een van de eerste uitingen van het begin van atherosclerose is het niet goed functioneren van de 
binnenbekleding van de vaatwand, het endotheel. De disfunctie van het endotheel leidt tot 
veranderingen in de functie van het bloedvat, zoals gemeten kan worden met FMD en NMD. In 
hoofdstuk 3 hebben we bepaald of FMD en NMD gerelateerd waren aan risicofactoren voor HVZ 
in de NBS populatie. We lieten zien dat FMD en NMD niet gerelateerd waren aan de 
risicofactoren voor HVZ en de aanwezigheid van manifest vaatlijden, en FMD was niet 
gerelateerd aan IMT(r=0.04; p=0.625), een meting van structurele vaatwandschade. Een 
opmerkelijke bevinding van deze studie was dat de diameter van de armslagader (arterie 
brachialis), de basismeting van FMD en NMD, niet alleen geassocieerd was met de risicofactoren 
voor HVZ, maar ook met manifest vaatlijden en IMT (r=0.25; p <0.001). De diameter van de 
armslagader kan eenvoudig en zeer betrouwbaar worden gemeten en zou dus een bruikbare 
meting kunnen zijn in de risicostratificatie voor HVZ in laagrisico populaties van middelbare 
leeftijd, maar FMD niet. 
 
De clustering van specifieke risicofactoren speelt een belangrijke rol in de ontwikkeling en 
toename van atherosclerose, en deze clustering is ook wel bekend als het Metabool Syndroom 
(MetS). Veel verschillende definities zijn ontwikkeld de afgelopen jaren, en velen zijn gebaseerd 
op overgewicht (obesitas), afwijkingen in cholesterolwaarden, verhoogde bloeddruk en 
insulineresistentie of glucose-intolerantie. In hoofdstuk 4 onderzochten we de impact van drie 
verschillende definities van het MetS en de individuele componenten op subklinische 
atherosclerose, gemeten met NIMA. We lieten zien dat zowel mannen als vrouwen met het 
MetS, ongeacht welke definitie werd gebruikt, meer subklinische atherosclerose hadden, wat 
gereflecteerd werd door minder gunstige uitkomsten van alle 6 NIMA-parameters. Personen 
met het MetS hadden een lagere ABI in rust (M:-5.2%; V:-3.1%) en na inspanning (M:-7.7%; V:-
6.6%), een hogere AIx (M:+4.8%; V:+1.9%), PWV (M:+22.8%; V:+20.5%), IMT (M:+9.3%; V:+6.9%) 
en dikkere plaques (M:+17.6%; V:+26.6%) dan degenen zonder het MetS. Belangrijker nog was 
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dat het aantal aanwezige componenten van het MetS sterk gerelateerd was aan de mate van de 
subklinische atherosclerose; de uitkomsten van NIMA waren al minder gunstig bij de 
aanwezigheid van slechts 1 component en verslechterden zelfs ook nog bij de aanwezigheid van 
4 of 5 componenten. Daarom concludeerden wij dat het voor de voorspelling van HVZ 
belangrijker is om de aanwezigheid en het aantal van de afzonderlijke risicofactoren te 
identificeren dan de diagnose MetS te stellen.  
 
Obesitas (overgewicht), en dan vooral de ophoping van vetweefsel in de buik, is een bekende 
risicofactor voor HVZ en kan gemakkelijk met een centimeter worden gemeten. Onlangs werd 
adiponectine ontdekt, dat door het vetweefsel wordt geproduceerd. Mensen met obesitas 
hebben echter een lage adiponectinespiegel en dit gaat gepaard met een verhoogd risico op 
HVZ. Er wordt verondersteld dat adiponectine de ontbrekende schakel zou zijn tussen obesitas 
en HVZ. In hoofdstuk 5 vergeleken wij de impact van de buikomvang, gemeten met een 
centimeter, met de meting van de adiponectinespiegel in het bloed op de uitkomsten van NIMA. 
Zowel mannen als vrouwen met een grote buikomvang (M>104 cm; V>95 cm) hadden een 
verhoogde PWV (M:+9.4%; V:+8.3%) en een grotere IMT (M:+7.3%; V:+4.3%) en vrouwen 
hadden ook dikkere plaques (+16.6%) vergeleken met degenen met een kleine buikomvang. Na 
correctie voor andere risicofactoren voor HVZ, hadden zowel mannen als vrouwen met een 
grote buikomvang een grotere IMT (M:+4.8%; V:+2.8%) en mannen een toegenomen PWV 
(+9.6%). De belangrijkste voorspellers van IMT waren de buikomvang en de polsdruk. Zowel 
mannen als vrouwen met een lage adiponectinespiegel (M<2.2 mg/l; V< 3.5 mg/l) hadden een 
verlaagde ABI na inspanning (M:-9.5%; V:-3.9%) en een grotere IMT (M:+3.7%; V:+3.6%); 
vrouwen hadden een toegenomen PWV (+6.8%), echter na correctie voor andere risicofactoren 
voor HVZ was een lage adiponectinespiegel niet meer geassocieerd met minder gunstige 
uitkomsten van NIMA.  
Een toegenomen buikomvang was onafhankelijk van andere risicofactoren voor HVZ 
geassocieerd met subklinische atherosclerose, terwijl de associatie van een lage 
adiponectinespiegel met subklinische atherosclerose afhankelijk was van andere risicofactoren 
voor HVZ. De atherogene invloed van een lage adiponectinespiegel lijkt het gevolg te zijn van de 
aanwezigheid van andere risicofactoren voor HVZ en niet intrinsiek door de adiponectinespiegel.  
 
De hoogte van het slechte LDL-cholesterol is medebepalend voor het risico op HVZ, maar veel 
studies hebben al laten zien dat de concentratie van het apolipoproteine B (apoB) en het non-
HDL-c betere voorspellers van HVZ zijn dan LDL-c. In hoofdstuk 6 hebben wij onderzocht in 
welke mate apoB, non-HDL-c, en LDL-c verschillen in het identificeren van personen met een 
verhoogd risico op HVZ aan de hand van het totale cardiovasculaire risicoprofiel inclusief de 
aanwezigheid en mate van subklinische atherosclerose. Zowel mannen als vrouwen met 
toenemende apoB en non-HDL-c spiegels waren dikker, hadden een hogere bloeddruk en 
nuchter glucose gehalte en een meer atherogeen lipidenprofiel. We vergeleken de uitkomsten 
van de niet-invasieve metingen tussen personen met een apoB en non-HDL-c gehalte in het 
hoogste kwartiel met de uitkomsten van personen met apoB, non-HDL-c, en LDL-c spiegels in de 
laagste kwartielen (de referentiegroep). Vergeleken met de referentiegroep, hadden personen 
met een verhoogd apoB als ook personen met een verhoogd non-HDL-c een toegenomen 
hoeveelheid subklinische atherosclerose, wat gereflecteerd werd door minder gunstige 
uitkomsten van nagenoeg alle NIMA-parameters. Zij hadden een lagere enkel-arm index in rust 
(-3.5% en -3.1%) en na inspanning (-6.3% en -4.7%), een dikkere vaatwand (+5.7% en +5.3%) en 
meer plaquevorming (+54.2% en +54.3%). Ook waren alle stijfheidsparameters verhoogd 
vergeleken met de referentiegroep (bv PWV +3.6%). 
Wanneer we personen selecteerden op basis van een hoge LDL-c spiegel, waren de verschillen in 
cardiovasculair risicoprofiel en aanwezigheid van subklinische atherosclerose minder duidelijk. 
Nog belangrijker was dat een verhoogd apoB zowel mannen en vrouwen identificeerde met HVZ, 
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maar LDL-c niet, en non-HDL-c identificeerde alleen mannen, maar geen vrouwen met HVZ. De 
voorspellende waarde van risicofactoren voor bijvoorbeeld HVZ kan vergeleken worden door het 
berekenen van de oppervlakte onder de zogenoemde ROC-curve. Hoe groter de oppervlakte 
onder de curve is hoe beter het risico op HVZ voorspeld wordt. De oppervlakte onder de ROC 
curve was 0.60 (P <0.001) voor apoB, 0.57 (P =0.001) voor non-HDL-c, en 0.54 (P =0.108) voor 
LDL-c. Dit laat zien dat het onderscheidend vermogen voor de aanwezigheid van HVZ het grootst 
is voor apoB. De uitkomsten van deze studie onderschrijven dat in de klinische praktijk meting 
van apoB de beste meting is om mensen uit de algemene bevolking (50-70 jaar) te identificeren 
met een verhoogd risico op HVZ en dat non-HDL-c tweede keus is. Zowel apoB als non-HDL-c zijn 
beter in het identificeren van personen met een verhoogd risico op HVZ dan LDL-c.  
 
Recent is een algoritme ontwikkeld om op eenvoudige wijze onderscheid te kunnen maken 
tussen verschillende vormen van dyslipoproteïnemie op basis van apolipoproteïne B, 
triglyceriden (TG), en totaal cholesterol. In hoofdstuk 7 hebben wij dit algoritme toegepast op de 
NBS-populatie. Doel was om de prevalentie van de dyslipoproteïnemiën vast te stellen in een 
steekproef uit de algemene bevolking (50-70 jaar) en om de bijbehorende cardiovasculaire 
risicoprofielen te bepalen, inclusief de mate van subklinische atherosclerose, gemeten met 
NIMA. De prevalentie van de dyslipoproteïnemiën was ~ 40% in onze steekproef van de 
Nijmeegse bevolking. Personen met een dyslipoproteïnemie (hyperapoB ≥ 1.2 g/l en/of hyperTG 
≥ 1.5 mmol/l) werden gekarakteriseerd door een slechter cardiovasculair profiel en minder 
gunstige uitkomsten van de NIMA-metingen vergeleken met mensen in de referentiegroep 
(apoB <1.2 g/l en TG < 1.5 mmol/l). De prevalentie van hyperapoB-hyperTG was 15.1% en deze 
mensen lieten de grootste veranderingen in de uitkomsten van de “atheroma”-gerelateerde 
parameters zien; zij hadden een verlaagde enkel-arm index in rust (-3.5%) en na inspanning (-
9.8%), een grotere IMT (+5.5%), en meer plaques (+39.1%). De prevalentie van normoapoB-
hyperTG op basis van verhoogd VLDL was 18.1% en op basis van verhoogde chylomicronen en 
VLDL 2.3%. Beide groepen met normoapoB-hyperTG lieten de grootste verandering zien in de 
“stijfheids”-gerelateerde parameters (bv PWV+7.6% en +5.2%, respectievelijk) vergeleken met 
de referentiegroep. ApoB, TG, en andere bekende risicofactoren voor HVZ lieten een 
verschillend effect zien op verschillende NIMA-parameters. De NIMA-parameters gemeten in 
deze studie reflecteren verschillende aspecten van het atherosclerotisch proces en verder 
onderzoek is nodig om te bepalen welke risicofactoren voor HVZ de minder gunstige uitkomsten 
van de diverse NIMA-parameters veroorzaken. Een andere belangrijke uitkomst van deze studie 
was dat het toepassen van het algoritme een groot aantal mensen identificeerde die een 
verhoogd risico op HVZ hadden, maar die hiervoor niet behandeld werden.  
   
 
 
Deel II: Niet-invasieve afmetingen van atherosclerose in relatie tot cardiovasculaire 
risicofactoren en hart- en vaatziekten bij patiënten met familiaire gecombineerde 
hyperlipidemie (FCH) 
  
Familiaire gecombineerde hyperlipidemie (FCH) wordt gekenmerkt door afwijkingen in de 
serum-lipiden, obesitas, en insulineresistentie, en is geassocieerd met een verhoogd risico op 
hart- en vaatziekten. In hoofdstuk 8 onderzocht wij of patiënten met FCH een vermindering van 
de functie van het endotheel hadden in vergelijking tot hun niet-aangedane familieleden met 
behulp van FMD. Tevens hebben we de onafhankelijke voorspellers van FMD bepaald. Tegen de 
verwachting in hadden de patiënten met FCH (N=98) geen verminderde functie van het 
endotheel vergeleken met hun niet-aangedane familieleden (N=230). Patiënten met FCH hadden 
een FMD van 2.9% (2.3-3.6%) en hun niet-aangedane familieleden hadden een FMD van 2.8% 
(2.5-3.2%). IMT was alleen een voorspeller van FMD wanneer er plaques in de halsslagaders 
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aanwezig waren, zowel in FCH-patiënten als in de groep familieleden. Deze resultaten zetten 
vraagtekens bij het gebruik van FMD als onafhankelijke voorspeller van HVZ in hoogrisico 
populaties.  
 
In hoofdstuk 9 onderzochten we de relatie van arteriële stijfheid met FCH en of de niet-invasieve 
metingen van de stijfheid van de slagaders bij zouden kunnen dragen aan de voorspelling van 
het cardiovasculaire risico in de FCH-families. De conclusie van deze studie was dat patiënten 
met FCH werden gekenmerkt door een verhoogde PWV vergeleken met hun niet-aangedane 
familieleden (9.1 ± 2.8 m/s versus 8.3 ± 2.6 m/s; p=0.005). Er werd echter geen verschil in AIx 
gevonden (21.6 ± 12.7% versus 15.6 ± 14.1%; p=0.96). PWV voorspelde de aanwezigheid van 
HVZ net zo goed als een combinatie van traditionele klinische- en biochemische risicofactoren 
(TC, HDL-c, en systolische bloeddruk). De oppervlakte onder de ROC-curve was 0.83 (0.76-0.90) 
voor PWV en 0.84 (0.78-0.91) voor de combinatie van risicofactoren (p=0.83), maar PWV had 
geen toegevoegde waarde bovenop de voorspelling van HVZ door traditionele risicofactoren in 
deze families met FCH.  
 
In hoofdstuk 10 onderzochten we welke van de klinische en biochemische karakteristieken van 
FCH patiënten de grootste bijdrage leverden aan het verhoogde risico op HVZ. Hiervoor 
bepaalden we de associaties van een breed scala aan cardiovasculaire risicofactoren met IMT. 
Patiënten met FCH hadden een aanzienlijk grotere (voor leeftijd en geslacht gecorrigeerde) IMT 
in vergelijking met hun niet-aangedane familieleden (0.77 mm [0.75-0.79mm] versus 0.74 mm 
[0.72-0.75mm]; p=0.047). De verhouding tussen taille en heupen, de polsdruk, de hoogte van 
apoB in plasma, en de verhouding VLDL-c/TG waren de onafhankelijke voorspellers van IMT. De 
VLDL-c/TG is een maat voor atherogene vetdeeltjes in het bloed en deze verhouding was 
gerelateerd aan IMT in patiënten met FCH, maar niet in hun niet-aangedane familieleden. De 
aanwezigheid van deze atherogene vetdeeltjes in het bloed lijkt een belangrijke rol te spelen in 
de pathofysiologie van HVZ in FCH.  
 
 
 
 
Conclusies:  
 
1. Endotheel-dysfunctie gemeten met flow-gemedieerde dilatatie (FMD) is niet 
gerelateerd aan bekende risicofactoren voor hart- en vaatziekten (HVZ), manifest 
vaatlijden, of andere metingen van subklinische atherosclerose in zowel een 
laagrisico als een hoogrisico populatie.  
2. Zowel in een laagrisico als in een hoogrisico populatie is arteriële vaatwandstijfheid, 
gemeten met de polsgolfsnelheid (PWV), geassocieerd met bekende risicofactoren 
voor HVZ. In patiënten met familiair gecombineerde hyperlipidemie (FCH) is PWV 
een even goede voorspeller van HVZ als een combinatie van traditionele 
risicofactoren. Echter, wanneer arteriële vaatwandstijfheid wordt gemeten met de 
augmentatie-index (AIx), dan is deze niet verhoogd in FCH-patiënten en niet 
geassocieerd met risicofactoren voor HVZ in een laagrisico populatie.  
3. De dikte van de vaatwand (IMT) is geassocieerd met de risicofactoren voor HVZ en 
manifest vaatlijden in zowel de laagrisico als de hoogrisico populatie. In FCH-
patiënten zijn atherogene “remnant particles” de belangrijkste voorspeller van IMT. 
In de laagrisico populatie zijn buikomvang en polsdruk de belangrijkste voorspellers 
van IMT.  
4. In de laagrisico populatie geldt dat hoe meer risicofactoren aanwezig zijn, hoe meer 
subklinische atherosclerose aanwezig is, wat geconcludeerd kan worden uit de 
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minder gunstige uitkomsten van de niet-invasieve metingen van atherosclerose 
(NIMA). De aanwezigheid van en het aantal risicofactoren dat iemand heeft, is 
belangrijker voor het bepalen van het risico op HVZ dan het stellen van de diagnose 
Metabool Syndroom.  
5. Een toegenomen buikomvang, gemeten met een centimeter, is, onafhankelijk van 
andere risicofactoren voor HVZ, geassocieerd met meer subklinische atherosclerose 
(wat gereflecteerd wordt door minder gunstige uitkomsten van de NIMA-
parameters), maar een lage adiponectinespiegel niet.  
6. Stratificatie van personen op basis van een hoog apolipoproteine B (apoB) of een 
hoog non-HDL-c identificeert individuen met een slechter cardiovasculair 
risicoprofiel, inclusief een toename in subklinische atherosclerose, wat gereflecteerd 
wordt door minder gunstige uitkomsten van bijna alle 10 gemeten NIMA-
parameters. Op basis van een verhoogd apoB worden zowel mannen als vrouwen 
met HVZ geïdentificeerd, op basis van een verhoogd non-HDL-c worden alleen 
mannen met HVZ geïdentificeerd. LDL-c laat de slechtste resultaten zien in het 
identificeren van personen met een slechter cardiovasculair risico profiel en HVZ in 
de laagrisico populatie. Onze resultaten ondersteunen dat het beter is om apoB, en 
als tweede keus non-HDL-c, te meten in de klinische praktijk om mensen met een 
verhoogd cardiovasculair risico en/of HVZ op te sporen in de algemene bevolking, en 
beide zijn beter dan LDL-c.  
7. Het toepassen van het nieuwe diagnostische algoritme voor dyslipoproteinemiën op 
basis van apoB, triglyceriden (TG),  en totaal cholesterol laat zien dat de prevalentie 
van dyslipoproteïnemiën in de algemene bevolking ongeveer 40% is. Alle 
dyslipoproteïnemiën worden gekarakteriseerd door een slechter cardiovasculair 
risicoprofiel en minder gunstige uitkomsten van de NIMA-parameters. Wel hebben 
apoB, TG, en andere risicofactoren voor HVZ verschillend effect op de diverse NIMA-
parameters.  
8. Dyslipoproteinemiën die gekarakteriseerd worden door hyperapoB-hyperTG laten 
de grootste afwijkingen zien in de “atheroma”-gerelateerde NIMA-parameters zoals 
de enkel-arm index, IMT, en plaquevorming, terwijl dyslipoproteinemiën die 
gekarakteriseerd worden door normoapoB-hyperTG  de grootste afwijkingen in 
stijfheids-gerelateerde NIMA-parameters laten zien, zoals PWV, AIx, en centrale 
bloeddruk-parameters. 
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Het kleinste wordt groot als je het met liefde doet  
(Pater Damiaan) 
 
Promoveren is een teamsport. Als je er alleen voor zou staan, kwam het waarschijnlijk nooit 
klaar! Zonder hulp van anderen zou dit boekje er nooit gekomen zijn en daarom wil ik een aantal 
mensen in het bijzonder bedanken. 
 
Allereerst een groot woord van dank voor alle FCH patiënten, hun familieleden en alle vrijwillige 
deelnemers van de Nijmegen Biomedische Studie die mee hebben gewerkt aan dit onderzoek. 
Zonder hen hadden we dit onderzoek niet kunnen uitvoeren. Ik heb veel plezier beleefd aan alle 
metingen bij zoveel verschillende mensen. Jullie hebben mijn blikveld verruimd, mijn denken 
over de oudere medemens genuanceerd, en vele plezierig uurtjes van gezelligheid bezorgd. Het 
was een waar genoegen jullie levensverhalen te mogen meekrijgen. Hartelijk dank voor jullie 
bloed, zweet (van jullie actie op de lopende band) en urine. En natuurlijk jullie geduld om de 
vragenlijsten in te vullen en de metingen te ondergaan. 
Veel dank ook aan mijn collega’s van de afdeling Vaatfunctie-onderzoek. Jullie inzet bij het 
uitvoeren van de metingen en jullie geduld met mij als spring-in-‘t-veld op de afdeling waardeer 
ik enorm. Jullie zijn een grote steun geweest, vooral tijdens de jaren waarin ik zowel 
leidinggevende als promovenda was. Het was worstelen met de tijd en jullie steunden mij zoveel 
het kon. 
 
Jacqueline, jij was degene die me kennis liet maken met de wetenschap. Vanaf het eerste uur 
betrok je me bij de NIMA studie waar je subsidie voor had verworven. Jij was ook degene die 
opperde dat ik misschien wel promovenda kon worden op het project. Dank dat je in me hebt 
geloofd! Heel veel dank voor je onvoorwaardelijke steun en enorme inzet bij het corrigeren van 
de manuscripten. Je heldere kijk en kritische blik hielden mij scherp. Wanneer de moed mij soms 
in de schoenen zonk wist jij me zonder moeite weer te motiveren. Je bent een fantastische 
coach, goede leermeester en bovenal een prachtig mens. Ik kan alleen maar hopen in de rest 
van mijn carrière (en daarnaast) omringd te worden door mensen als jij! 
 
Martin, wat stelde ik je statistische geduld soms op de proef. Dank voor al je analyses! 
Langzaamaan stuurde je me in de richting van zelf analyses doen; dank zij jou is mijn statische 
kennis enorm gegroeid en wordt me door mijn kamergenoot zelfs verbaasd gevraagd of ik de 
statistiek ECHT leuk ben gaan vinden. Ik kan alleen maar ja antwoorden, al weet ik nog maar zo 
weinig vergeleken bij jou. Dank voor de discussies die mijn inzicht in de methoden hebben 
vergroot en ik weet het, ik ben soms erg hardleers…. Jij leerde me kijken door mijn oogharen 
heen….. 
 
Anton, dank dat je me de kans hebt gegeven om het promotietraject in te gaan. Vanwege mijn 
optimistische planningen en onervarenheid kwam ik menig keer vragen om verlenging van het 
contract. Dank voor je geduld hierin; dank dat je me deze gelegenheid hebt geboden en ik hoop 
dat ik nog veel voor het vasculaire onderzoek kan betekenen in de toekomst! 
 
Ewoud, samen startten we het onderzoek op en jij nam het voortouw. Dank voor je steun en 
gezelligheid. Ik heb enorm bewondering voor je snelheid van schrijven. Ik leerde veel van je 
relativeringsvermogen en vond het leerzaam en gezellig om met je samen te kunnen werken. 
Het heeft even geduurd, maar nu is dan ook mijn boekje klaar! 
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Michelle, jij hebt me enorm veel werk uit handen genomen. Alsof je nooit anders gedaan had 
ging je aan de slag met het zeer nauwkeurig bijhouden van de database en het uitnodigen van 
de deelnemers. We brachten vele gezellige uurtjes door! Daarnaast heb je laten zien dat je zelf 
ook ambities hebt in onderzoek doen; je schreef een artikel van je wetenschappelijke stage en 
mocht zelfs een poster presenteren in Milaan! Ik ben blij dat je na je stage in Tanzania mij 
terzijde wilt staan als mijn paranimf voor je weer vertrekt naar Londen voor je hoofdstage! 
 
Allan, thank you for the lively discussions on the impact of apoB on the NIMA, which might 
better be named NIMVA. I learned a lot from the email-discussions. I appreciate your 
contribution to the articles. Although you were having holidays, you drove miles to download 
and print the documents, and sent your comments within a day! I admire your enthusiasm and I 
hope we will be able to work together on other articles in the future! 
 
Helga, Heidi, Magda, en Anneke, collega’s van Researchlab van de Interne, dank jullie wel voor 
de enorme berg werk die jullie hebben verzet voor de NIMA studie! Wanneer het prikken niet 
lukte konden we jullie bellen, maar de grootste klus was het verwerken en invriezen van het 
bloed van 1860 vrijwilligers. In totaal draaiden jullie 5580 buizen af en hebben jullie bijna 10.000 
epjes gevuld en ingevroren. En dan hebben we het nog niet eens gehad over al de extra 
bepalingen die jullie deden na het weer ontdooien van monsters. Enorm bedankt voor jullie 
inzet! 
 
Til en Evertine, dank voor jullie hulp bij het prikken als er niemand beschikbaar was of het niet 
lukte om bloed af te nemen. En Evertine dank voor je inzet bij het uitvoeren van de laatste 
metingen. Op de valreep werden we kamergenootjes, dank voor je luisterend oor gedurende de 
laatste loodjes en vooral voor de gezelligheid! 
 
De organisatie van de Nijmegen Biomedische Studie en in het bijzonder Lian en Femmie bedankt 
voor het versturen van de uitnodigingen en aanleveren van de deelnemers. Na wat 
opstartproblemen hadden jullie aardig de vaart erin! 
Uiteraard veel dank aan alle coauteurs voor jullie bijdrage aan de manuscripten in dit boekje en 
aan de manuscripten die nog in de maak zijn! Verder dank ik alle collega’s in het 
lipidenonderzoek en van de interne geneeskunde; Rinke, Tim, Berry, Patricia, Mirjam, Helène, 
José, Geralien, Willeke. 
Alle meiden op de gang in de buitenhoek dank voor de nodige afleiding gedurende de lunch en 
koffiedrinken met verjaardagen! Ook al gunde ik me er niet altijd de tijd voor, jullie zorgden wel 
voor de broodnodige afleiding.  
 
Lieve vrienden en familie; zonder jullie had ik dit niet gekund. Jullie hebben mijn verhalen aan 
moeten horen, mijn frustraties, maar vooral ook de levendige verhalen van wat ik nu toch weer 
beleefd had. Dank voor de heerlijke afleiding, soms door een lief kaartje, een bloemetje of 
gewoon door even lekker bij te kletsen! Ik weet dat het soms moeilijk te begrijpen was dat ik 
niet kon afspreken omdat ik zo druk was….. Jullie weten hoe moeilijk dat voor me was, want zo 
ben ik eigenlijk helemaal niet! Ook mijn buurtgenootjes veel dank voor de broodnodige 
afleiding. Door voor me te koken of door een chocoladetoetje te brengen met de vraag of ik wel 
goed genoeg voor mezelf zorgde, door dansen in het Wijnfort of een dagje strand hield ik de 
benen eronder.  
Marije, mijn loopmaatje, je weet niet half hoe goed de loopsessies me deden; na een pittig 
stukje rennen waarin we ook lekker konden bijkletsen kreeg ik weer de energie om toch nog 
even door te gaan. Een bijzonder bedankje ook voor de pizza-club! Jullie trokken me achter mijn 
PC vandaan voor de wekelijkse pizza; een heerlijke afleiding en inmiddels een gezellige traditie! 
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Echte vriendschap is zeldzaam. Ik ben een gelukkig mens met zoveel echte vrienden om me 
heen. Als ik de keus had stond hier een hele schare paranimfen! Als een vriend iets vraagt, 
bestaat er geen morgen…. 
Lieve Jelly, we hebben vaak gelachen om onze eerste indruk van elkaar. Hoe anders bleek de 
werkelijkheid! Als een rode draad loopt onze vriendschap door mijn werkende en studerende 
leven. Ik vind het heerlijk dat jij vandaag aan mijn zijde wil staan als mijn paranimf! Jouw 
relativerende vermogen en enorm gevoel voor humor hebben mij door menig lastig uurtje 
gesleept en ik vertrouw erop dat dat ook vandaag gaat lukken! Ik denk dat onze vriendschap 
bewijst dat afstand relatief is en ik hoop dat het tot achter de geraniums zal duren! 
Lieve Suus, dank voor je onvoorwaardelijke steun en vriendschap. Ik heb veel van je geleerd over 
het leven en laten leven. Het voelt heerlijk om zo thuis bij jou en je gezin te mogen zijn. Ik hoop 
nog vele liters thee met je te mogen drinken terwijl we bijna struikelen over de woorden omdat 
we elkaar nog zoveel te vertellen hebben…. 
 
Lieve mam, ik kon maar niet uitleggen dat ik alweer aan het “studeren” was, wanneer was ik nu 
eens klaar. Het boekje is nu af, maar ja wie weet wat volgt?! Dank dat je er altijd voor me bent; 
je bent de liefste moeder van de hele wereld!! Lieve pap, helaas maak je dit niet mee, maar ik 
hoop dat je het toch kan zien! Ik weet dat je trots op me zou zijn. Jij was de motor achter mijn 
studies, als ik geen zin meer had in die onzin wist jij me toch weer zover te krijgen! Dank je wel, 
ook al ging ik geen medicijnen studeren zoals jij graag had gezien, nu ga ik toch nog promoveren! 
Wie had nou gedacht…. Ik mis je en draag dit boekje aan jou en mama op. 
 
Nou lieve mensen, hiervoor was het allemaal te doen! Ik kan niet iedereen persoonlijk 
bedanken, dat zou bijna een boekje op zich worden. Maar voor iedereen geldt; dank voor jullie 
liefde en vriendschap; jullie zijn onmisbaar en wat het leven de moeite waard maakt! 
 
 
 
 
Het geluk is het enige dat zich verdubbelt als men het deelt! 
(Albert Sweitzer) 
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